U.S. patent application number 15/173926 was filed with the patent office on 2016-09-29 for novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors.
The applicant listed for this patent is Nivalis Therapeutics, Inc.. Invention is credited to Jian Qiu, Adam Stout, Xicheng Sun.
Application Number | 20160279117 15/173926 |
Document ID | / |
Family ID | 46245126 |
Filed Date | 2016-09-29 |
United States Patent
Application |
20160279117 |
Kind Code |
A1 |
Sun; Xicheng ; et
al. |
September 29, 2016 |
Novel Substituted Bicyclic Aromatic Compounds as
S-Nitrosoglutathione Reductase Inhibitors
Abstract
The present invention is directed to novel substituted bicyclic
aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR)
inhibitors, pharmaceutical compositions comprising such compounds,
and methods of making and using the same.
Inventors: |
Sun; Xicheng; (Broomfield,
CO) ; Qiu; Jian; (Longmont, CO) ; Stout;
Adam; (Ann Arbor, MI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Nivalis Therapeutics, Inc. |
Boulder |
CO |
US |
|
|
Family ID: |
46245126 |
Appl. No.: |
15/173926 |
Filed: |
June 6, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14944468 |
Nov 18, 2015 |
9364481 |
|
|
15173926 |
|
|
|
|
14637223 |
Mar 3, 2015 |
9221810 |
|
|
14944468 |
|
|
|
|
14326686 |
Jul 9, 2014 |
9012646 |
|
|
14637223 |
|
|
|
|
13991972 |
Jun 6, 2013 |
8785643 |
|
|
PCT/US2011/065490 |
Dec 16, 2011 |
|
|
|
14326686 |
|
|
|
|
61423799 |
Dec 16, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 409/14 20130101;
C07D 239/74 20130101; A61P 11/06 20180101; C07D 217/04 20130101;
A61K 31/53 20130101; A61P 1/16 20180101; C07D 213/79 20130101; C07D
401/10 20130101; C07D 241/42 20130101; C07D 257/04 20130101; C07D
409/04 20130101; A61P 43/00 20180101; C07D 217/16 20130101; A61P
11/00 20180101; A61P 7/02 20180101; C07D 239/34 20130101; C07D
413/10 20130101; A61K 31/472 20130101; A61K 31/47 20130101; A61P
1/00 20180101; C07D 239/26 20130101; C12N 9/99 20130101; A61P 11/08
20180101; C07D 249/18 20130101; A61K 31/4709 20130101; C07D 403/10
20130101; C07D 241/24 20130101; C07D 239/28 20130101; C12Y
101/01284 20130101; C07D 401/04 20130101; A61P 9/12 20180101; C07D
215/06 20130101; C07C 65/105 20130101; C07D 417/10 20130101; A61P
29/00 20180101; A61P 35/00 20180101; A61P 9/10 20180101; C07D
253/10 20130101; A61K 31/517 20130101; C07C 65/24 20130101; C07D
295/155 20130101; C12N 9/0065 20130101; C07D 405/04 20130101; A61P
1/04 20180101; A61K 31/498 20130101; C07C 65/17 20130101; C07D
215/60 20130101; C07D 237/24 20130101; C12N 9/0006 20130101; C07D
215/20 20130101 |
International
Class: |
A61K 31/47 20060101
A61K031/47; A61K 31/517 20060101 A61K031/517; C12N 9/99 20060101
C12N009/99; A61K 31/53 20060101 A61K031/53; A61K 31/472 20060101
A61K031/472; A61K 31/4709 20060101 A61K031/4709; A61K 31/498
20060101 A61K031/498 |
Claims
1. A method of inhibiting the activity of the enzyme
S-nitrosoglutathione reductase (GSNOR) comprising the step of
contacting said enzyme with a compound of Formula I: ##STR00114##
wherein Z.sub.1 is selected from the group consisting of CR.sub.2a
and N; Z.sub.2 is selected from the group consisting of CR.sub.2b
and N; Z.sub.3 is selected from the group consisting of CR.sub.2c
and N; with the proviso that at least 1 of Z.sub.1, Z.sub.2, or
Z.sub.3 must be N; m is selected from the group consisting of 0, 1,
2, or 3; R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; R.sub.2a, R.sub.2b, and
R.sub.2c, are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; X is selected from the group consisting of
##STR00115## n is selected from 0, 1, and 2; R.sub.3 is
independently selected from the group consisting of halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4 and
R.sub.4' are independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with R.sub.4'
form a ring with 3 to 6 members; A is selected from the group
consisting of ##STR00116## or a pharmaceutically acceptable salt,
stereoisomer, or N-oxide thereof.
2. The method of claim 1 wherein when Z.sub.1 and Z.sub.2 are both
N, and Z.sub.3 is CR.sub.2c, then R.sub.2c is selected from the
group consisting of hydrogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, and cyano.
3. The method of claim 1 wherein m is selected from the group
consisting of 0 and 1; R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and
N(CH.sub.3).sub.2; n is selected from the group consisting of 0 and
1; and R.sub.3 is independently selected from the group consisting
of fluoro, chloro, methyl, trifluoromethyl, cyano, methoxy, and
NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are methyl, or
alternatively together with the said N form the ring aziridin-1-yl
or morpholino.
4. The method of claim 3 wherein X is ##STR00117##
5. The method of claim 4 wherein A is COOH.
6. The method of claim 1, wherein the compound is a compound of
Formula II ##STR00118## wherein Z.sub.2 is selected from the group
consisting of CR.sub.2b and N; Z.sub.3 is selected from the group
consisting of CR.sub.2c and N; m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2b and
R.sub.2c are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; X is selected from the group consisting of
##STR00119## R.sub.3 is independently selected from the group
consisting of halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are independently
selected from the group consisting of C.sub.1-C.sub.3 alkyl, or
R.sub.4 when taken together with R.sub.4' form a ring with 3 to 6
members; n is selected from 0, 1, and 2; A is selected from the
group consisting of ##STR00120## or a pharmaceutically acceptable
salt, stereoisomer, or N-oxide thereof.
7. The method of claim 6 wherein when Z.sub.2 is N, and Z.sub.3 is
CR.sub.2c, then R.sub.2c is selected from the group consisting of
hydrogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
and cyano.
8. The method of claim 6 wherein m is selected from the group
consisting of 0 and 1; R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and
N(CH.sub.3).sub.2; n is selected from the group consisting of 0 and
1; and R.sub.3 is independently selected from the group consisting
of fluoro, chloro, methyl, trifluoromethyl, cyano, methoxy, and
NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are methyl, or
alternatively together with the said N form the ring aziridin-1-yl
or morpholino.
9. The method of claim 1, wherein the compound is a compound of
Formula III ##STR00121## wherein Z.sub.2 is selected from the group
consisting of CR.sub.2b and N; Z.sub.3 is selected from the group
consisting of CR.sub.2c and N; with the proviso that at least 1 of
Z.sub.2 or Z.sub.3 must be N; m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2a,
R.sub.2b, and R.sub.2c, are independently selected from the group
consisting of hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; X is selected from the group consisting of
##STR00122## R.sub.3 is independently selected from the group
consisting of halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are independently
selected from the group consisting of C.sub.1-C.sub.3 alkyl, or
R.sub.4 when taken together with R.sub.4' form a ring with 3 to 6
members; n is selected from 0, 1, and 2; A is selected from the
group consisting of ##STR00123## or a pharmaceutically acceptable
salt, stereoisomer, or N-oxide thereof.
10. The method of claim 1 wherein the compound is a compound of
Formula V: ##STR00124## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2c is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; X is selected from
the group consisting of ##STR00125## n is selected from 0, 1, and
2; R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; A is selected from the
group consisting of ##STR00126## or a pharmaceutically acceptable
salt, stereoisomer, or N-oxide thereof.
11. The method of claim 10 wherein R.sub.2c is selected from the
group consisting of hydrogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, and cyano.
12. The method of claim 10 wherein the compound is selected from
the group consisting of 4-(6-hydroxyquinazolin-2-yl)benzoic acid;
4-(6-hydroxy-4-methylquinazolin-2-yl)benzoic acid;
3-chloro-4-(6-hydroxyquinazolin-2-yl)benzoic acid;
4-(6-hydroxyquinazolin-2-yl)-3-methylbenzoic acid;
4-(6-hydroxyquinazolin-2-yl)-3-methoxybenzoic acid;
3-fluoro-4-(6-hydroxyquinazolin-2-yl)benzoic acid; and
1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylic acid.
13. The method of claim 1 wherein the compound is a compound of
Formula VI: ##STR00127## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2b is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; X is selected from
the group consisting of ##STR00128## n is selected from 0, 1, and
2; R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; A is selected from the
group consisting of ##STR00129## or a pharmaceutically acceptable
salt, stereoisomer, or N-oxide thereof.
14. The method of claim 13 wherein the compound is selected from
the group consisting of
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic acid;
2-(4-(2H-tetrazol-5-yl)phenyl)-3-(trifluoromethyl)quinoxalin-6-ol;
1-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)piperidine-4-carboxylic
acid;
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohex-3-enecarbo-
xylic acid;
3-chloro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid; 4-(6-hydroxyquinoxalin-2-yl)benzoic acid;
3-fluoro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid;
(1r,4r)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarbox-
ylic acid; and
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarbox-
ylic acid.
15. The method of claim 1 wherein the compound is a compound of
Formula VII: ##STR00130## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; X is selected
from the group consisting of ##STR00131## n is selected from 0, 1,
and 2; R.sub.3 is independently selected from the group consisting
of halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3
alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where
R.sub.4 and R.sub.4' are independently selected from the group
consisting of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together
with R.sub.4' form a ring with 3 to 6 members; A is selected from
the group consisting of ##STR00132## or a pharmaceutically
acceptable salt, stereoisomer, or N-oxide thereof.
16. The method of claim 15 wherein the compound is selected from
the group consisting of
3-(4-carboxyphenyl)-7-hydroxybenzo[e][1,2,4]triazine 1-oxide;
4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic acid;
3-(4-carboxy-2-fluorophenyl)-7-hydroxybenzo[e][1,2,4]triazine
1-oxide; and
3-fluoro-4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic acid.
17. The method of claim 1 wherein the compound is a compound of
Formula VIII: ##STR00133## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2a and
R.sub.2c are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; X is selected from the group consisting of
##STR00134## n is selected from 0, 1, and 2; R.sub.3 is
independently selected from the group consisting of halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4 and
R.sub.4' are independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with R.sub.4'
form a ring with 3 to 6 members; A is selected from the group
consisting of ##STR00135## or a pharmaceutically acceptable salt,
stereoisomer, or N-oxide thereof.
18. The method of claim 17 wherein the compound is selected from
the group consisting of 4-(7-hydroxyisoquinolin-3-yl)benzoic acid;
3-fluoro-4-(7-hydroxyisoquinolin-3-yl)benzoic acid; and
4-(7-hydroxy-4-methylisoquinolin-3-yl)benzoic acid.
19. The method of claim 1 wherein the compound is a compound of
Formula IX: ##STR00136## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2a and
R.sub.2b are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; X is selected from the group consisting of
##STR00137## n is selected from 0, 1, and 2; R.sub.3 is
independently selected from the group consisting of halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4 and
R.sub.4' are independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with R.sub.4'
form a ring with 3 to 6 members; A is selected from the group
consisting of ##STR00138## or a pharmaceutically acceptable salt,
stereoisomer, or N-oxide thereof.
20. The method of claim 19 wherein the compound is selected from
the group consisting of 4-(7-hydroxyquinolin-3-yl)benzoic acid; and
3-(4-carboxyphenyl)-7-hydroxyquinoline 1-oxide.
21. The method of claim I wherein the compound is a compound of
Formula X: ##STR00139## wherein m is selected from the group
consisting of 0, 1, 2, or 3; R.sub.1 is independently selected from
the group consisting of chloro, fluoro, and bromo; R.sub.2a is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; X is selected from
the group consisting of ##STR00140## n is selected from 0, 1, and
2; R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; A is selected from the
group consisting of ##STR00141## or a pharmaceutically acceptable
salt, stereoisomer, or N-oxide thereof.
22. The method of claim 1 wherein the compound is selected from the
group consisting of
3-chloro-4-(5-fluoro-6-hydroxyquinolin-2-yl)benzoic acid; and
4-(5-fluoro-6-hydroxyquinolin-2-yl)-3-methylbenzoic acid.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/944,468, filed Nov. 18, 2015. U.S. application Ser. No.
14/944,468, is a continuation of U.S. application Ser. No.
14/637,223, filed Mar. 3, 2015, issued as U.S. Pat. No. 9,221,810.
U.S. application Ser. No. 14/637,223 is a continuation of U.S.
application Ser. No. 14/326,686, filed Jul. 9, 2014, issued as U.S.
Pat. No. 9,012,646. U.S. application Ser. No. 14/326,686 is a
continuation of U.S. application Ser. No. 13/991,972, filed Jun. 6,
2013, issued as U.S. Pat. No. 8,785,643. U.S. application Ser. No.
13/991,972 is a 35 U.S.C. .sctn.371 national phase application of
PCT/US2011/065490, filed Dec. 16, 2011 (WO 2012/083165).
PCT/US2011/065490 claims priority to U.S. Provisional Application
Ser. No. 61/423,799, filed Dec. 16, 2010. Each of these
applications is incorporated herein by reference in its entirety
for all purposes as if fully set forth herein.
FIELD OF THE INVENTION
[0002] The present invention is directed to novel bicyclic aromatic
compounds, pharmaceutical compositions comprising such compounds,
and methods of making and using the same. These compounds are
useful as inhibitors of S-nitrosoglutathione reductase (GSNOR).
BACKGROUND
[0003] The chemical compound nitric oxide is a gas with chemical
formula NO. NO is one of the few gaseous signaling molecules known
in biological systems, and plays an important role in controlling
various biological events. For example, the endothelium uses NO to
signal surrounding smooth muscle in the walls of arterioles to
relax, resulting in vasodilation and increased blood flow to
hypoxic tissues. NO is also involved in regulating smooth muscle
proliferation, platelet function, and neurotransmission, and plays
a role in host defense. Although NO is highly reactive and has a
lifetime of a few seconds, it can both diffuse freely across
membranes and bind to many molecular targets. These attributes make
NO an ideal signaling molecule capable of controlling biological
events between adjacent cells and within cells.
[0004] NO is a free radical gas, which makes it reactive and
unstable, thus NO is short lived in vivo, having a half life of 3-5
seconds under physiologic conditions. In the presence of oxygen, NO
can combine with thiols to generate a biologically important class
of stable NO adducts called S-nitrosothiols (SNO's). This stable
pool of NO has been postulated to act as a source of bioactive NO
and as such appears to be critically important in health and
disease, given the centrality of NO in cellular homeostasis
(Stamler et al., Proc. Natl. Acad. Sci. USA, 89:7674-7677 (1992)).
Protein SNO's play broad roles in the function of cardiovascular,
respiratory, metabolic, gastrointestinal, immune, and central
nervous system (Foster et al., Trends in Molecular Medicine, 9
(4):160-168, (2003)). One of the most studied SNO's in biological
systems is S-nitrosoglutathione (GSNO) (Gaston et al., Proc. Natl.
Acad. Sci. USA 90:10957-10961 (1993)), an emerging key regulator in
NO signaling since it is an efficient trans-nitrosating agent and
appears to maintain an equilibrium with other S-nitrosated proteins
(Liu et al., Nature, 410:490-494 (2001)) within cells. Given this
pivotal position in the NO-SNO continuum, GSNO provides a
therapeutically promising target to consider when NO modulation is
pharmacologically warranted.
[0005] In light of this understanding of GSNO as a key regulator of
NO homeostasis and cellular SNO levels, studies have focused on
examining endogenous production of GSNO and SNO proteins, which
occurs downstream from the production of the NO radical by the
nitric oxide synthetase (NOS) enzymes. More recently there has been
an increasing understanding of enzymatic catabolism of GSNO which
has an important role in governing available concentrations of GSNO
and consequently available NO and SNO's.
[0006] Central to this understanding of GSNO catabolism,
researchers have recently identified a highly conserved
S-nitrosoglutathione reductase (GSNOR) (Jensen et al., Biochem J.,
331:659-668 (1998); Liu et al., (2001)). GSNOR is also known as
glutathione-dependent formaldehyde dehydrogenase (GSH-FDH), alcohol
dehydrogenase 3 (ADH-3) (Uotila and Koivusalo, Coenzymes and
Cofactors., D. Dolphin, ed. pp. 517-551 (New York, John Wiley &
Sons, (1989)), and alcohol dehydrogenase 5 (ADH-5). Importantly
GSNOR shows greater activity toward GSNO than other substrates
(Jensen et al., (1998); Liu et al., (2001)) and appears to mediate
important protein and peptide denitrosating activity in bacteria,
plants, and animals. GSNOR appears to be the major
GSNO-metabolizing enzyme in eukaryotes (Liu et al., (2001)). Thus,
GSNO can accumulate in biological compartments where GSNOR activity
is low or absent (e.g., airway lining fluid) (Gaston et al.,
(1993)).
[0007] Yeast deficient in GSNOR accumulate S-nitrosylated proteins
which are not substrates of the enzyme, which is strongly
suggestive that GSNO exists in equilibrium with SNO-proteins (Liu
et al., (2001)). Precise enzymatic control over ambient levels of
GSNO and thus SNO-proteins raises the possibility that GSNO/GSNOR
may play roles across a host of physiological and pathological
functions including protection against nitrosative stress wherein
NO is produced in excess of physiologic needs. Indeed, GSNO
specifically has been implicated in physiologic processes ranging
from the drive to breathe (Lipton et al., Nature, 413:171-174
(2001)) to regulation of the cystic fibrosis transmembrane
regulator (Zaman et al., Biochem Biophys Res Commun, 284:65-70
(2001)), to regulation of vascular tone, thrombosis, and platelet
function (de Belder et al., Cardiovasc Res.; 28(5):691-4 (1994)),
Z. Kaposzta, et al., Circulation; 106(24): 3057-3062, (2002)) as
well as host defense (de Jesus-Berrios et al., Curr. Biol.,
13:1963-1968 (2003)). Other studies have found that GSNOR protects
yeast cells against nitrosative stress both in vitro (Liu et al.,
(2001)) and in vivo (de Jesus-Berrios et al., (2003)).
[0008] Collectively, data suggest GSNO as a primary physiological
ligand for the enzyme S-nitrosoglutathione reductase (GSNOR), which
catabolizes GSNO and consequently reduces available SNO's and NO in
biological systems (Liu et al., (2001)), (Liu et al., Cell, 116(4),
617-628 (2004)), and (Que et al., Science, 308, (5728):1618-1621
(2005)). As such, this enzyme plays a central role in regulating
local and systemic bioactive NO. Since perturbations in NO
bioavailability has been linked to the pathogenesis of numerous
disease states, including hypertension, atherosclerosis,
thrombosis, asthma, gastrointestinal disorders, inflammation, and
cancer, agents that regulate GSNOR activity are candidate
therapeutic agents for treating diseases associated with NO
imbalance.
[0009] Nitric oxide (NO), S-nitrosoglutathione (GSNO), and
S-nitrosoglutathione reductase (GSNOR) regulate normal lung
physiology and contribute to lung pathophysiology. Under normal
conditions, NO and GSNO maintain normal lung physiology and
function via their anti-inflammatory and bronchodilatory actions.
Lowered levels of these mediators in pulmonary diseases such as
asthma, chronic obstructive pulmonary disease (COPD) may occur via
up-regulation of GSNOR enzyme activity. These lowered levels of NO
and GSNO, and thus lowered anti-inflammatory capabilities, are key
events that contribute to pulmonary diseases and which can
potentially be reversed via GSNOR inhibition.
[0010] S-nitrosoglutathione (GSNO) has been shown to promote repair
and/or regeneration of mammalian organs, such as the heart (Lima et
al., 2010), blood vessels (Lima et al., 2010) skin (Georgii et al.,
2010), eye or ocular structures (Haq et al., 2007) and liver
(Prince et al., 2010). S-nitrosoglutathione reductase (GSNOR) is
the major catabolic enzyme of GSNO. Inhibition of GSNOR is thought
to increase endogenous GSNO.
[0011] Inflammatory bowel diseases (IBD's), including Crohn's and
ulcerative colitis, are chronic inflammatory disorders of the
gastrointestinal (GI) tract, in which NO, GSNO, and GSNOR can exert
influences. Under normal conditions, NO and GSNO function to
maintain normal intestinal physiology via anti-inflammatory actions
and maintenance of the intestinal epithelial cell barrier. In IBD,
reduced levels of GSNO and NO are evident and likely occur via
up-regulation of GSNOR activity. The lowered levels of these
mediators contribute to the pathophysiology of IBD via disruption
of the epithelial barrier via dysregulation of proteins involved in
maintaining epithelial tight junctions. This epithelial barrier
dysfunction, with the ensuing entry of micro-organisms from the
lumen, and the overall lowered anti-inflammatory capabilities in
the presence of lowered NO and GSNO, are key events in IBD
progression that can be potentially influenced by targeting
GSNOR.
[0012] Cell death is the crucial event leading to clinical
manifestation of hepatotoxicity from drugs, viruses and alcohol.
Glutathione (GSH) is the most abundant redox molecule in cells and
thus the most important determinant of cellular redox status.
Thiols in proteins undergo a wide range of reversible redox
modifications during times of exposure to reactive oxygen and
reactive nitrogen species, which can affect protein activity. The
maintenance of hepatic GSH is a dynamic process achieved by a
balance between rates of GSH synthesis, GSH and GSSG efflux, GSH
reactions with reactive oxygen species and reactive nitrogen
species and utilization by GSH peroxidase. Both GSNO and GSNOR play
roles in the regulation of protein redox status by GSH.
[0013] Acetaminophen overdoses are the leading cause of acute liver
failure (ALF) in the United States, Great Britain and most of
Europe. More than 100,000 calls to the U.S. Poison Control Centers,
56,000 emergency room visits, 2600 hospitalizations, nearly 500
deaths are attributed to acetaminophen in this country annually.
Approximately, 60% recover without needing a liver transplant, 9%
are transplanted and 30% of patients succumb to the illness. The
acetaminophen-related death rate exceeds by at least three-fold the
number of deaths due to all other idiosyncratic drug reactions
combined (Lee, Hepatol Res 2008; 38 (Suppl. 1):S3-S8).
[0014] Liver transplantation has become the primary treatment for
patients with fulminant hepatic failure and end-stage chronic liver
disease, as well as certain metabolic liver diseases. Thus, the
demand for transplantation now greatly exceeds the availability of
donor organs. It has been estimated that more than 18 000 patients
are currently registered with the United Network for Organ Sharing
(LINOS) and that an additional 9000 patients are added to the liver
transplant waiting list each year, yet less than 5000 cadaveric
donors are available for transplantation.
[0015] Currently, there is a great need in the art for diagnostics,
prophylaxis, ameliorations, and treatments for medical conditions
relating to increased NO synthesis and/or increased NO bioactivity.
In addition, there is a significant need for novel compounds,
compositions, and methods for preventing, ameliorating, or
reversing other NO-associated disorders. The present invention
satisfies these needs.
SUMMARY
[0016] The present invention provides novel bicyclic aromatic
compounds. These compounds are useful as S-nitrosoglutathione
reductase ("GSNOR") inhibitors. The invention encompasses
pharmaceutically acceptable salts, stereoisomers, prodrugs,
metabolites, and N-oxides of the described compounds. Also
encompassed by the invention are pharmaceutical compositions
comprising at least one compound of the invention and at least one
pharmaceutically acceptable carrier.
[0017] The compositions of the present invention can be prepared in
any suitable pharmaceutically acceptable dosage form.
[0018] The present invention provides a method for inhibiting GSNOR
in a subject in need thereof. Such a method comprises administering
a therapeutically effective amount of a pharmaceutical composition
comprising at least one GSNOR inhibitor or a pharmaceutically
acceptable salt, stereoisomer, prodrug, metabolite or N-oxide
thereof, in combination with at least one pharmaceutically
acceptable carrier. The GSNOR inhibitor can be a novel compound
according to the invention, or it can be a known compound which
previously was not known to be an inhibitor of GSNOR.
[0019] The present invention also provides a method of treating a
disorder ameliorated by NO donor therapy in a subject in need
thereof. Such a method comprises administering a therapeutically
effective amount of a pharmaceutical composition comprising at
least one GSNOR inhibitor or a pharmaceutically acceptable salt,
stereoisomer, prodrug, metabolite, or N-oxide thereof, in
combination with at least one pharmaceutically acceptable carrier.
The GSNOR inhibitor can be a novel compound according to the
invention, or it can be a known compound which previously was not
known to be an inhibitor of GSNOR.
[0020] The present invention also provides a method of treating a
cell proliferative disorder in a subject in need thereof. Such a
method comprises administering a therapeutically effective amount
of a pharmaceutical composition comprising at least one GSNOR
inhibitor or a pharmaceutically acceptable salt, stereoisomer,
prodrug, metabolite, or N-oxide thereof, in combination with at
least one pharmaceutically acceptable carrier. The GSNOR inhibitor
can be a novel compound according to the invention, or it can be a
known compound which previously was not known to be an inhibitor of
GSNOR.
[0021] The methods of the invention encompass administration with
one or more secondary active agents. Such administration can be
sequential or in a combination composition.
[0022] Although methods and materials similar or equivalent to
those described herein can be used in the practice or testing of
the present invention, suitable methods and materials are described
below. All publicly available publications, patent applications,
patents, and other references mentioned herein are incorporated by
reference in their entirety. In the case of conflict, the present
specification, including definitions, will control.
[0023] Both the foregoing summary and the following detailed
description are exemplary and explanatory and are intended to
provide further details of the compositions and methods as claimed.
Other objects, advantages, and novel features will be readily
apparent to those skilled in the art from the following detailed
description.
DETAILED DESCRIPTION
[0024] A. Overview of the Invention
[0025] Until recently, S-nitrosoglutathione reductase (GSNOR) was
known to oxidize the formaldehyde glutathione adduct,
S-hydroxymethylglutathione. GSNOR has since been identified in a
variety of bacteria, yeasts, plants, and animals and is well
conserved. The proteins from E. coli, S. cerevisiae and mouse
macrophages share over 60% amino acid sequence identity. GSNOR
activity (i.e., decomposition of GSNO when NADH is present as a
required cofactor) has been detected in E. coli, in mouse
macrophages, in mouse endothelial cells, in mouse smooth muscle
cells, in yeasts, and in human HeLa, epithelial, and monocyte
cells. Human GSNOR nucleotide and amino acid sequence information
can be obtained from the National Center for Biotechnology
Information (NCBI) databases under Accession Nos. M29872,
NM_000671. Mouse GSNOR nucleotide and amino acid sequence
information can be obtained from NCBI databases under Accession
Nos. NM_007410. In the nucleotide sequence, the start site and stop
site are underlined. CDS designates coding sequence. SNP designates
single nucleotide polymorphism. Other related GSNOR nucleotide and
amino acid sequences, including those of other species, can be
found in U.S. Patent Application 2005/0014697.
[0026] In accord with the present invention, GSNOR has been shown
to function in vivo and in vitro to metabolize S-nitrosoglutathione
(GSNO) and protein S-nitrosothiols (SNOs) to modulate NO
bioactivity, by controlling the intracellular levels of low mass NO
donor compounds and preventing protein nitrosylation from reaching
toxic levels.
[0027] Based on this, it follows that inhibition of this enzyme
potentiates bioactivity in diseases in which NO donor therapy is
indicated, inhibits the proliferation of pathologically
proliferating cells, and increases NO bioactivity in diseases where
this is beneficial.
[0028] The present invention provides pharmaceutical agents that
are potent inhibitors of GSNOR. In particular, provided are
substituted bicyclic aromatic analogs having the structures
depicted below (Formula I), or a pharmaceutically acceptable salt,
stereoisomer, prodrug, metabolite, or N-oxide thereof.
##STR00001##
wherein [0029] Z.sub.1 is selected from the group consisting of
CR.sub.2a and N; [0030] Z.sub.2 is selected from the group
consisting of CR.sub.2b and N; [0031] Z.sub.3 is selected from the
group consisting of CR.sub.2c and N; [0032] with the proviso that
at least 1 of Z.sub.1, Z.sub.2, or Z.sub.3 must be N; [0033] m is
selected from the group consisting of 0, 1, 2, or 3; [0034] R.sub.1
is independently selected from the group consisting of chloro,
fluoro, and bromo; [0035] R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0036] X is
selected from the group consisting of
[0036] ##STR00002## [0037] n is selected from 0, 1, and 2; [0038]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; [0039] A is selected from
the group consisting of
##STR00003##
[0040] As used in this context, the term "analog" refers to a
compound having similar chemical structure and function as
compounds of Formula I that retains the bicyclic aromatic ring.
[0041] Some bicyclic aromatic analogs of the invention can also
exist in various isomeric forms, including configurational,
geometric, and conformational isomers, as well as existing in
various tautomeric forms, particularly those that differ in the
point of attachment of a hydrogen atom. As used herein, the term
"isomer" is intended to encompass all isomeric forms of a compound
including tautomeric forms of the compound.
[0042] Illustrative compounds having asymmetric centers can exist
in different enantiomeric and diastereomeric forms. A compound can
exist in the form of an optical isomer or a diastereomer.
Accordingly, the invention encompasses compounds in the forms of
their optical isomers, diastereomers and mixtures thereof,
including racemic mixtures.
[0043] It should be noted that if there is a discrepancy between a
depicted structure and a name given to that structure, the depicted
structure controls. In addition, if the stereochemistry of a
structure or a portion of a structure is not indicated with, for
example, bold, wedged, or dashed lines, the structure or portion of
the structure is to be interpreted as encompassing all
stereoisomers of the described compound.
[0044] B. S-Nitrosoglutathione Reductase Inhibitors
[0045] 1. Inventive Compounds
[0046] In one of its aspects the present invention provides
compounds having the structure shown in Formula I, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00004##
wherein [0047] Z.sub.1 is selected from the group consisting of
CR.sub.2a and N; [0048] Z.sub.2 is selected from the group
consisting of CR.sub.2b and N; [0049] Z.sub.3 is selected from the
group consisting of CR.sub.2c and N; [0050] with the proviso that
at least 1 of Z.sub.1, Z.sub.2, or Z.sub.3 must be N; [0051] m is
selected from the group consisting of 0, 1, 2, or 3; [0052] R.sub.1
is independently selected from the group consisting of chloro,
fluoro, and bromo; [0053] R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0054] X is
selected from the group consisting of
[0054] ##STR00005## [0055] n is selected from 0, 1, and 2; [0056]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4', where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0057] A is selected
from the group consisting of
##STR00006##
[0058] In a further aspect of the invention wherein when Z.sub.1
and Z.sub.2 are both N, and Z.sub.3 is CR.sub.2c, then R.sub.2c is
selected from the group consisting of hydrogen, C.sub.1-C.sub.3
alkyl, fluorinated C.sub.1-C.sub.3 alkyl, and cyano.
[0059] In a further aspect of the invention, m is selected from the
group consisting of 0 and 1; R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and
N(CH.sub.3).sub.2; n is selected from the group consisting of 0 and
1; and R.sub.3 is independently selected from the group consisting
of fluoro, chloro, methyl, trifluoromethyl, cyano, methoxy, and
NR.sub.4R.sub.4'where R.sub.4 and R.sub.4' are methyl, or
alternatively together with the said N form the ring aziridin-1-yl
or morpholino.
[0060] In a further aspect of the invention, X is
##STR00007##
[0061] In a further aspect of the invention, A is COOH.
[0062] In one of its aspects the present invention provides a
compound having a structure shown in Formula II, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00008##
wherein [0063] Z.sub.2 is selected from the group consisting of
CR.sub.2b and N; [0064] Z.sub.3 is selected from the group
consisting of CR.sub.2c and N; [0065] m is selected from the group
consisting of 0, 1, 2, or 3; [0066] R.sub.1 is independently
selected from the group consisting of chloro, fluoro, and bromo;
[0067] R.sub.2b and R.sub.2c are independently selected from the
group consisting of hydrogen, halogen, C.sub.1-C.sub.3 alkyl,
fluorinated C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy,
and N(CH.sub.3).sub.2; [0068] X is selected from the group
consisting of
[0068] ##STR00009## [0069] n is selected from 0, 1, and 2; [0070]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0071] A is selected
from the group consisting of
##STR00010##
[0072] In a further aspect of the invention, when Z.sub.2 of
Formula II is N and Z.sub.3 is CR.sub.2c, then R.sub.2c is selected
from the group consisting of hydrogen, C.sub.1-C.sub.3 alkyl,
fluorinated C.sub.1-C.sub.3 alkyl, and cyano.
[0073] In a further aspect of the invention, m of Formula II is
selected from the group consisting of 0 and 1; R.sub.2a, R.sub.2b,
and R.sub.2c, are independently selected from the group consisting
of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano,
methoxy, and N(CH.sub.3).sub.2; [0074] n is selected from the group
consisting of 0 and 1; and R.sub.3 is independently selected from
the group consisting of fluoro, chloro, methyl, trifluoromethyl,
cyano, methoxy, and NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are
methyl, or alternatively together with the said N form the ring
aziridin-1-yl or morpholino.
[0075] In one of its aspects the present invention provides a
compound having a structure shown in Formula III, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00011##
wherein [0076] Z.sub.2 is selected from the group consisting of
CR.sub.2b and N; [0077] Z.sub.3 is selected from the group
consisting of CR.sub.2c and N; [0078] with the proviso that at
least 1 of Z.sub.2 or Z.sub.3 must be N; [0079] m is selected from
the group consisting of 0, 1, 2, or 3; [0080] R.sub.1 is
independently selected from the group consisting of chloro, fluoro,
and bromo; [0081] R.sub.2a, R.sub.2b, and R.sub.2c, are
independently selected from the group consisting of hydrogen,
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0082] X is
selected from the group consisting of
[0082] ##STR00012## [0083] n is selected from 0, 1, and 2; [0084]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0085] A is selected
from the group consisting of
##STR00013##
[0086] In one of its aspects the present invention provides a
compound having a structure shown in Formula IV, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00014##
wherein [0087] m is selected from the group consisting of 0, 1, 2,
or 3; [0088] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0089] R.sub.2b and
R.sub.2c are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; [0090] X is selected from the group consisting
of
[0090] ##STR00015## [0091] n is selected from 0, 1, and 2; [0092]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0093] A is selected
from the group consisting of
##STR00016##
[0094] In a further aspect of the invention, m of Formula IV is
selected from the group consisting of 0 and 1; R.sub.2a, R.sub.2b,
and R.sub.2c, are independently selected from the group consisting
of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano,
methoxy, and N(CH.sub.3).sub.2; [0095] n is selected from the group
consisting of 0 and 1; and R.sub.3 is independently selected from
the group consisting of fluoro, chloro, methyl, trifluoromethyl,
cyano, methoxy, and NR.sub.4R.sub.4' where R.sub.4 and R.sub.4' are
methyl, or alternatively together with the said N form the ring
aziridin-1-yl or morpholino.
[0096] In a further aspect of the invention, X of Formula IV is
##STR00017##
[0097] In a further aspect of the invention, A of Formula IV is
COOH.
[0098] In a further aspect of the invention, suitable compounds of
Formula IV include, but are not limited to: [0099]
4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid; [0100]
2-(4-(1H-tetrazol-5-yl)phenyl)-3-methylquinolin-6-ol; [0101]
4-(6-hydroxyquinolin-2-yl)benzoic acid; [0102]
2-(4-(1H-tetrazol-5-yl)phenyl)quinolin-6-ol; [0103]
1-(6-hydroxyquinolin-2-yl)piperidine-4-carboxylic acid; [0104]
(1r,4r)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic acid;
[0105] (1s,4s)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid; [0106] 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid;
[0107] 2-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid; [0108]
2-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid; [0109]
2-(4-(2H-tetrazol-5-yl)phenyl)-4-chloroquinolin-6-ol; [0110]
3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(2H)-one;
[0111] 3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid; [0112]
4-(6-hydroxyquinolin-2-yl)-3-methoxybenzoic acid; [0113]
5-(6-hydroxyquinolin-2-yl)thiophene-2-carboxylic acid; [0114]
4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylic acid; [0115]
4-(3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid; [0116]
4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid; [0117]
4-(3-chloro-6-hydroxyquinolin-2-yl)benzoic acid; [0118]
3-(2-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one;
[0119]
3-(3-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H-
)-one; [0120] 4-(4-chloro-6-hydroxyquinolin-2-yl)benzoic acid;
[0121] 2-(2-chloro-4-(2H-tetrazol-5-yl)phenyl)quinolin-6-ol; [0122]
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one;
[0123] 3-(dimethylamino)-4-(6-hydroxyquinolin-2-yl)benzoic acid;
[0124] 4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid; [0125]
4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid; [0126]
4-(3-chloro-6-hydroxyquinolin-2-yl)-3-fluorobenzoic acid; [0127]
3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-5(2H)-one;
[0128] 4-(6-hydroxyquinolin-2-yl)-3-(trifluoromethyl)benzoic acid;
[0129] 4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)benzoic acid;
[0130] 2-(4-carboxyphenyl)-6-hydroxyquinoline 1-oxide; [0131]
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-thiadiazol-2(3H)-one;
[0132]
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-3(2H)-one;
[0133]
(1r,4r)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid; [0134]
(1s,4s)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid; [0135] 3-chloro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid; [0136] 2-(5-(2H-tetrazol-5-yl)thiophen-2-yl)quinolin-6-ol;
[0137]
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-3(2H)-one;
[0138] 3-fluoro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;
[0139]
1-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)piperidine-4-carboxylic
acid; [0140] 4-(5-chloro-6-hydroxyquinolin-2-yl)benzoic acid;
[0141]
(1r,4r)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid; [0142]
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid; [0143] 3-chloro-4-(5-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid; and [0144]
4-(5-fluoro-6-hydroxyquinolin-2-yl)-3-methylbenzoic acid.
[0145] In one of its aspects the present invention provides a
compound having a structure shown in Formula V, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00018##
wherein [0146] m is selected from the group consisting of 0, 1, 2,
or 3; [0147] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0148] R.sub.2c is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0149] X is selected
from the group consisting of
[0149] ##STR00019## [0150] n is selected from 0, 1, and 2; [0151]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0152] A is selected
from the group consisting of
##STR00020##
[0153] In a further aspect of the invention, R.sub.2c is selected
from the group consisting of hydrogen, C.sub.1-C.sub.3 alkyl,
fluorinated C.sub.1-C.sub.3 alkyl, and cyano.
[0154] In a further aspect of the invention, suitable compounds of
Formula V include, but are not limited to: [0155]
4-(6-hydroxyquinazolin-2-yl)benzoic acid; [0156]
4-(6-hydroxy-4-methylquinazolin-2-yl)benzoic acid; [0157]
3-chloro-4-(6-hydroxyquinazolin-2-yl)benzoic acid; [0158]
4-(6-hydroxyquinazolin-2-yl)-3-methylbenzoic acid; [0159]
4-(6-hydroxyquinazolin-2-yl)-3-methoxybenzoic acid; [0160]
3-fluoro-4-(6-hydroxyquinazolin-2-yl)benzoic acid; and [0161]
1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylic acid.
[0162] In one of its aspects the present invention provides a
compound having a structure shown in Formula VI, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00021##
wherein [0163] m is selected from the group consisting of 0, 1, 2,
or 3; [0164] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0165] R.sub.2b is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0166] X is selected
from the group consisting of
[0166] ##STR00022## [0167] n is selected from 0, 1, and 2; [0168]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0169] A is selected
from the group consisting of
##STR00023##
[0170] In a further aspect of the invention, suitable compounds of
Formula VI include, but are not limited to: [0171]
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic acid;
[0172]
2-(4-(2H-tetrazol-5-yl)phenyl)-3-(trifluoromethyl)quinoxalin-6-ol;
[0173]
1-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)piperidine-4-carboxylic
acid; [0174]
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohex-3-enecarboxylic
acid; [0175]
3-chloro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid; [0176] 4-(6-hydroxyquinoxalin-2-yl)benzoic acid; [0177]
3-fluoro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid; [0178]
(1r,4r)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexan-
ecarboxylic acid; and [0179]
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarbox-
ylic acid.
[0180] In one of its aspects the present invention provides a
compound having a structure shown in Formula VII, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00024##
wherein [0181] m is selected from the group consisting of 0, 1, 2,
or 3; [0182] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0183] X is selected from
the group consisting of
[0183] ##STR00025## [0184] n is selected from 0, 1, and 2; [0185]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0186] A is selected
from the group consisting of
##STR00026##
[0187] In a further aspect of the invention, suitable compounds of
Formula VII include, but are not limited to: [0188]
3-(4-carboxyphenyl)-7-hydroxybenzo[e][1,2,4]triazine 1-oxide;
[0189] 4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic acid; [0190]
3-(4-carboxy-2-fluorophenyl)-7-hydroxybenzo[e][1,2,4]triazine
1-oxide; and [0191]
3-fluoro-4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic acid.
[0192] In one of its aspects the present invention provides a
compound having a structure shown in Formula VIII, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00027##
wherein [0193] m is selected from the group consisting of 0, 1, 2,
or 3; [0194] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0195] R.sub.2a and
R.sub.2c are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; [0196] X is selected from the group consisting
of
[0196] ##STR00028## [0197] n is selected from 0, 1, and 2; [0198]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0199] A is selected
from the group consisting of
##STR00029##
[0200] In a further aspect of the invention, a suitable compound of
Formula VIII includes, but is not limited to: [0201]
4-(7-hydroxyisoquinolin-3-yl)benzoic acid; [0202]
3-fluoro-4-(7-hydroxyisoquinolin-3-yl)benzoic acid; and [0203]
4-(7-hydroxy-4-methylisoquinolin-3-yl)benzoic acid.
[0204] In one of its aspects the present invention provides a
compound having a structure shown in Formula IX, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00030##
wherein [0205] m is selected from the group consisting of 0, 1, 2,
or 3; [0206] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0207] R.sub.2a and
R.sub.2b are independently selected from the group consisting of
hydrogen, halogen, C.sub.1-C.sub.3 alkyl, fluorinated
C.sub.1-C.sub.3 alkyl, cyano, C.sub.1-C.sub.3 alkoxy, and
N(CH.sub.3).sub.2; [0208] X is selected from the group consisting
of
[0208] ##STR00031## [0209] n is selected from 0, 1, and 2; [0210]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; and [0211] A is selected
from the group consisting of
##STR00032##
[0212] In a further aspect of the invention, suitable compounds of
Formula IX include, but are not limited to: [0213]
4-(7-hydroxyquinolin-3-yl)benzoic acid; and [0214]
3-(4-carboxyphenyl)-7-hydroxyquinoline 1-oxide.
[0215] In one of its aspects the present invention provides a
compound having a structure shown in Formula X, or a
pharmaceutically acceptable salt, stereoisomer, prodrug,
metabolite, or N-oxide thereof:
##STR00033##
wherein [0216] m is selected from the group consisting of 0, 1, 2,
or 3; [0217] R.sub.1 is independently selected from the group
consisting of chloro, fluoro, and bromo; [0218] R.sub.2a is
selected from the group consisting of hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl, cyano,
C.sub.1-C.sub.3 alkoxy, and N(CH.sub.3).sub.2; [0219] X is selected
from the group consisting of
[0219] ##STR00034## [0220] n is selected from 0, 1, and 2; [0221]
R.sub.3 is independently selected from the group consisting of
halogen, C.sub.1-C.sub.3 alkyl, fluorinated C.sub.1-C.sub.3 alkyl,
cyano, C.sub.1-C.sub.3 alkoxy, and NR.sub.4R.sub.4' where R.sub.4
and R.sub.4' are independently selected from the group consisting
of C.sub.1-C.sub.3 alkyl, or R.sub.4 when taken together with
R.sub.4' form a ring with 3 to 6 members; [0222] A is selected from
the group consisting of
##STR00035##
[0223] When a bond to a substituent is shown to cross a bond
connecting two atoms in a ring, then such substituent may be bonded
to any atom in the ring. When a substituent is listed without
indicating the atom via which such substituent is bonded to the
rest of the compound of a given formula, then such substituent may
be bonded via any atom in such substituent. Combinations of
substituents and/or variables are permissible, but only if such
combinations result in stable compounds.
[0224] The compounds described herein may have asymmetric centers.
Compounds of the present invention containing an asymmetrically
substituted atom may be isolated in optically active or racemic
forms. It is well known in the art how to prepare optically active
forms, such as by resolution of racemic forms or by synthesis from
optically active starting materials. Many geometric isomers of
olefins, C.dbd.N double bonds, and the like can also be present in
the compounds described herein, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms. All chiral, diastereomeric, racemic, and geometric isomeric
forms of a structure are intended, unless the specific
stereochemistry or isomeric form is specifically indicated. All
tautomers of shown or described compounds are also considered to be
part of the present invention.
[0225] It is to be understood that isomers arising from such
asymmetry (e.g., all enantiomers and diastereomers) are included
within the scope of the invention, unless indicated otherwise. Such
isomers can be obtained in substantially pure form by classical
separation techniques and by stereochemically controlled synthesis.
Furthermore, the structures and other compounds and moieties
discussed in this application also include all tautomers thereof.
Alkenes can include either the E- or Z-geometry, where
appropriate.
[0226] 2. Representative Compounds
[0227] Examples 1-71 list representative novel substituted bicyclic
aromatic analogs of the invention. The synthetic methods that can
be used to prepare each compound are detailed in Examples 1-71,
with reference to the synthetic schemes depicted before Example 1,
and reference to intermediates described in Example 72. Supporting
mass spectrometry data and/or proton NMR data for each compound is
also included in Examples 1-71. GSNOR inhibitor activity was
determined by the assay described in Example 73 and IC.sub.50
values were obtained. GSNOR inhibitor compounds in Examples 1-71
had an IC.sub.50 of about <10 .mu.M. GSNOR inhibitor compounds
in Examples 1-4, 6, 8, 10-14, 16-35, 37-43, 45, 47-50, 52-62,
65-68, 70-71 had an IC.sub.50 of about <0.5 .mu.M. GSNOR
inhibitor compounds in Examples 1-4, 8, 10-14, 17-28, 30, 31, 37,
40-41, 43, 45, 47-50, 52-58, 60-61, 65, 67-68, and 70-71 had an
IC.sub.50 of about <0.1 .mu.M.
[0228] C. Definitions
[0229] As used herein, "about" will be understood by persons of
ordinary skill in the art and will vary to some extent on the
context in which it is used. If there are uses of the term which
are not clear to persons of ordinary skill in the art given the
context in which it is used, "about" will mean up to plus or minus
10% of the particular term.
[0230] The term "acyl" includes compounds and moieties that contain
the acetyl radical (CH.sub.3CO--) or a carbonyl group to which a
straight or branched chain lower alkyl residue is attached.
[0231] The term "alkyl" as used herein refers to a straight or
branched chain, saturated hydrocarbon having the indicated number
of carbon atoms. For example, (C.sub.1-C.sub.6) alkyl is meant to
include, but is not limited to methyl, ethyl, propyl, isopropyl,
butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl,
isohexyl, and neohexyl. An alkyl group can be unsubstituted or
optionally substituted with one or more substituents as described
herein.
[0232] The term "alkenyl" as used herein refers to a straight or
branched chain unsaturated hydrocarbon having the indicated number
of carbon atoms and at least one double bond. Examples of a
(C.sub.2-C.sub.8) alkenyl group include, but are not limited to,
ethylene, propylene, 1-butylene, 2-butylene, isobutylene,
sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 2-hexene,
3-hexene, isohexene, 1-heptene, 2-heptene, 3-heptene, isoheptene,
1-octene, 2-octene, 3-octene, 4-octene, and isooctene. An alkenyl
group can be unsubstituted or optionally substituted with one or
more substituents as described herein.
[0233] The term "alkynyl" as used herein refers to a straight or
branched chain unsaturated hydrocarbon having the indicated number
of carbon atoms and at least one triple bond. Examples of a
(C.sub.2-C.sub.8) alkynyl group include, but are not limited to,
acetylene, propyne, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne,
1-hexyne, 2-hexyne, 3-hexyne, 1-heptyne, 2-heptyne, 3-heptyne,
1-octyne, 2-octyne, 3-octyne, and 4-octyne. An alkynyl group can be
unsubstituted or optionally substituted with one or more
substituents as described herein.
[0234] The term "alkoxy" as used herein refers to an --O-alkyl
group having the indicated number of carbon atoms. For example, a
(C.sub.1-C.sub.6) alkoxy group includes --O-methyl, --O-ethyl,
--O-propyl, --O-isopropyl, --O-butyl, --O-sec-butyl,
--O-tert-butyl, --O-pentyl, --O-isopentyl, --O-neopentyl,
--O-hexyl, --O-isohexyl, and --O-neohexyl.
[0235] The term "aminoalkyl" as used herein, refers to an alkyl
group (typically one to six carbon atoms) wherein one or more of
the C.sub.1-C.sub.6 alkyl group's hydrogen atoms is replaced with
an amine of formula --N(R.sup.c).sub.2, wherein each occurrence of
R.sup.c is independently --H or (C.sub.1-C.sub.6) alkyl. Examples
of aminoalkyl groups include, but are not limited to,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2N(CH.sub.3).sub.2, t-butylaminomethyl,
isopropylaminomethyl, and the like.
[0236] The term "aryl" as used herein refers to a 5- to 14-membered
monocyclic, bicyclic, or tricyclic aromatic ring system. Examples
of an aryl group include phenyl and naphthyl. An aryl group can be
unsubstituted or optionally substituted with one or more
substituents as described herein below. Examples of aryl groups
include phenyl or aryl heterocycles such as, pyrrole, furan,
thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole,
pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and
pyrimidine, and the like.
[0237] As used herein, the term "bioactivity" indicates an effect
on one or more cellular or extracellular process (e.g., via
binding, signaling, etc.) which can impact physiological or
pathophysiological processes.
[0238] The term "carbonyl" includes compounds and moieties which
contain a carbon connected with a double bond to an oxygen atom.
Examples of moieties containing a carbonyl include, but are not
limited to, aldehydes, ketones, carboxylic acids, amides, esters,
anhydrides, etc.
[0239] The term "carboxy" or "carboxyl" means a --COOH group or
carboxylic acid.
[0240] "Acidic moiety" as used herein is defined as a carboxylic
acid or a carboxylic acid bioisostere. Bioisosteres are
substituents or groups with similar physical or chemical properties
which produce broadly similar biological properties to a chemical
compound. For a review of bioisosteres, see J. Med. Chem, 2011, 54,
2529-2591. Examples of "acidic moiety" include but are not limited
to
##STR00036##
[0241] "Pharmacophore" is defined as "a set of structural features
in a molecule that is recognized at a receptor site and is
responsible for that molecule's biological activity" (Gund, Prog.
Mol. Subcell. Biol., 5: pp 117-143 (1977)).
[0242] The term "C.sub.m-C.sub.n" means "m" number of carbon atoms
to "n" number of carbon atoms. For example, the term
"C.sub.1-C.sub.6" means one to six carbon atoms (C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, or C.sub.6). The term "C.sub.2-C.sub.6"
includes two to six carbon atoms (C.sub.2, C.sub.3, C.sub.4,
C.sub.5, or C.sub.6). The term "C.sub.3-C.sub.6" includes three to
six carbon atoms (C.sub.3, C.sub.4, C.sub.5, or C.sub.6).
[0243] The term "cycloalkyl" as used herein refers to a 3- to
14-membered saturated or unsaturated non-aromatic monocyclic,
bicyclic, or tricyclic hydrocarbon ring system. Included in this
class are cycloalkyl groups which are fused to a benzene ring.
Representative cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl,
cyclopentadienyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadienyl,
cycloheptyl, cycloheptenyl, 1,3-cycloheptadienyl,
1,4-cycloheptadienyl, -1,3,5-cycloheptatrienyl, cyclooctyl,
cyclooctenyl, 1,3-cyclooctadienyl, 1,4-cyclooctadienyl,
-1,3,5-cyclooctatrienyl, decahydronaphthalene,
octahydronaphthalene, hexahydronaphthalene, octahydroindene,
hexahydroindene, tetrahydroinden, decahydrobenzocycloheptene,
octahydrobenzocycloheptene, hexahydrobenzocycloheptene,
tetrahydrobenzocyclopheptene, dodecahydroheptalene,
decahydroheptalene, octahydroheptalene, hexahydroheptalene,
tetrahydroheptalene, (1s,3s)-bicyclo[1.1.0]butane,
bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, Bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane,
bicyclo[3.3.1]nonane, bicyclo[3.3.2]decane, bicyclo [3.3.]undecane,
bicyclo[4.2.2]decane, and bicyclo[4.3.1]decane. A cycloalkyl group
can be unsubstituted or optionally substituted with one or more
substituents as described herein below.
[0244] The term "halogen" includes fluorine, bromine, chlorine,
iodine, etc.
[0245] The term "haloalkyl," as used herein, refers to a
C.sub.1-C.sub.6 alkyl group wherein from one or more of the
C.sub.1-C.sub.6 alkyl group's hydrogen atom is replaced with a
halogen atom, which can be the same or different. Examples of
haloalkyl groups include, but are not limited to, trifluoromethyl,
2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl,
pentachloroethyl, and 1,1,1-trifluoro-2-bromo-2-chloroethyl.
[0246] The term "heteroalkyl," by itself or in combination with
another term, means, unless otherwise stated, a stable straight or
branched chain alkyl, or combinations thereof, consisting of carbon
atoms and from one to three heteroatoms selected from the group
consisting of O, N, and S, and wherein the nitrogen and sulfur
atoms may optionally be oxidized and the nitrogen heteroatom may
optionally be quaternized. The heteroatom(s) O, N, and S can be
placed at any position of the heteroalkyl group. Examples include
--CH.sub.2--CH.sub.2--O--CH.sub.3,
--CH.sub.2--CH.sub.2--NH--CH.sub.3,
--CH.sub.2--CH.sub.2--N(CH.sub.3)--CH.sub.3,
--CH.sub.2--S--CH.sub.2--CH.sub.3,
--CH.sub.2--CH.sub.2--S(O)--CH.sub.3,
--CH.sub.2--CH.sub.2--S(O).sub.2--CH.sub.3, and
--CH.sub.2--CH.dbd.N--OCH.sub.3. Up to two heteroatoms can be
consecutive, for example, --CH.sub.2--NH--OCH.sub.3. When a prefix
such as (C.sub.2-C.sub.8) is used to refer to a heteroalkyl group,
the number of carbons (2 to 8, in this example) is meant to include
the heteroatoms as well. For example, a C.sub.2-heteroalkyl group
is meant to include, for example, --CH.sub.2OH (one carbon atom and
one heteroatom replacing a carbon atom) and --CH.sub.2SH.
[0247] To further illustrate the definition of a heteroalkyl group,
where the heteroatom is oxygen, a heteroalkyl group can be an
oxyalkyl group. For instance, (C.sub.2-C.sub.5) oxyalkyl is meant
to include, for example --CH.sub.2--O--CH.sub.3 (a C.sub.3-oxyalkyl
group with two carbon atoms and one oxygen replacing a carbon
atom), --CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH,
--OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH,
--OCH.sub.2CH(OH)CH.sub.2OH, and the like.
[0248] The term "heteroaryl" as used herein refers to an aromatic
heterocycle ring of 5 to 14 members and having at least one
heteroatom selected from nitrogen, oxygen, and sulfur, and
containing at least 1 carbon atom, including monocyclic, bicyclic,
and tricyclic ring systems. Representative heteroaryls are
triazolyl, tetrazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl,
thienyl, benzothienyl, quinolinyl, pyrrolyl, indolyl, oxazolyl,
benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl,
benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl,
pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl,
quinazolinyl, pyrimidyl, azepinyl, oxepinyl, quinoxalinyl and
oxazolyl. A heteroaryl group can be unsubstituted or optionally
substituted with one or more substituents as described herein
below.
[0249] As used herein, the term "heteroatom" is meant to include
oxygen (O), nitrogen (N), and sulfur (S).
[0250] As used herein, the term "heterocycle" refers to 3- to
14-membered ring systems which are either saturated, unsaturated,
or aromatic, and which contains from 1 to 4 heteroatoms
independently selected from nitrogen, oxygen, and sulfur, and
wherein the nitrogen and sulfur heteroatoms can be optionally
oxidized, and the nitrogen heteroatom can be optionally
quaternized, including monocyclic, bicyclic, and tricyclic ring
systems. The bicyclic and tricyclic ring systems may encompass a
heterocycle or heteroaryl fused to a benzene ring. The heterocycle
can be attached via any heteroatom or carbon atom, where chemically
acceptable. Heterocycles include heteroaryls as defined above.
Representative examples of heterocycles include, but are not
limited to, aziridinyl, oxiranyl, thiiranyl, triazolyl, tetrazolyl,
azirinyl, diaziridinyl, diazirinyl, oxaziridinyl, azetidinyl,
azetidinonyl, oxetanyl, thietanyl, piperidinyl, piperazinyl,
morpholinyl, pyrrolyl, oxazinyl, thiazinyl, diazinyl, dioxanyl,
triazinyl, tetrazinyl, imidazolyl, tetrazolyl, pyrrolidinyl,
isoxazolyl, furanyl, furazanyl, pyridinyl, oxazolyl, benzoxazolyl,
benzisoxazolyl, thiazolyl, benzthiazolyl, thienyl, pyrazolyl,
triazolyl, pyrimidinyl, benzimidazolyl, isoindolyl, indazolyl,
benzodiazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl,
purinyl, indolyl, isoquinolinyl, quinolinyl, and quinazolinyl. A
heterocycle group can be unsubstituted or optionally substituted
with one or more substituents as described herein below.
[0251] The term "heterocycloalkyl," by itself or in combination
with other terms, represents, unless otherwise stated, cyclic
versions of "heteroalkyl." Additionally, a heteroatom can occupy
the position at which the heterocycle is attached to the remainder
of the molecule. Examples of heterocycloalkyl include
1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl,
3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl,
tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl,
1-piperazinyl, 2-piperazinyl, and the like.
[0252] The term "hydroxyalkyl," as used herein, refers to an alkyl
group having the indicated number of carbon atoms wherein one or
more of the hydrogen atoms in the alkyl group is replaced with an
--OH group. Examples of hydroxyalkyl groups include, but are not
limited to, --CH.sub.2OH, --CH.sub.2CH.sub.2OH,
--CH.sub.2CH.sub.2CH.sub.2OH, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH, and branched
versions thereof.
[0253] The term "hydroxy" or "hydroxyl" includes groups with an
--OH or --O--.
[0254] As used herein, N-oxide, or amine oxide, refers to a
compound derived from a tertiary amine by the attachment of one
oxygen atom to the nitrogen atom, R.sub.3N.sup.+--O.sup.-. By
extension the term includes the analogous derivatives of primary
and secondary amines.
[0255] As used herein and unless otherwise indicated, the term
"stereoisomer" means one stereoisomer of a compound that is
substantially free of other stereoisomers of that compound. For
example, a stereomerically pure compound having one chiral center
will be substantially free of the opposite enantiomer of the
compound. A stereomerically pure compound having two chiral centers
will be substantially free of other diastereomers of the compound.
In some embodiments, a stereomerically pure compound comprises
greater than about 80% by weight of one stereoisomer of the
compound and less than about 20% by weight of other stereoisomers
of the compound, for example greater than about 90% by weight of
one stereoisomer of the compound and less than about 10% by weight
of the other stereoisomers of the compound, or greater than about
95% by weight of one stereoisomer of the compound and less than
about 5% by weight of the other stereoisomers of the compound, or
greater than about 97% by weight of one stereoisomer of the
compound and less than about 3% by weight of the other
stereoisomers of the compound.
[0256] As used herein, "protein" is used synonymously with
"peptide," "polypeptide," or "peptide fragment". A "purified"
polypeptide, protein, peptide, or peptide fragment is substantially
free of cellular material or other contaminating proteins from the
cell, tissue, or cell-free source from which the amino acid
sequence is obtained, or substantially free from chemical
precursors or other chemicals when chemically synthesized.
[0257] As used herein, "modulate" is meant to refer to an increase
or decrease in the levels of a peptide or a polypeptide, or to
increase or decrease the stability or activity of a peptide or a
polypeptide. The term "inhibit" is meant to refer to a decrease in
the levels of a peptide or a polypeptide or to a decrease in the
stability or activity of a peptide or a polypeptide. In preferred
embodiments, the peptide which is modulated or inhibited is
S-nitrosoglutathione (GSNO) or protein S-nitrosothiols (SNOs).
[0258] As used here, the terms "nitric oxide" and "NO" encompass
uncharged nitric oxide and charged nitric oxide species,
particularly including nitrosonium ion (NO.sup.+) and nitroxyl ion
(NO.sup.-). The reactive form of nitric oxide can be provided by
gaseous nitric oxide. Compounds having the structure X-NO.sub.y
wherein X is a nitric oxide releasing, delivering, or transferring
moiety, including any and all such compounds which provide nitric
oxide to its intended site of action in a form active for their
intended purpose, and Y is 1 or 2.
[0259] Repair" means recovering of structural integrity and normal
physiologic function. By way of example, the oral and upper airway
respiratory epithelium can repair damage done by thermal injury or
viral infection.
[0260] "Regeneration" means the ability of an organ to enter
non-malignant cellular, vascular and stromal growth to restore
functional organ tissue. By way of example, wound healing involves
regeneration of tissue and organs (e.g. skin, gastric and
intestinal mucosa), as does bone following fracture, and the liver
following partial surgical removal and exposure to infectious or
toxic insult.
[0261] As utilized herein, the term "pharmaceutically acceptable"
means approved by a regulatory agency of a federal or a state
government or listed in the U.S. Pharmacopoeia or other generally
recognized pharmacopoeia for use in animals and, more particularly,
in humans. The term "carrier" refers to a diluent, adjuvant,
excipient, or vehicle with which the therapeutic is administered
and includes, but is not limited to such sterile liquids as water
and oils.
[0262] A "pharmaceutically acceptable salt" or "salt" of a compound
of the invention is a product of the disclosed compound that
contains an ionic bond, and is typically produced by reacting the
disclosed compound with either an acid or a base, suitable for
administering to a subject. A pharmaceutically acceptable salt can
include, but is not limited to, acid addition salts including
hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen
sulphates, alkylsulphonates, arylsulphonates, arylalkylsulfonates,
acetates, benzoates, citrates, maleates, fumarates, succinates,
lactates, and tartrates; alkali metal cations such as Li, Na, and
K, alkali earth metal salts such as Mg or Ca, or organic amine
salts.
[0263] A "pharmaceutical composition" is a formulation comprising
the disclosed compounds in a form suitable for administration to a
subject. A pharmaceutical composition of the invention is
preferably formulated to be compatible with its intended route of
administration. Examples of routes of administration include, but
are not limited to, oral and parenteral, e.g., intravenous,
intradermal, subcutaneous, inhalation, topical, transdermal,
transmucosal, and rectal administration.
[0264] The term "substituted," as used herein, means that any one
or more hydrogens on the designated atom is replaced with a
selection from the indicated group, provided that the designated
atom's normal valency is not exceeded, and that the substitution
results in a stable compound. When a substituent is keto (i.e.,
.dbd.O), then 2 hydrogens on the atom are replaced. Ring double
bonds, as used herein, are double bonds that are formed between two
adjacent ring atoms (e.g., C.dbd.C, C.dbd.N, or N.dbd.N).
[0265] Substituents for the groups referred to as alkyl,
heteroalkyl, alkylene, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl can be
selected from a variety of groups including --OR.sup.d', .dbd.O,
.dbd.NR.sup.d', .dbd.N--OR.sup.d', --NR.sup.d'R.sup.d'',
--SR.sup.d', -halo, --SiR.sup.d'R.sup.d''R.sup.d''',
--OC(O)R.sup.d', --C(O)R.sup.d', --CO.sub.2R.sup.d',
--CONR.sup.d'R.sup.d'', --OC(O)NR.sup.d'R.sup.d'',
--NR.sup.d''C(O)R.sup.d', --NR.sup.d'''C(O)NR.sup.d'R.sup.d'',
--NR.sup.d'''SO.sub.2NR.sup.d'R.sup.d'',
--NR.sup.d''CO.sub.2R.sup.d', --NHC(NH.sub.2).dbd.NH,
--NR.sup.a'C(NH.sub.2).dbd.NH, --NHC(NH.sub.2).dbd.NR .sup.d',
--S(O)R.sup.d', --SO.sub.2R.sup.c', --SO.sub.2NR.sup.d'R.sup.d'',
--NR.sup.d''SO.sub.2R.sup.d', --CN, and --NO.sub.2, in a number
ranging from zero to three, with those groups having zero, one or
two substituents being exemplary.
[0266] R.sup.d', R.sup.d'', and R.sup.d''' each independently refer
to hydrogen, unsubstituted (C.sub.1-C.sub.8)alkyl, unsubstituted
hetero(C.sub.1-C.sub.8) alkyl, unsubstituted aryl, and aryl
substituted with one to three substituents selected from -halo,
unsubstituted alkyl, unsubstituted alkoxy, unsubstituted
thioalkoxy, and unsubstituted aryl (C.sub.1-C.sub.4)alkyl. When
R.sup.d' and R.sup.d'' are attached to the same nitrogen atom, they
can be combined with the nitrogen atom to form a 5- , 6-, or
7-membered ring. For example, --NR.sup.d'R.sup.d'' can represent
1-pyrrolidinyl or 4-morpholinyl.
[0267] Typically, an alkyl or heteroalkyl group will have from zero
to three substituents, with those groups having two or fewer
substituents being exemplary of the present invention. An alkyl or
heteroalkyl radical can be unsubstituted or monosubstituted. In
some embodiments, an alkyl or heteroalkyl radical will be
unsubstituted.
[0268] Exemplary substituents for the alkyl and heteroalkyl
radicals include, but are not limited to --OR.sup.d', .dbd.O,
.dbd.NR.sup.d', .dbd.N--OR.sup.d'', --NR.sup.d'R.sup.d'',
--SR.sup.d', -halo, --SiR.sup.d'R.sup.d''R.sup.d''',
--OC(O)R.sup.d', --C(O)R.sup.d', --CO.sub.2R.sup.d',
--CONR.sup.d'R.sup.d'', --OC(O)NR.sup.d'R.sup.d'',
--NR.sup.d''C(O)R.sup.d', --NR.sup.d'''C(O)NR.sup.d'R.sup.d'',
--NR.sup.d'''SO.sub.2NR.sup.d'R.sup.d'',
--NR.sup.d''CO.sub.2R.sup.d', --NHC(NH.sub.2).dbd.NH,
--NR.sup.a'C(NH.sub.2).dbd.NH, --NHC(NH.sub.2).dbd.NR.sup.d',
--S(O)R.sup.d', --SO.sub.2R.sup.d', --SO.sub.2NR.sup.d'R.sup.d'',
--NR.sup.d''SO.sub.2R.sup.d', --CN, and --NO.sub.2, where R.sup.d',
R.sup.d'', and R.sup.d''' are as defined above. Typical
substituents can be selected from: --OR.sup.d', .dbd.O,
--NR.sup.d'R.sup.d'', -halo, --OC(O)R.sup.d', --CO.sub.2R.sup.d',
--C(O)NR.sup.d'R.sup.d'', --OC(O)NR.sup.d'R.sup.d'',
--NR.sup.d''C(O)R.sup.d', --NR.sup.d''CO.sub.2R.sup.d',
--NR.sup.d'''SO.sub.2NR.sup.d'R.sup.d'', --SO.sub.2R.sup.d',
--SO.sub.2NR.sup.d'R.sup.d'', --NR.sup.d''SO.sub.2R.sup.d', --CN,
and --NO.sub.2.
[0269] Similarly, substituents for the aryl and heteroaryl groups
are varied and selected from: -halo, --OR.sup.e', --OC(O)R.sup.e',
--NR.sup.e'R.sup.e'', --SR.sup.e', --R.sup.e', --CN, --NO.sub.2,
--CO.sub.2R.sup.e', --C(O)NR.sup.e'R.sup.e'', --C(O)R.sup.e',
--OC(O)NR.sup.e'R.sup.e'', --NR.sup.e''C(O)R.sup.e',
--NR.sup.e''CO.sub.2R.sup.e', --NR.sup.e'''C(O)NR.sup.e'R.sup.e'',
--NR.sup.e'''SO.sub.2NR.sup.e'R.sup.e'', --NHC(NH.sub.2).dbd.NH,
--NR.sup.e'C(NH.sub.2).dbd.NH, --NH--C(NH.sub.2).dbd.NR.sup.e',
--S(O)R.sup.e', --SO.sub.2R.sup.e', --SO.sub.2NR.sup.e'R.sup.e'',
--NR.sup.e''SO.sub.2R.sup.e', --N.sub.3, --CH(Ph).sub.2,
perfluoroalkoxy, and perfluoro(C.sub.1-C.sub.4)alkyl, in a number
ranging from zero to the total number of open valences on the
aromatic ring system.
[0270] R.sup.e', R.sup.e'' and R.sup.e''' are independently
selected from hydrogen, unsubstituted (C.sub.1-C.sub.8) alkyl,
unsubstituted hetero(C.sub.1-C.sub.8) alkyl, unsubstituted aryl,
unsubstituted heteroaryl, unsubstituted aryl(C.sub.1-C.sub.4)
alkyl, and unsubstituted aryloxy(C.sub.1-C.sub.4) alkyl. Typically,
an aryl or heteroaryl group will have from zero to three
substituents, with those groups having two or fewer substituents
being exemplary in the present invention. In one embodiment of the
invention, an aryl or heteroaryl group will be unsubstituted or
monosubstituted. In another embodiment, an aryl or heteroaryl group
will be unsubstituted.
[0271] Two of the substituents on adjacent atoms of an aryl or
heteroaryl ring in an aryl or heteroaryl group as described herein
may optionally be replaced with a substituent of the formula
--T--C(O)--(CH.sub.2).sub.q--U--, wherein T and U are independently
--NH--, --O--, --CH.sub.2-- or a single bond, and q is an integer
of from 0 to 2. Alternatively, two of the substituents on adjacent
atoms of the aryl or heteroaryl ring may optionally be replaced
with a substituent of the formula -J-(CH.sub.2).sub.r-K-, wherein J
and K are independently --CH.sub.2--, --O--, --NH--, --S--,
--S(O)--, --S(O).sub.2--, --S(O).sub.2NR.sup.f'--, or a single
bond, and r is an integer of from 1 to 3. One of the single bonds
of the new ring so formed may optionally be replaced with a double
bond. Alternatively, two of the substituents on adjacent atoms of
the aryl or heteroaryl ring may optionally be replaced with a
substituent of the formula
--(CH.sub.2).sub.s--X--(CH.sub.2).sub.t--, where s and t are
independently integers of from 0 to 3, and X is --O--,
--NR.sup.f'--, --S--, --S(O)--, --S(O).sub.2--, or
--S(O).sub.2NR.sup.a'--. The substituent R.sup.f' in --NR.sup.f'--
and --S(O).sub.2NR.sup.f'-- is selected from hydrogen or
unsubstituted (C.sub.1-C.sub.6) alkyl.
[0272] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0273] As used herein the term "therapeutically effective amount"
generally means the amount necessary to ameliorate at least one
symptom of a disorder to be prevented, reduced, or treated as
described herein. The phrase "therapeutically effective amount" as
it relates to the GSNOR inhibitors of the present invention shall
mean the GSNOR inhibitor dosage that provides the specific
pharmacological response for which the GSNOR inhibitor is
administered in a significant number of subjects in need of such
treatment. It is emphasized that a therapeutically effective amount
of a GSNOR inhibitor that is administered to a particular subject
in a particular instance will not always be effective in treating
the conditions/diseases described herein, even though such dosage
is deemed to be a therapeutically effective amount by those of
skill in the art.
[0274] The term "biological sample" includes, but is not limited
to, samples of blood (e.g., serum, plasma, or whole blood), urine,
saliva, sweat, breast milk, vaginal secretions, semen, hair
follicles, skin, teeth, bones, nails, or other secretions, body
fluids, tissues, or cells. In accordance with the invention, the
levels of the GSNOR in the biological sample can be determined by
the methods described in U.S. Patent Application Publication No.
2005/0014697.
[0275] D. Pharmaceutical Compositions
[0276] The invention encompasses pharmaceutical compositions
comprising at least one compound of the invention described herein
and at least one pharmaceutically acceptable carrier. Suitable
carriers are described in "Remington: The Science and Practice,
Twentieth Edition," published by Lippincott Williams & Wilkins,
which is incorporated herein by reference. Pharmaceutical
compositions according to the invention may also comprise one or
more non-inventive compound active agents.
[0277] The pharmaceutical compositions of the invention can
comprise novel compounds described herein, the pharmaceutical
compositions can comprise known compounds which previously were not
known to have GSNOR inhibitor activity, or a combination
thereof.
[0278] The compounds of the invention can be utilized in any
pharmaceutically acceptable dosage form, including, but not limited
to injectable dosage forms, liquid dispersions, gels, aerosols,
ointments, creams, lyophilized formulations, dry powders, tablets,
capsules, controlled release formulations, fast melt formulations,
delayed release formulations, extended release formulations,
pulsatile release formulations, mixed immediate release and
controlled release formulations, etc. Specifically, the compounds
of the invention described herein can be formulated: (a) for
administration selected from the group consisting of oral,
pulmonary, intravenous, intra-arterial, intrathecal,
intra-articular, rectal, ophthalmic, colonic, parenteral, otic,
intracisternal, intravaginal, intraperitoneal, local, buccal,
nasal, and topical administration; (b) into a dosage form selected
from the group consisting of liquid dispersions, gels, aerosols,
ointments, creams, tablets, sachets, and capsules; (c) into a
dosage form selected from the group consisting of lyophilized
formulations, dry powders, fast melt formulations, controlled
release formulations, delayed release formulations, extended
release formulations, pulsatile release formulations, and mixed
immediate release and controlled release formulations; or (d) any
combination thereof.
[0279] For respiratory infections, an inhalation formulation can be
used to achieve high local concentrations. Formulations suitable
for inhalation include dry power or aerosolized or vaporized
solutions, dispersions, or suspensions capable of being dispensed
by an inhaler or nebulizer into the endobronchial or nasal cavity
of infected patients to treat upper and lower respiratory bacterial
infections.
[0280] Solutions or suspensions used for parenteral, intradermal,
or subcutaneous application can comprise one or more of the
following components: (1) a sterile diluent such as water for
injection, saline solution, fixed oils, polyethylene glycols,
glycerine, propylene glycol, or other synthetic solvents; (2)
antibacterial agents such as benzyl alcohol or methyl parabens; (3)
antioxidants such as ascorbic acid or sodium bisulfite; (4)
chelating agents such as ethylenediaminetetraacetic acid; (5)
buffers such as acetates, citrates, or phosphates; and (5) agents
for the adjustment of tonicity such as sodium chloride or dextrose.
The pH can be adjusted with acids or bases, such as hydrochloric
acid or sodium hydroxide. A parenteral preparation can be enclosed
in ampoules, disposable syringes, or multiple dose vials made of
glass or plastic.
[0281] Pharmaceutical compositions suitable for injectable use may
comprise sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. For intravenous
administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.), or
phosphate buffered saline (PBS). In all cases, the composition must
be sterile and should be fluid to the extent that easy
syringability exists. The pharmaceutical composition should be
stable under the conditions of manufacture and storage and should
be preserved against the contaminating action of microorganisms
such as bacteria and fungi.
[0282] The carrier can be a solvent or dispersion medium
comprising, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol, and the
like), and suitable mixtures thereof. The proper fluidity can be
maintained, for example, by the use of a coating such as lecithin,
by the maintenance of the required particle size in the case of
dispersion, and by the use of surfactants. Prevention of the action
of microorganisms can be achieved by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol,
ascorbic acid, thimerosal, and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
polyalcohols such as manitol or sorbitol, and inorganic salts such
as sodium chloride in the composition. Prolonged absorption of the
injectable compositions can be brought about by including in the
composition an agent which delays absorption, for example, aluminum
monostearate and gelatin.
[0283] Sterile injectable solutions can be prepared by
incorporating the active reagent in the required amount in an
appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating at least one
compound of the invention into a sterile vehicle that contains a
basic dispersion medium and any other required ingredients. In the
case of sterile powders for the preparation of sterile injectable
solutions, exemplary methods of preparation include vacuum drying
and freeze-drying, both of which yield a powder of a compound of
the invention plus any additional desired ingredient from a
previously sterile-filtered solution thereof.
[0284] Oral compositions generally include an inert diluent or an
edible carrier. They can be enclosed, for example, in gelatin
capsules or compressed into tablets. For the purpose of oral
therapeutic administration, the compound of the invention can be
incorporated with excipients and used in the form of tablets,
troches, or capsules. Oral compositions can also be prepared using
a fluid carrier for use as a mouthwash, wherein the compound in the
fluid carrier is applied orally and swished and expectorated or
swallowed. Pharmaceutically compatible binding agents, and/or
adjuvant materials can be included as part of the composition.
[0285] For administration by inhalation, the compounds are
delivered in the form of an aerosol spray from pressured container
or dispenser that contains a suitable propellant, e.g., a gas such
as carbon dioxide, a nebulized liquid, or a dry powder from a
suitable device. For transmucosal or transdermal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the art,
and include, for example, for transmucosal administration,
detergents, bile salts, and fusidic acid derivatives. Transmucosal
administration can be accomplished through the use of nasal sprays
or suppositories. For transdermal administration, the active
reagents are formulated into ointments, salves, gels, or creams as
generally known in the art. The reagents can also be prepared in
the form of suppositories (e.g., with conventional suppository
bases such as cocoa butter and other glycerides) or retention
enemas for rectal delivery.
[0286] In one embodiment, the compounds of the invention are
prepared with carriers that will protect against rapid elimination
from the body. For example, a controlled release formulation can be
used, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene
vinyl acetate, polyanhydrides, polyglycolic acid, collagen,
polyorthoesters, and polylactic acid. Methods for preparation of
such formulations will be apparent to those skilled in the art.
[0287] Liposomal suspensions (including liposomes targeted to
infected cells with monoclonal antibodies to viral antigens) can
also be used as pharmaceutically acceptable carriers. These can be
prepared according to methods known to those skilled in the art,
for example, as described in U.S. Pat. No. 4,522,811.
[0288] Additionally, suspensions of the compounds of the invention
may be prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils, such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate,
triglycerides, or liposomes. Non-lipid polycationic amino polymers
may also be used for delivery. Optionally, the suspension may also
include suitable stabilizers or agents to increase the solubility
of the compounds and allow for the preparation of highly
concentrated solutions.
[0289] It is especially advantageous to formulate oral or
parenteral compositions in dosage unit form for ease of
administration and uniformity of dosage. Dosage unit form as used
herein refers to physically discrete units suited as unitary
dosages for the subject to be treated; each unit containing a
predetermined quantity of the compound of the invention calculated
to produce the desired therapeutic effect in association with the
required pharmaceutical carrier. The specification for the dosage
unit forms of the invention are dictated by and directly dependent
on the unique characteristics of the compound of the invention and
the particular therapeutic effect to be achieved, and the
limitations inherent in the art of compounding such an active agent
for the treatment of individuals.
[0290] Pharmaceutical compositions according to the invention
comprising at least one compound of the invention can comprise one
or more pharmaceutical excipients. Examples of such excipients
include, but are not limited to binding agents, filling agents,
lubricating agents, suspending agents, sweeteners, flavoring
agents, preservatives, buffers, wetting agents, disintegrants,
effervescent agents, and other excipients. Such excipients are
known in the art. Exemplary excipients include: (1) binding agents
which include various celluloses and cross-linked
polyvinylpyrrolidone, microcrystalline cellulose, such as
Avicel.RTM. PH101 and Avicel.RTM. PH102, silicified
microcrystalline cellulose (ProSolv SMCC.TM.), gum tragacanth and
gelatin; (2) filling agents such as various starches, lactose,
lactose monohydrate, and lactose anhydrous; (3) disintegrating
agents such as alginic acid, Primogel, corn starch, lightly
crosslinked polyvinyl pyrrolidone, potato starch, maize starch, and
modified starches, croscarmellose sodium, cross-povidone, sodium
starch glycolate, and mixtures thereof; (4) lubricants, including
agents that act on the flowability of a powder to be compressed,
include magnesium stearate, colloidal silicon dioxide, such as
Aerosil.RTM. 200, talc, stearic acid, calcium stearate, and silica
gel; (5) glidants such as colloidal silicon dioxide; (6)
preservatives, such as potassium sorbate, methylparaben,
propylparaben, benzoic acid and its salts, other esters of
parahydroxybenzoic acid such as butylparaben, alcohols such as
ethyl or benzyl alcohol, phenolic compounds such as phenol, or
quaternary compounds such as benzalkonium chloride; (7) diluents
such as pharmaceutically acceptable inert fillers, such as
microcrystalline cellulose, lactose, dibasic calcium phosphate,
saccharides, and/or mixtures of any of the foregoing; examples of
diluents include microcrystalline cellulose, such as Avicel.RTM.
PH101 and Avicel.RTM. PH102; lactose such as lactose monohydrate,
lactose anhydrous, and Pharmatose.RTM. DCL21; dibasic calcium
phosphate such as Emcompress.RTM.; mannitol; starch; sorbitol;
sucrose; and glucose; (8) sweetening agents, including any natural
or artificial sweetener, such as sucrose, saccharin sucrose,
xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame;
(9) flavoring agents, such as peppermint, methyl salicylate, orange
flavoring, Magnasweet.RTM. (trademark of MAFCO), bubble gum flavor,
fruit flavors, and the like; and (10) effervescent agents,
including effervescent couples such as an organic acid and a
carbonate or bicarbonate. Suitable organic acids include, for
example, citric, tartaric, malic, fumaric, adipic, succinic, and
alginic acids and anhydrides and acid salts. Suitable carbonates
and bicarbonates include, for example, sodium carbonate, sodium
bicarbonate, potassium carbonate, potassium bicarbonate, magnesium
carbonate, sodium glycine carbonate, L-lysine carbonate, and
arginine carbonate. Alternatively, only the sodium bicarbonate
component of the effervescent couple may be present.
[0291] E. Kits Comprising the Compositions of the Invention
[0292] The present invention also encompasses kits comprising the
compositions of the invention. Such kits can comprise, for example,
(1) at least one compound of the invention; and (2) at least one
pharmaceutically acceptable carrier, such as a solvent or solution.
Additional kit components can optionally include, for example: (1)
any of the pharmaceutically acceptable excipients identified
herein, such as stabilizers, buffers, etc., (2) at least one
container, vial, or similar apparatus for holding and/or mixing the
kit components; and (3) delivery apparatus, such as an inhaler,
nebulizer, syringe, etc.
[0293] F. Methods of Preparing Compounds of the Invention
[0294] The compounds of the invention can readily be synthesized
using known synthetic methodologies or via a modification of known
synthetic methodologies. As would be readily recognized by a
skilled artisan, the methodologies described below allow the
synthesis of bicyclic aromatic compounds having a variety of
substituents. Exemplary synthetic methods are described in the
Examples section below.
[0295] If needed, further purification and separation of
enantiomers and diastereomers can be achieved by routine procedures
known in the art. Thus, for example, the separation of enantiomers
of a compound can be achieved by the use of chiral HPLC and related
chromatographic techniques. Diastereomers can be similarly
separated. In some instances, however, diastereomers can simply be
separated physically, such as, for example, by controlled
precipitation or crystallization.
[0296] The process of the invention, when carried out as prescribed
herein, can be conveniently performed at temperatures that are
routinely accessible in the art. In one embodiment, the process is
performed at a temperature in the range of about 25.degree. C. to
about 110.degree. C. In another embodiment, the temperature is in
the range of about 40.degree. C. to about 100.degree. C. In yet
another embodiment, the temperature is in the range of about
50.degree. C. to about 95.degree. C.
[0297] Synthetic steps that require a base are carried out using
any convenient organic or inorganic base. Typically, the base is
not nucleophilic. Thus, in one embodiment, the base is selected
from carbonates, phosphates, hydroxides, alkoxides, salts of
disilazanes, and tertiary amines.
[0298] The process of the invention, when performed as described
herein, can be substantially complete after several minutes to
after several hours depending upon the nature and quantity of
reactants and reaction temperature. The determination of when the
reaction is substantially complete can be conveniently evaluated by
ordinary techniques known in the art such as, for example, HPLC,
LCMS, TLC, and .sup.1H NMR.
[0299] G. Methods of Treatment
[0300] The invention encompasses methods of preventing or treating
(e.g., alleviating one or more symptoms of) medical conditions
through use of one or more of the disclosed compounds. The methods
comprise administering a therapeutically effective amount of a
compound of the invention to a patient in need. The compositions of
the invention can also be used for prophylactic therapy.
[0301] The compound of the invention used in the methods of
treatment according to the invention can be: (1) a novel compound
described herein, or a pharmaceutically acceptable salt thereof, a
stereoisomer thereof, a prodrug thereof, a metabolite thereof, or
an N-oxide thereof; (2) a compound which was known prior to the
present invention, but wherein it was not known that the compound
is a GSNOR inhibitor, or a pharmaceutically acceptable salt
thereof, a stereoisomer thereof, a prodrug thereof, a metabolite
thereof, or an N-oxide thereof; or (3) a compound which was known
prior to the present invention, and wherein it was known that the
compound is a GSNOR inhibitor, but wherein it was not known that
the compound is useful for the methods of treatment described
herein, or a pharmaceutically acceptable salt, a stereoisomer, a
prodrug, a metabolite, or an N-oxide thereof.
[0302] The patient can be any animal, domestic, livestock, or wild,
including, but not limited to cats, dogs, horses, pigs, and cattle,
and preferably human patients. As used herein, the terms patient
and subject may be used interchangeably.
[0303] As used herein, "treating" describes the management and care
of a patient for the purpose of combating a disease, condition, or
disorder and includes the administration of a compound of the
present invention to prevent the onset of the symptoms or
complications, alleviating the symptoms or complications, or
eliminating the disease, condition, or disorder. More specifically,
"treating" includes reversing, attenuating, alleviating,
minimizing, suppressing, or halting at least one deleterious
symptom or effect of a disease (disorder) state, disease
progression, disease causative agent (e.g., bacteria or viruses),
or other abnormal condition. Treatment is continued as long as
symptoms and/or pathology ameliorate.
[0304] In general, the dosage, i.e., the therapeutically effective
amount, ranges from 1 .mu.g/kg to 10 g/kg and often ranges from 10
.mu.g/kg to 1 g/kg or 10 .mu.g/kg to 100 mg/kg body weight of the
subject being treated, per day.
[0305] H. GSNOR Uses
[0306] In subjects with deleteriously high levels of GSNOR or GSNOR
activity, modulation may be achieved, for example, by administering
one or more of the disclosed compounds that disrupts or
down-regulates GSNOR function, or decreases GSNOR levels. These
compounds may be administered with other GSNOR inhibitor agents,
such as anti-GSNOR antibodies or antibody fragments, GSNOR
antisense, iRNA, or small molecules, or other inhibitors, alone or
in combination with other agents as described in detail herein.
[0307] The present invention provides a method of treating a
subject afflicted with a disorder ameliorated by NO donor therapy.
Such a method comprises administering to a subject a
therapeutically effective amount of a GSNOR inhibitor.
[0308] The disorders can include pulmonary disorders associated
with hypoxemia and/or smooth muscle constriction in the lungs and
airways and/or lung infection and/or lung inflammation and/or lung
injury (e.g., pulmonary hypertension, ARDS, asthma, pneumonia,
pulmonary fibrosis/interstitial lung diseases, cystic fibrosis,
COPD); cardiovascular disease and heart disease (e.g.,
hypertension, ischemic coronary syndromes, atherosclerosis, heart
failure, glaucoma); diseases characterized by angiogenesis (e.g.,
coronary artery disease); disorders where there is risk of
thrombosis occurring; disorders where there is risk of restenosis
occurring; inflammatory diseases (e.g., AIDS related dementia,
inflammatory bowel disease (IBD), Crohn's disease, colitis, and
psoriasis); functional bowel disorders (e.g., irritable bowel
syndrome (IBS)); diseases where there is risk of apoptosis
occurring (e.g., heart failure, atherosclerosis, degenerative
neurologic disorders, arthritis, and liver injury (e.g., drug
induced, ischemic or alcoholic)); impotence; sleep apnea; diabetic
wound healing; cutaneous infections; treatment of psoriasis;
obesity caused by eating in response to craving for food; stroke;
reperfusion injury (e.g., traumatic muscle injury in heart or lung
or crush injury); and disorders where preconditioning of heart or
brain for NO protection against subsequent ischemic events is
beneficial, central nervous system (CNS) disorders (e.g., anxiety,
depression, psychosis, and schizophrenia); and infections caused by
bacteria (e.g., tuberculosis, C. difficile infections, among
others).
[0309] In one embodiment, the disorder is liver injury. Liver
injury can include, for example, acute liver toxicity. Acute liver
toxicity can result in acute liver failure. Acute liver failure
(ALF) is an uncommon but potentially lethal drug-related adverse
effect that often leads to liver transplantation (LT) or death.
Acetoaminophen is the most common cause of acute liver toxicity and
acute liver failure, although acute liver toxicity can be due to
other agents, such as alcohol and other drugs. Regardless of
whether it occurs as a result of a single overdose or after
repeated supratherapeutic ingestion, the progression of
acetaminophen poisoning can be categorized into four stages:
preclinical toxic effects (a normal serum alanine aminotransferase
concentration), hepatic injury (an elevated alanine
aminotransferase concentration), hepatic failure (hepatic injury
with hepatic encephalopathy), and recovery. As long as sufficient
glutathione is present, the liver is protected from injury.
Overdoses of acetaminophen (either a single large ingestion or
repeated supratherapeutic ingestion) can deplete hepatic
glutathione stores and allow liver injury to occur. Compounds of
the invention are capable of treating and/or preventing liver
injury and/or acute liver toxicity. In this embodiment, appropriate
amounts of compounds of the present invention are an amount
sufficient to treat and/or prevent liver injury and can be
determined without undue experimentation by preclinical and/or
clinical trials. In one embodiment, the amount to treat is at least
0.001 mg/kg, at least 0.002 mg/kg, at least 0.003 mg/kg, at least
0.004 mg/kg, at least 0.005 mg/kg, at least 0.006 mg/kg, at least
0.007 mg/kg, at least 0.008 mg/kg, at least 0.009 mg/kg, at least
0.01 mg/kg, at least 0.02 mg/kg, at least 0.03 mg/kg, at least 0.04
mg/kg, at least 0.05 mg/kg, at least at least 0.06 mg/kg, at least
0.07 mg/kg, at least 0.08 mg/kg, at least 0.09 mg/kg, at least 0.1
mg/kg, at least 0.2 mg/kg, at least 0.3 mg/kg, at least 0.4 mg/kg,
at least 0.5 mg/kg, at least 0.6 mg/kg, at least 0.7 mg/kg, at
least 0.8 mg/kg, at least 0.9 mg/kg, at least 1 mg/kg, at least 1.5
mg/kg, at least 2 mg/kg, at least 2.5 mg/kg, at least 3 mg/kg, at
least 3.5 mg/kg, at least 4 mg/kg, at least 4.5 mg/kg, at least 5
mg/kg, at least 6 mg/kg, at least 7 mg/kg, at least 8 mg/kg, at
least 9 mg/kg, at least 10 mg/kg, at least 15 mg/kg, at least 20
mg/kg, at least 30 mg/kg, at least 40 mg/kg, at least 50 mg/kg, at
least 60 mg/kg, at least 70 mg/kg, at least 80 mg/kg, at least 90
mg/kg, at least 100 mg/kg. The dosing can be hourly, four times,
twice, or once daily, or four times, twice, or once per week, or
weekly, or every other week, every third week, or monthly.
[0310] In one embodiment, the disorder is trauma (including surgery
and thermal), infectious, toxic, aging, and ischemic damage to
organs of known regenerative capacity, such as skin, gastric
mucosa, airway epithelial and cartilaginous structures, liver,
neuronal structures such as the spinal cord, bone marrow and bone.
We have shown that inhibition of GSNOR by the use of highly
specific small molecules treats, repairs, and promotes regeneration
of mammalian tissue. By way of example, small molecule inhibitors
are effective in treating, and promoting repair and regeneration of
mammalian lung tissue damaged by instillation of a chemical agent
known to cause severe lung injury (porcine pancreatic elastase)
(Blonder et al., ATS 2011 abstract reference). In this embodiment,
appropriate amounts of compounds of the present invention are an
amount sufficient to regenerate tissue/organs and can be determined
without undue experimentation by preclinical and/or clinical
trials.
[0311] In one embodiment the disorder is trauma (including surgery
and thermal), infectious, toxic, aging, and ischemic damage to
organs of not commonly known to have regenerative capacity.
Examples include regeneration of: the heart, the lung, the kidney,
the central nervous system, the peripheral nervous system,
peripheral vascular tissue, liver, pancreas, adrenal gland,
thyroid, testes, ovary, retina, tongue, bone, bladder, esophagus,
larynx, thymus, spleen, cartilaginous structures of the head, and
cartilaginous structures of the joints. In this embodiment,
appropriate amounts of compounds of the present invention are an
amount sufficient to regenerate tissue/organs and can be determined
without undue experimentation by preclinical and/or clinical
trials.
[0312] In one embodiment ex and in vivo implantation and
regeneration of organs and structures, including stem cells. In
this embodiment, appropriate amounts of compounds of the present
invention are an amount sufficient to regenerate tissue/organs and
can be determined without undue experimentation by preclinical
and/or clinical trials.
[0313] In one embodiment, the compounds of the present invention or
a pharmaceutically acceptable salt thereof, or a prodrug,
stereoisomer, metabolite, or N-oxide thereof, can be administered
in combination with an NO donor. An NO donor donates nitric oxide
or a related redox species and more generally provides nitric oxide
bioactivity, that is activity which is identified with nitric
oxide, e.g., vasorelaxation or stimulation or inhibition of a
receptor protein, e.g., ras protein, adrenergic receptor, NFKB. NO
donors including S-nitroso, O-nitroso, C-nitroso, and N-nitroso
compounds and nitro derivatives thereof and metal NO complexes, but
not excluding other NO bioactivity generating compounds, useful
herein are described in "Methods in Nitric Oxide Research,"
Feelisch et al. eds., pages 71-115 (J. S., John Wiley & Sons,
New York, 1996), which is incorporated herein by reference. NO
donors which are C-nitroso compounds where nitroso is attached to a
tertiary carbon which are useful herein include those described in
U.S. Pat. No. 6,359,182 and in WO 02/34705. Examples of S-nitroso
compounds, including S-nitrosothiols useful herein, include, for
example, S-nitrosoglutathione, S-nitroso-N-acetylpenicillamine,
S-nitroso-cysteine and ethyl ester thereof, S-nitroso cysteinyl
glycine, S-nitroso-gamma-methyl-L-homocysteine,
S-nitroso-L-homocysteine, S-nitroso-gamma-thio-L-leucine,
S-nitroso-delta-thio-L-leucine, and S-nitrosoalbumin. Examples of
other NO donors useful herein are sodium nitroprusside (nipride),
ethyl nitrite, isosorbide, nitroglycerin, SIN 1 which is
molsidomine, furoxamines, N-hydroxy (N-nitrosamine), and
perfluorocarbons that have been saturated with NO or a hydrophobic
NO donor.
[0314] The combination of a GSNOR inhibitor with R(+) enantiomer of
amlodipine, a known NO releaser (Zhang at al., J. Cardiovasc.
Pharm. 39: 208-214 (2002)) is also an embodiment of the present
invention.
[0315] The present invention also provides a method of treating a
subject afflicted with pathologically proliferating cells where the
method comprises administering to said subject a therapeutically
effective amount of an inhibitor of GSNOR. The inhibitors of GSNOR
are the compounds as defined above, or a pharmaceutically
acceptable salt thereof, or a stereoisomer, prodrug, metabolite, or
N-oxide thereof, in combination with a pharmaceutically acceptable
carrier. Treatment is continued as long as symptoms and/or
pathology ameliorate.
[0316] In another embodiment, the pathologically proliferating
cells can be pathologically proliferating microbes. The microbes
involved can be those where GSNOR is expressed to protect the
microbe from nitrosative stress or where a host cell infected with
the microbe expresses the enzyme, thereby protecting the microbe
from nitrosative stress. The term "pathologically proliferating
microbes" is used herein to mean pathologic microorganisms
including, but not limited to, pathologic bacteria, pathologic
viruses, pathologic Chlamydia, pathologic protozoa, pathologic
Rickettsia, pathologic fungi, and pathologic mycoplasmata. More
detail on the applicable microbes is set forth at columns 11 and 12
of U.S. Pat. No. 6,057,367. The term "host cells infected with
pathologic microbes" includes not only mammalian cells infected
with pathologic viruses but also mammalian cells containing
intracellular bacteria or protozoa, e.g., macrophages containing
Mycobacterium tuberculosis, Mycobacterium leper (leprosy), or
Salmonella typhi (typhoid fever).
[0317] In another embodiment, the pathologically proliferating
cells can be pathologic helminths. The term "pathologic helminths"
is used herein to refer to pathologic nematodes, pathologic
trematodes and pathologic cestodes. More detail on the applicable
helminths is set forth at column 12 of U.S. Pat. No. 6,057,367.
[0318] In another embodiment, the pathologically proliferating
cells can be pathologically proliferating mammalian cells. The term
"pathologically proliferating mammalian cells" as used herein means
cells of the mammal that grow in size or number in said mammal so
as to cause a deleterious effect in the mammal or its organs. The
term includes, for example, the pathologically proliferating or
enlarging cells causing restenosis, the pathologically
proliferating or enlarging cells causing benign prostatic
hypertrophy, the pathologically proliferating cells causing
myocardial hypertrophy, and proliferating cells at inflammatory
sites such as synovial cells in arthritis or cells associated with
a cell proliferation disorder.
[0319] As used herein, the term "cell proliferative disorder"
refers to conditions in which the unregulated and/or abnormal
growth of cells can lead to the development of an unwanted
condition or disease, which can be cancerous or non-cancerous, for
example a psoriatic condition. As used herein, the term "psoriatic
condition" refers to disorders involving keratinocyte
hyperproliferation, inflammatory cell infiltration, and cytokine
alteration. The cell proliferative disorder can be a precancerous
condition or cancer. The cancer can be primary cancer or metastatic
cancer, or both.
[0320] As used herein, the term "cancer" includes solid tumors,
such as lung, breast, colon, ovarian, pancreas, prostate,
adenocarcinoma, squamous carcinoma, sarcoma, malignant glioma,
leiomyosarcoma, hepatoma, head and neck cancer, malignant melanoma,
non-melanoma skin cancers, as well as hematologic tumors and/or
malignancies, such as leukemia, childhood leukemia and lymphomas,
multiple myeloma, Hodgkin's disease, lymphomas of lymphocytic and
cutaneous origin, acute and chronic leukemia such as acute
lymphoblastic, acute myelocytic, or chronic myelocytic leukemia,
plasma cell neoplasm, lymphoid neoplasm, and cancers associated
with AIDS.
[0321] In addition to psoriatic conditions, the types of
proliferative diseases which may be treated using the compositions
of the present invention are epidermic and dermoid cysts, lipomas,
adenomas, capillary and cutaneous hemangiomas, lymphangiomas, nevi
lesions, teratomas, nephromas, myofibromatosis, osteoplastic
tumors, and other dysplastic masses, and the like. In one
embodiment, proliferative diseases include dysplasias and disorders
of the like.
[0322] In one embodiment, treating cancer comprises a reduction in
tumor size, decrease in tumor number, a delay of tumor growth,
decrease in metastatic lesions in other tissues or organs distant
from the primary tumor site, an improvement in the survival of
patients, or an improvement in the quality of patient life, or at
least two of the above.
[0323] In another embodiment, treating a cell proliferative
disorder comprises a reduction in the rate of cellular
proliferation, reduction in the proportion of proliferating cells,
a decrease in size of an area or zone of cellular proliferation, or
a decrease in the number or proportion of cells having an abnormal
appearance or morphology, or at least two of the above.
[0324] In yet another embodiment, the compounds of the present
invention or a pharmaceutically acceptable salt thereof, a
stereoisomer thereof, a prodrug thereof, a metabolite thereof, or
an N-oxide thereof can be administered in combination with a second
chemotherapeutic agent. In a further embodiment, the second
chemotherapeutic agent is selected from the group consisting of
tamoxifen, raloxifene, anastrozole, exemestane, letrozole,
cisplatin, carboplatin, paclitaxel, cyclophosphamide, lovastatin,
minosine, gemcitabine, araC, 5-fluorouracil, methotrexate,
docetaxel, goserelin, vincristin, vinblastin, nocodazole,
teniposide, etoposide, epothilone, navelbine, camptothecin,
daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin,
epirubicin, idarubicin imatanib, gefitinib, erlotinib, sorafenib,
sunitinib malate, trastuzumab, rituximab, cetuximab, and
bevacizumab.
[0325] In one embodiment, the compounds of the present invention or
a pharmaceutically acceptable salt thereof, a stereoisomer thereof,
a prodrug thereof, a metabolite thereof, or an N-oxide thereof, can
be administered in combination with an agent that imposes
nitrosative or oxidative stress. Agents for selectively imposing
nitrosative stress to inhibit proliferation of pathologically
proliferating cells in combination therapy with GSNOR inhibitors
herein and dosages and routes of administration therefor include
those disclosed in U.S. Pat. No. 6,057,367, which is incorporated
herein. Supplemental agents for imposing oxidative stress (i.e.,
agents that increase GSSG (oxidized glutathione) over GSH
(glutathione) ratio or NAD(P) over NAD(P)H ratio or increase
thiobarbituric acid derivatives) in combination therapy with GSNOR
inhibitors herein include, for example, L-buthionine-S-sulfoximine
(BSO), glutathione reductase inhibitors (e.g., BCNU), inhibitors or
uncouplers of mitochondrial respiration, and drugs that increase
reactive oxygen species (ROS), e.g., adriamycin, in standard
dosages with standard routes of administration.
[0326] GSNOR inhibitors may also be co-administered with a
phosphodiesterase inhibitor (e.g., rolipram, cilomilast,
roflumilast, Viagra.RTM. (sildenifil citrate), Cialis.RTM.
(tadalafil), Levitra.RTM. (vardenifil), etc.), a .beta.-agonist, a
steroid, an anti-muscarinics, or a leukotriene antagonist (LTD-4).
Those skilled in the art can readily determine the appropriate
therapeutically effective amount depending on the disorder to be
ameliorated.
[0327] GSNOR inhibitors may be used as a means to improve
.beta.-adrenergic signaling. In particular, inhibitors of GSNOR
alone or in combination with .beta.-agonists could be used to treat
or protect against heart failure, or other vascular disorders such
as hypertension and asthma. GSNOR inhibitors can also be used to
modulate G protein coupled receptors (GPCRs) by potentiating Gs
G-protein, leading to smooth muscle relaxation (e.g., airway and
blood vessels), and by attenuating Gq G-protein, and thereby
preventing smooth muscle contraction (e.g., in airway and blood
vessels).
[0328] The therapeutically effective amount for the treatment of a
subject afflicted with a disorder ameliorated by NO donor therapy
is the GSNOR inhibiting amount in vivo that causes amelioration of
the disorder being treated or protects against a risk associated
with the disorder. For example, for asthma, a therapeutically
effective amount is a bronchodilating effective amount; for cystic
fibrosis, a therapeutically effective amount is an airway
obstruction ameliorating effective amount; for ARDS, a
therapeutically effective amount is a hypoxemia ameliorating
effective amount; for heart disease, a therapeutically effective
amount is an angina relieving or angiogenesis inducing effective
amount; for hypertension, a therapeutically effective amount is a
blood pressure reducing effective amount; for ischemic coronary
disorders, a therapeutic amount is a blood flow increasing
effective amount; for atherosclerosis, a therapeutically effective
amount is an endothelial dysfunction reversing effective amount;
for glaucoma, a therapeutic amount is an intraocular pressure
reducing effective amount; for diseases characterized by
angiogenesis, a therapeutically effective amount is an angiogenesis
inhibiting effective amount; for disorders where there is risk of
thrombosis occurring, a therapeutically effective amount is a
thrombosis preventing effective amount; for disorders where there
is risk of restenosis occurring, a therapeutically effective amount
is a restenosis inhibiting effective amount; for chronic
inflammatory diseases, a therapeutically effective amount is an
inflammation reducing effective amount; for disorders where there
is risk of apoptosis occurring, a therapeutically effective amount
is an apoptosis preventing effective amount; for impotence, a
therapeutically effective amount is an erection attaining or
sustaining effective amount; for obesity, a therapeutically
effective amount is a satiety causing effective amount; for stroke,
a therapeutically effective amount is a blood flow increasing or a
TIA protecting effective amount; for reperfusion injury, a
therapeutically effective amount is a function increasing effective
amount; and for preconditioning of heart and brain, a
therapeutically effective amount is a cell protective effective
amount, e.g., as measured by troponin or CPK.
[0329] The therapeutically effective amount for the treatment of a
subject afflicted with pathologically proliferating cells means a
GSNOR inhibiting amount in vivo which is an antiproliferative
effective amount. Such antiproliferative effective amount as used
herein means an amount causing reduction in rate of proliferation
of at least about 20%, at least about 10%, at least about 5%, or at
least about 1%.
[0330] I. Uses in an Apparatus
[0331] The compounds of the present invention or a pharmaceutically
acceptable salt thereof, or a stereoisomer, prodrug, metabolite, or
N-oxide thereof, can be applied to various apparatus in
circumstances when the presence of such compounds would be
beneficial. Such apparatus can be any device or container, for
example, implantable devices in which a compound of the invention
can be used to coat a surgical mesh or cardiovascular stent prior
to implantation in a patient. The compounds of the invention can
also be applied to various apparatus for in vitro assay purposes or
for culturing cells.
[0332] The compounds of the present invention or a pharmaceutically
acceptable salt thereof, or a stereoisomer, a prodrug, a
metabolite, or an N-oxide thereof, can also be used as an agent for
the development, isolation or purification of binding partners to
compounds of the invention, such as antibodies, natural ligands,
and the like. Those skilled in the art can readily determine
related uses for the compounds of the present invention.
EXAMPLES
[0333] The following examples are given to illustrate the present
invention. It should be understood, however, that the invention is
not to be limited to the specific conditions or details described
in these examples. Throughout the specification, any and all
references to a publicly available document, including a U.S.
patent, are specifically incorporated by reference.
[0334] Examples 1-71 list representative novel analogs of Formula I
useful as GSNOR inhibitors of the invention. Exemplary schemes
below illustrate some general methods of making analogs of Formula
I. Synthetic methods that can be used to prepare each compound are
described in Examples 1-71. Supporting mass spectrometry data
and/or proton NMR data for each compound is also included in
Examples 1-71. Synthetic details for corresponding Intermediates
are detailed in Example 72.
[0335] Schemes 1-6 below illustrate general methods for preparing
analogs.
##STR00037##
[0336] For a detailed example of General Scheme 1 see Compound IV-1
in Example 1.
##STR00038##
[0337] For a detailed example of Scheme 2, A conditions, see
Compound IV-2 in Example 2.
[0338] For a detailed example of Scheme 2, B conditions, see
Compound IV-8 in Example 8.
##STR00039##
[0339] For a detailed example of Scheme 3, see Compound IV-9 in
Example 9.
##STR00040##
[0340] For a detailed example of Scheme 4, Route A, see Compound
IV-11 in Example 11.
[0341] For a detailed example of Scheme 4, Route B, see Compound
IV-12 in Example 12.
##STR00041##
[0342] For a detailed example of Scheme 5, Compound A, see Compound
IV-33 in Example 33.
[0343] For a detailed example of Scheme 5, Compound B, see Compound
IV-24 in Example 24.
[0344] For a detailed example of Scheme 5, Compound C, see Compound
IV-23 in Example 23.
##STR00042##
[0345] For a detailed example of Scheme 6, A conditions, see
Compound V-1 in Example 45.
[0346] For a detailed example of Scheme 6, B conditions, see
Compound V-2 in Example 46.
Example 1
Compound IV-1: 4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid
##STR00043##
[0348] Followed Scheme 1
[0349] Step 1: Synthesis of Methyl
4-(6-methoxy-3-methylquinolin-2-yl)benzoate.
[0350] To a mixture of 2-chloro-6-methoxy-3-methylquinoline (100
mg, 0.482 mmol), 4-(methoxycarbonyl)phenylboronic acid (184 mg,
1.02 mmol), TEA (0.35 mL, 2.41 mmol), and PdCl.sub.2(dppf) (35 mg,
0.048 mmol) was added 2 mL of DMF under argon. The mixture was then
stirred for 2.5 h at 120.degree. C. in a microwave reactor. The
crude mixture was then diluted with water (25 mL) and extracted
with EtOAc (25 mL.times.2). The organics were washed with brine (50
mL), dried over sodium sulfate, and concentrated to yield 250 mg of
crude material. The crude was purified via column chromatography
with a gradient of 5% EtOAc in hexanes to 80% EtOAc in hexanes to
yield 37 mg (25% yield) of methyl
4-(6-methoxy-3-methylquinolin-2-yl)benzoate.
[0351] Step 2: Synthesis of
4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid.
[0352] Methyl 4-(6-methoxy-3-methylquinolin-2-yl)benzoate (37 mg,
0.121 mmol) was dissolved in 2 mL of DCM and BBr.sub.3 (150 .mu.L)
was added. The mixture was stirred at room temperature for 1 day
followed by addition of 10 mL of H.sub.2O. The solution was stirred
vigorously for 1 h followed by filtration of the solids. The solids
were washed with H.sub.2O and dried in vacuo to yield 9.5 mg (28%
yield) of Compound IV-1. .sup.1H NMR (DMSO-d.sub.6, 400 MHz):
.delta. 8.37 (s, 1H), 8.10 (d, 2H), 7.94 (d, 1H), 7.78 (d, 2H),
7.42-7.39 (dd, 1H), 7.24-7.23 (d, 1H), 2.43 (s, 3H). MS (ESI): m/z
280.10 [M+H].sup.+.
Example 2
Compound IV-2:
2-(4-(1H-tetrazol-5-yl)phenyl)-3-methylquinolin-6-ol
##STR00044##
[0354] Followed Scheme 2: A Conditions
[0355] Step 1: Synthesis of
2-(4-(1H-tetrazol-5-yl)phenyl)-6-methoxy-3-methylquinoline: To a
mixture of 2-chloro-6-methoxy-3-methylquinoline (100 mg, 0.482
mmol), 4-(1H-tetrazol-5-yl)phenylboronic acid (91.2 mg, 0.482
mmol), K.sub.2CO.sub.3 (199 mg, 1.45 mmol), and PdCl.sub.2(dppf)
(17.6 mg, 0.024 mmol) was added 7 mL of DEGME and 3 mL of H.sub.2O
under argon. The mixture was stirred at 150.degree. C. in a
microwave reactor for 1.5 hours. The crude mixture was diluted with
1N NaOH (10 mL) and slowly acidified to a pH of 4.0 using conc.
HCl. The solids were filtered to yield 128 mg (84% yield) of the
desired product.
[0356] Step 2: Synthesis of
(2-(4-(1H-tetrazol-5-yl)phenyl)-3-methylquinolin-6-ol).
[0357] 2-(4-(1H-tetrazol-5-yl)phenyl)-6-methoxy-3-methylquinoline
(128 mg, 0.40 mmol) was dissolved in 5 mL of NMP and Na.sub.2S (47
mg, 0.60 mmol) was added to it. The mixture was then stirred for 4
hours at 140.degree. C. in a microwave reactor. After concentration
in vacuo the crude was dissolved in 5 mL of 1N NaOH and slowly
acidified with 1N HCl to a pH of 4. The solids were filtered and
dried in vacuo to afford 46.2 mg (38% yield) of Compound IV-2.
.sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 10.10-10.00 (bs, 1H),
8.18-8.15 (d, 2H), 8.08 (s, 1H), 7.87-7.84 (m, 3H), 7.30-7.26 (d,
1H), 7.13 (s, 1H), 2.45 (s, 3H). MS (ESI): m/z 304.11
[M+H].sup.+.
Example 3
Compound IV-3: 4-(6-hydroxyquinolin-2-yl)benzoic acid
##STR00045##
[0359] Followed Scheme 2, A conditions: Starting materials:
2-chloro-6-methoxyquinoline (Intermediate 1) (100 mg, 0.52 mmol)
and (4-(methoxycarbonyl)phenyl)boronic acid. .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 13.06-12.90 (bs, 1H), 10.14 (s,
1H), 8.36-8.33 (d, 2H), 8.30-8.27 (d, 1H), 8.11-8.06 (m, 3H),
7.97-7.94 (d, 1H), 7.38-7.34 (dd, 1H), 7.20 (s, 1H). MS (ESI): m/z
266.08 [M+H].sup.+.
Example 4
Compound IV-4: 2-(4-(1H-tetrazol-5-yl)phenyl)quinolin-6-ol
##STR00046##
[0361] Followed Scheme 2, A conditions: Starting materials:
2-chloro-6-methoxyquinoline (Intermediate 1) and
(4-(1H-tetrazol-5-yl)phenyl)boronic acid. .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 10.15 (s, 1H), 8.45 (d, 2H),
8.31-8.28 (d, 1H), 8.22-8.12 (m, 3H), 7.98-7.95 (d, 1H), 7.39-7.35
(dd, 1H), 7.21 (s, 1H). MS (ESI): m/z 290.08 [M+H].sup.+.
Example 5
Compound IV-5: 1-(6-hydroxyquinolin-2-yl)piperidine-4-carboxylic
acid
##STR00047##
[0363] Step 1: Synthesis of ethyl
4-(6-methoxyquinolin-2-yl)cyclohexane carboxylate: Ethyl
piperidine-4-carboxylate (100 mg) was treated with
2-chloro-6-methoxyquinoline (Intermediate 1) (90 mg) in MeCN (0.8
mL) and TEA (100 mg) in a sealed tube at 180.degree. C. for 6 h in
a microwave reactor. After aqueous work-up with EtOAc and column
purification, eluting with EtOAc/hexane, ethyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (90 mg) was
afforded as a solid.
[0364] Step 2: Synthesis of Compound IV-5: Ethyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (90 mg) was
treated with sodium ethanethiolate (150 mg) in NMP (2 mL) at
100.degree. C. over 48 h. The desired product (50 mg) was purified
by a Dowex 50W X8 cation exchange column, eluting with water and 2N
NH.sub.4OH solution. .sup.1H NMR (DMSO-d.sub.6, 300 MHz): .delta.
7.82 (1H, d, J=9 Hz), 7.42 (1H, d, J=9 hz), 7.13 (1H, d, J=9 Hz),
7.08 (1H, dd, J=3, 9 Hz), 6.93 (1H, d, J=3Hz), 4.2-4.4 (2H, m),
2.88-2.97 (2H, m), 2.15-2.21 (1H, m), 1.80-1.86 (2H, m), 1.45-1.60
(1H, m) ppm. MS (ESI): m/z 273.0 [M+1].sup.+.
Example 6
Compound IV-6:
(1r,4r)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic acid
##STR00048##
[0366] Step 1: Synthesis of (1r,4r)-methyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate and (1s,4s)-methyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate: Methyl
4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylate (261 mg)
(Compound IV-16) was dissolved in EtOAc (10 mL) and mixed with 10%
Pd/C (38.5 mg). The system was vacuumed shortly and charged with
hydrogen. This procedure was repeated three times. The reaction
mixture was stirred under hydrogen for 3 h. After filtration to
remove the catalyst and concentration under reduced pressure, the
resultant mixtures were separated by flash silica gel
chromatography eluting with EtOAc/hexane to afford (1s,4s)-methyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (153 mg) and
(1r,4r)-methyl 4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (72
mg) separately.
[0367] Step 2: Synthesis of Compound IV-6: Followed the procedure
described in Step 2 of Example 5, starting from (1r,4r)-methyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (72 mg, above
product) to give the desired Compound IV-6. .sup.1H NMR
(DMSO-d.sub.6, 300 MHz): .delta. 8.03 (1H, d, J=9 Hz), 7.75 (1H, d,
J=9 hz), 7.33 (1H, d, J=9 Hz), 7.24 (1H, dd, J=3, 9 Hz), 7.08 (1H,
d, J=3Hz), 3.30 (1H, m), 2.76 (1H, m), 2.25-1.90 (4H, m) 1.75-1.50
(4H, m) ppm. MS (ESI): m/z 272.0 [M+1].sup.+.
Example 7
Compound IV-7:
(1s,4s)-4-(6-hydroxyquinolin-2-yl)cyclohexanecarboxylic acid
##STR00049##
[0369] Followed the procedure described in Step 2 of Example 5,
starting from (1s,4s)-methyl
4-(6-methoxyquinolin-2-yl)cyclohexanecarboxylate (72 mg, see
Example 6 Step 1 for synthesis) to give the desired Compound IV-7.
.sup.1H NMR (DMSO-d.sub.6, 300 MHz): .delta. 7.97 (1H, d, J=9 Hz),
7.74 (1H, d, J=9 hz), 7.26 (1H, dd, J=3, 9 Hz), 7.24 (1H, d, J=9
Hz), 7.08 (1H, d, J=3Hz), 3.34 (1H, m), 2.75 (1H, m), 2.25-1.50
(8H, m) ppm. MS (ESI): m/z 272.0 [M+1].sup.+.
Example 8
Compound IV-8: 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid
##STR00050##
[0371] Followed Scheme 2, B Conditions:
[0372] Step 1: Synthesis of
3-chloro-4-(6-methoxyquinolin-2-yl)benzoic acid:
[0373] A mixture of 2-chloro-6-methoxyquinoline (Intermediate 1)
(200 mg, 1.04 mmol), 4-carboxy-2-chlorophenylboronic acid (247 mg,
1.24 mmol) and K.sub.2CO.sub.3 (369 mg, 2.70 mmol) in
DEGME/H.sub.2O (7.0 mL/2.0 mL) was degassed three times under
N.sub.2 atmosphere. Then PdCl.sub.2(dppf) (75 mg, 0.104 mmol) was
added and the mixture was heated to 110.degree. C. for 3 hours
under N.sub.2 atmosphere. The reaction mixture was diluted with
EtOAc (100 mL) and filtered. The filtrate was washed with brine (20
mL), dried over Na.sub.2SO.sub.4, filtered and concentrated to give
3-chloro-4-(6-methoxyquinolin-2-yl)benzoic acid (150 mg, yield 46%)
as a yellow solid, which was used for the next step without further
purification.
[0374] Step 2: Synthesis of Compound IV-8: To a suspension of
3-chloro-4-(6-methoxyquinolin-2-yl)benzoic acid (150 mg, 0.479
mmol) in anhydrous CH.sub.2Cl.sub.2 (5 mL) was added AlCl.sub.3
(320 mg, 2.40 mmol). The reaction mixture was refluxed overnight.
The mixture was quenched with saturated NH.sub.4Cl (10 mL) and the
aqueous layer was extracted with CH.sub.2Cl.sub.2/MeOH (v/v=10:1,
30 mL.times.3). The combined organic layer was washed with brine,
dried over Na.sub.2SO.sub.4, filtered, and concentrated to give the
crude product, which was purified by prep-HPLC (0.1% TFA as
additive) to give 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid
(25 mg, yield 18%). .sup.1H NMR (DMSO, 400 MHz): .delta. 10.20
(brs, 1H), 8.30 (d, J=8.4 Hz, 1H), 8.10-8.00 (m, 2H), 7.95 (d,
J=9.2 Hz, 1H), 7.80 (d, J=8.0 Hz, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.38
(dd, J=6.4, 2.8 Hz, 1H), 7.22 (d, J=2.4 Hz, 1H), MS (ESI): m/z
299.9 [M+H].sup.+.
Example 9
Compound IV-9: 2-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid
##STR00051##
[0376] Followed Scheme 3:
[0377] A mixture of 2-chloroquinolin-6-ol (Intermediate 2) (50 mg,
0.270 mmol), 4-borono-2-chlorobenzoic acid (55 mg, 0.270 mmol),
K.sub.2CO.sub.3 (75 mg, 0.540 mmol) and Pd(dppf)Cl.sub.2 (25 mg,
0.0306 mmol) in 2-(2-methoxyethoxy)ethanol (1.5 mL) and water (0.4
mL) was stirred under N.sub.2 atmosphere at 130.degree. C. for 3
hours. The resulting mixture was cooled to room temperature and
filtered. The filtrate was concentrated under reduced pressure and
the residue was purified by prep. HPLC (0.1% TFA as additive) to
give Compound IV-9 (33 mg, yield 40%) as yellow solid. .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 8.39 (d, J=8.4 Hz, 1H), 8.29 (d,
J=1.6 Hz, 1H), 8.16-8.02 (m, 4H), 7.47 (dd, J=9.2, 2.8 Hz, 1H),
7.25 (d, J=2.4 Hz, 1H). MS (ESI): m/z 298.0 [M-1].sup.-.
Example 10
Compound IV-10: 2-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid
##STR00052##
[0379] Followed Scheme 3: Starting Materials: 2-chloroquinolin-6-ol
(Intermediate 2) and 4-borono-2-fluorobenzoic acid. .sup.1H NMR
(CD.sub.3OD, 400 MHz): .delta. 8.54 (d, J=8.4 Hz, 1H), 8.20-8.06
(m, 3H), 8.06-7.96 (m, 2H), 7.55 (dd, J=9.2, 2.4 Hz, 1H), 7.32 (d,
J=2.8 Hz, 1H). MS (ESI): m/z 283.6 [M+1].sup.+.
Example 11
Compound IV-11:
2-(4-(2H-tetrazol-5-yl)phenyl)-4-chloroquinolin-6-ol
##STR00053##
[0381] Step 1: Synthesis of
4-(4-chloro-6-methoxyquinolin-2-yl)benzonitrile: Followed Scheme 2,
Step 1 starting from 4-cyanophenylboronic acid and
2,4-dichloro-6-methoxyquinoline, where the solvent used was DMF,
and the catalyst used was Pd(PPh.sub.3).sub.4. The mixture was
heated to 100.degree. C. for 3 h, allowed to cool, and then poured
into ice water. The resulting solid was isolated by filtration,
washed with water, and dried followed by recrystallization from
methanol to give the desired product.
[0382] Step 2: Synthesis of
4-(4-chloro-6-hydroxyquinolin-2-yl)benzonitrile: Followed the
procedure for Scheme 1, step 2, with an Ethyl Acetate/aqueous
workup. Purification by prep-TLC gave desired product.
[0383] Step 3: Synthesis of
2-(4-(2H-tetrazol-5-yl)phenyl)-4-chloroquinolin-6-ol: Followed
Scheme 4, route A. To a solution of
4-(4-chloro-6-hydroxyquinolin-2-yl)benzonitrile (65 mg, 0.23 mmol)
in toluene (2 mL), was added TMSN.sub.3 (455 mg, 4.18 mmol) and
Bu.sub.2SnO (15 mg, 0.069 mmol) at room temperature. The mixture
was heated to reflux overnight. The volatiles were removed under
reduced pressure. The residue was purified by prep-HPLC to afford
Compound IV-11 (10 mg, 13.5%). .sup.1H NMR (MeOD-d.sub.4, 500 MHz):
.delta. 8.34 (d, J=8.5 Hz, 2H), 8.21 (s, 1H), 8.19 (s, 2H), 8.07
(d, J=9.0 Hz, 1H), 7.51 (d, J=2.5 Hz, 1H), 7.47(dd, J=2.5 Hz, J=9.5
Hz, 1H). MS (ESI): m/z 324.0 [M+1].sup.+.
Example 12
Compound IV-12:
3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(2H)-one
##STR00054##
[0385] Step 1: Synthesis of 4-(6-hydroxyquinolin-2-yl)benzonitrile:
Followed Scheme 3 starting from 2-chloroquinolin-6-ol (Intermediate
2) and 4-cyanophenylboronic acid, and using 1,4-Dioxane:H.sub.2O
solution. Reaction was run at 100.degree. C. in a microwave reactor
for 1 hour. Ethyl acetate workup was followed by column
chromatography (5% to 50% EtOAc in hexanes gradient).
[0386] Step 2: Synthesis of
N-hydroxy-4-(6-hydroxyquinolin-2-yl)benzimidamide. See Scheme 4,
route B. 4-(6-hydroxyquinolin-2-yl)benzonitrile (900 mg, 3.68 mmol)
was dissolved in 25 mL of EtOH and to it was added NH.sub.2OH.HCl
(500 mg, 7.36 mmol) and TEA (1.5 mL). The mixture was stirred at
80.degree. C. for 2 hours followed by concentration in vacuo. The
crude solids were then suspended in 25 mL of H.sub.2O and stirred
for 1 hour. Filtration and drying of the solids yielded desired
product (800 mg, 78% yield).
[0387] Step 3: Synthesis of
(3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(2H)-one):
N-hydroxy-4-(6-hydroxyquinolin-2-yl)benzimidamide (800 mg, 2.86
mmol) was dissolved in 25 mL of THF and CDI (557 mg, 3.44 mmol) and
TEA (0.2 mL) was added. The mixture was stirred at 65.degree. C.
for 2 hours, followed by concentration in vacuo. The crude material
was dissolved in 10 mL 1N NaOH and filtered through Celite. The
mixture was then acidified with 1N HCl to a pH of 4.5 and the
solids were filtered and dried. The solids were slurried in 10 mL
of EtOAc overnight at 50.degree. C. followed by filtration to yield
Compound IV-12 (315 mg, 36% yield). .sup.1H NMR (DMSO-d.sub.6, 400
MHz): .delta. 10.19 (s, 1H), 8.42 (d, 2H), 8.28 (d, 1H), 8.14-8.11
(d, 1H), 8.00-7.94 (m, 3H), 7.39-7.35 (dd, 1H), 7.21 (s, 1H). MS
(ESI): m/z 306.44 [M+H].sup.+.
Example 13
Compound IV-13: 3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid
##STR00055##
[0389] Followed Scheme 3: Starting Materials: 2-chloroquinolin-6-ol
and 4-borono-3-fluorobenzoic acid. .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 8.31 (d, J=8.4 Hz, 1H), 7.94-7.86 (m, 3H), 7.81-7.74
(m, 2H), 7.35 (dd, J=9.2, 2.8 Hz, 1H), 7.15 (d, J=2.8 Hz, 1H). MS
(ESI): m/z 283.6 [M+H].sup.+.
Example 14
Compound IV-14: 4-(6-hydroxyquinolin-2-yl)-3-methoxybenzoic
acid
##STR00056##
[0391] Followed Scheme 3: Starting Materials: 2-chloroquinolin-6-ol
and 4-borono-3-methoxybenzoic acid. .sup.1H NMR (CD.sub.3OD, 400
MHz): .delta. 8.81 (d, J=8.4 Hz, 1H), 8.14 (d, J=9.2 Hz, 1H), 8.10
(d, J=8.4 Hz, 1H), 7.89 (dd, J=6.8, 1.6 Hz, 2H), 7.85 (d, J=8.4 Hz,
1H), 7.69 (dd, J=9.2, 2.8 Hz, 1H), 7.48 (d, J=2.8 Hz, 1H). MS
(ESI): m/z 295.7 [M+H].sup.+.
Example 15
Compound IV-15: 5-(6-hydroxyquinolin-2-yl)thiophene-2-carboxylic
acid
##STR00057##
[0393] Followed Scheme 3: Starting Materials: 2-chloroquinolin-6-ol
and 5-boronothiophene-2-carboxylic acid. .sup.1H NMR (CD.sub.3OD,
400 MHz): .delta. 8.25 (d, J=8.8 Hz, 1H), 7.97 (dd, J=9.2, 3.2 Hz,
2H), 7.88-7.82 (m, 2H), 7.41 (dd, J=9.2, 2.8 Hz, 1H), 7.19 (d,
J=2.4 Hz, 1H). MS (ESI): m/z 271.6 [M+H].sup.+.
Example 16
Compound IV-16: 4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylic
acid
##STR00058##
[0395] Step 1: Synthesis of methyl
4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylate: Followed
Scheme 3: Starting Materials: 2-chloroquinolin-6-ol and methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate.
[0396] Step 2: Synthesis of
4-(6-hydroxyquinolin-2-yl)cyclohex-3-enecarboxylic acid: Basic
hydrolysis conditions with LiOH gave the final desired product.
.sup.1H NMR (DMSO-d.sub.6, 300 MHz): .delta. 12.24 (1H, s), 9.92
(1H, s), 8.04 (1H, d, J=9 Hz), 7.75 (1H, d, J=9 hz), 7.66 (1H, d,
J=9 Hz), 7.24 (1H, dd, J=3, 9 Hz), 7.08 (1H, d, J=3Hz), 6.74 (1H,
s), 3.30 (1H, m), 2.84 (1H, m), 2.50 (4H, m), 2.08 (1H, m), 1.71
(1H, m) ppm. MS (ESI): m/z 270.0 [M+1].sup.+.
Example 17
Compound IV-17: 4-(3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid
##STR00059##
[0398] Step 1: Synthesis of
4-(4-chloro-3-fluoro-6-methoxyquinolin-2-yl)benzoic acid: Followed
Scheme 3 where the starting materials were
2,4-dichloro-3-fluoro-6-methoxyquinoline (Intermediate 3) and
4-boronobenzoic acid where the crude was purified by silica gel
column (PE/EtOAc=1/1) to give a mixture of compound
4-(4-chloro-3-fluoro-6-methoxyquinolin-2-yl)benzoic acid and
4-(3-fluoro-6-methoxyquinolin-2-yl)benzoic acid, which was used for
the next step without further purification.
[0399] Step 2: Synthesis of
4-(3-fluoro-6-methoxyquinolin-2-yl)benzoic acid: To a solution of
the mixture from Step 1 in absolute MeOH (5 mL) was added Pd/C (10%
Pd, 100 mg). The mixture was stirred at 25.degree. C. for 1 hour
under H.sub.2 atmosphere. The solids were filtered off and the
filtrate was concentrated to give the product (60 mg, two-step
yield 66%).
[0400] Step 3: Synthesis of
4-(3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid: Followed Scheme 2,
step 2, B conditions. .sup.1H NMR (DMSO, 400 MHz): .delta. 13.35
(brs, 1H), 10.40 (brs, 1H), 8.25 (d, J=12.8 Hz, 1H), 8.27 (s, 4H),
8.01 (d, J=9.2 Hz, 1H), 7.40 (dd, J=8.8, 2.4 Hz, 1H), 7.25 (d,
J=2.8 Hz, 1H).
Example 18
Compound IV-18: 4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid
##STR00060##
[0402] Step 1: Synthesis of
4-(4-chloro-3-fluoro-6-methoxyquinolin-2-yl)benzoic acid: Synthesis
described in Step 1 of Example 17.
[0403] Step 2: Synthesis of
4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid: Followed
Scheme 2, Step 2, B conditions. .sup.1H NMR (DMSO, 400 MHz):
.delta. 13.25 (brs, 1H), 10.75 (brs, 1H), 8.10 (s, 4H), 8.05 (d,
J=9.2 Hz, 1H), 7.41 (dd, J=9.2, 2.8 Hz, 1H), 7.35 (d, J=2.4 Hz,
1H).
Example 19
Compound IV-19: 4-(3-chloro-6-hydroxyquinolin-2-yl)benzoic acid
##STR00061##
[0405] Step 1: Synthesis of
4-(3-chloro-6-methoxyquinolin-2-yl)benzoic acid: Followed Scheme 3
where the starting materials were 2,3-dichloro-6-methoxyquinoline
(Intermediate 4) and 4-boronobenzoic acid.
[0406] Step 2: Synthesis of
4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid: Followed
Scheme 2, Step 2, B conditions. .sup.1H NMR (CD.sub.3OD, 400 MHz):
.delta. 8.35 (s, 1H), 8.17 (d, J=8.0 Hz, 2H), 7.95 (d, J=9.2 Hz,
1H), 7.80 (d, J=8.0 Hz, 2H), 7.40 (dd, J=9.2, 2.4 Hz, 1H), 7.15 (d,
J=2.8 Hz, 1H). MS (ESI): in/z 299.8 [M+H].sup.+.
Example 20
Compound IV-20:
3-(2-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one
##STR00062##
[0408] Step 1: Synthesis of
2-fluoro-4-(6-hydroxyquinolin-2-yl)benzonitrile: Followed Scheme 3
starting from 2-chloroquinolin-6-ol (Intermediate 2) and
4-cyano-3-fluorophenylboronic acid where crude was purified by
silica gel column chromatography.
[0409] Step 2 and 3: Synthesis of
3-(2-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one.
Followed Scheme 4, route B, step 1: After solvent was removed in
vacuo, the crude
2-fluoro-N-hydroxy-4-(6-hydroxyquinolin-2-yl)benzimidamide was
taken on without purification. Followed Scheme 4, route B, step 2:
Purification by silica gel column, eluting with 10% MeOH in DCM
gave desired product. .sup.1H NMR (DMSO-d.sub.6, 300 MHz): .delta.
10.22 (1H, s), 8.27-8.33 (2H, m), 8.16 (1H, d, J=9 Hz), 7.91-7.99
(2H, m), 7.66 (1H, d, J=9 Hz), 7.39 (1H, dd, J=3, 9 Hz), 7.21 (1H,
d, J=3Hz) ppm. MS (ESI): m/z 324.0 [M+1].sup.+.
Example 21
Compound IV-21:
3-(3-fluoro-4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one
##STR00063##
[0411] Followed procedure described for Compound IV-20 in Example
20 starting from 2-chloroquinolin-6-ol (Intermediate 2) and
4-cyano-2-fluorophenylboronic acid. .sup.1H NMR (DMSO-d.sub.6, 300
MHz): .delta. 10.22 (1H, s), 8.27-8.33 (2H, m), 7.97 (1H, d, J=9
Hz), 7.77-7.82 (2H, m), 7.39 (1H, dd, J=3, 9 Hz), 7.21 (1H, d,
J=3Hz) ppm. MS (ESI): m/z 324.0 [M+1].sup.+.
Example 22
Compound IV-22: 4-(4-chloro-6-hydroxyquinolin-2-yl)benzoic acid
##STR00064##
[0413] Step 1: Synthesis of
4-(4-chloro-6-hydroxyquinolin-2-yl)benzonitrile: Followed Step 2 of
Scheme 1 starting from
4-(4-chloro-6-methoxyquinolin-2-yl)benzonitrile (see step 1 of
Example 11 for synthesis).
[0414] Step 2: Synthesis of
4-(4-chloro-6-hydroxyquinolin-2-yl)benzoic acid: A solution of
4-(4-chloro-6-hydroxyquinolin-2-yl)benzonitrile (40 mg, 0.14 mmol),
con. HCl (1 mL) and dioxane (1 mL) was heated at 90.degree. C.
overnight. The mixture was extracted with ethyl acetate. The
organic layer was concentrated and purified by prep-HPLC to afford
Compound IV-22 (10 mg, yield: 23%). .sup.1H NMR (MeOD-d.sub.4, 500
MHz): 8.16 (d, J=8.0 Hz, 2H), 8.10 (d, J=8.5 Hz, 2H), 8.07 (s, 1H),
7.96 (d, J=9.0 Hz, 1H), 7.41 (d, J=2.5 Hz, 1H), 7.35 (dd, J=3.0 Hz,
J=9.0 Hz, 1H). MS (ESI): m/z 300 [M+1].sup.+.
Example 23
Compound IV-23:
2-(2-chloro-4-(2H-tetrazol-5-yl)phenyl)quinolin-6-ol
##STR00065##
[0416] Example procedure for Scheme 5, Compound C.
[0417] Step 1: Synthesis of
3-chloro-4-(6-hydroxyquinolin-2-yl)benzamide: A mixture of
3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid (Compound IV-8,
Example 8) (400 mg, 1.33 mmol) and SOCl.sub.2 (10 mL) was refluxed
for 1 hour, then concentrated under reduced pressure to give crude
product (400 mg) as off-white solid. To this solid was added
NH.sub.4OH (10 mL) and the reaction mixture was stirred at
30.degree. C. for 1 hour. The resulting mixture was acidified with
aqueous HCl (2 M) until pH=6 and extracted with EtOAc (50
mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated to give
crude product (360 mg) as a solid.
[0418] Step 2: Synthesis of
3-chloro-4-(6-hydroxyquinolin-2-yl)benzonitrile: A mixture of crude
3-chloro-4-(6-hydroxyquinolin-2-yl)benzamide (360 mg), TFAA (505
mg, 2.40 mmol) and Et.sub.3N (364 mg, 3.62 mmol) in DCM (20 mL) was
stirred at 30.degree. C. overnight. The resulting mixture was
suspended in water (50 mL) and extracted with EtOAc (50
mL.times.3). The combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The
residue was purified by column chromatography on silica gel
(PE/EtOAc=10/1) to give the product (250 mg, 3-step yield 67%) as a
solid.
[0419] Step 3: Synthesis of
2-(2-chloro-4-(2H-tetrazol-5-yl)phenyl)quinolin-6-ol: A mixture of
3-chloro-4-(6-hydroxyquinolin-2-yl)benzonitrile (230 mg, 0.819
mmol), NaN.sub.3 (55 mg, 0.820 mmol) and LiCl (70 mg, 1.64 mmol) in
diethylene glycol monomethyl ether (5 mL) was refluxed for 4 hours.
The resulting mixture was cooled, filtered through silica gel pad
and purified by prep-HPLC (0.1% TFA as additive) to give Compound
IV-23 (32 mg, yield 12%). .sup.1H NMR (CD.sub.3OD, 400 MHz):
.delta. 8.52 (d, J=8.4 Hz, 1H), 8.34 (s, 1H), 8.21 (d, J=8.0 Hz,
1H), 8.04 (d, J=9.2 Hz, 1H), 7.92-7.82 (m, 2H), 7.54 (dd, J=9.2,
2.0 Hz, 1H), 7.34 (d, J=2.0 Hz, 1H). MS (ESI): m/z 323.6
[M+H].sup.+.
Example 24
Compound IV-24:
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one
##STR00066##
[0421] Example procedure for Scheme 5, Compound B.
[0422] Step 1: Synthesis of tert-butyl
2-(4-(6-hydroxyquinolin-2-yl)benzoyl)hydrazinecarboxylate: A
mixture of 4-(6-hydroxyquinolin-2-yl)benzoic acid (Compound IV-3,
Example 3) (200 mg, 0.754 mmol), EDCI (145 mg, 0.754 mmol) and
BocNHNH.sub.2 (100 mg, 0.754 mmol) in DCM (10 mL) and DMF (10 mL)
was stirred at 25.degree. C. overnight, followed by an
aqueous/EtOAc workup. The crude was purified by column
chromatography on silica gel (PE/EtOAc=1/1) to give the product
(200 mg, yield 70%) as a yellow solid.
[0423] Step 2: Synthesis of
4-(6-hydroxyquinolin-2-yl)benzohydrazide: A mixture of tert-butyl
2-(4-(6-hydroxyquinolin-2-yl)benzoyl)hydrazinecarboxylate (240 mg,
0.633 mmol) and HCl/MeOH (20 mL, 4M) was stirred at 25.degree. C.
overnight. The resulting mixture was concentrated under reduced
pressure to dryness to give the product (120 mg, yield 68%).
[0424] Step 3: Synthesis of
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one: A
mixture of 4-(6-hydroxyquinolin-2-yl)benzohydrazide (90 mg, 0.322
mmol) and CDI (454 mg, 3.22 mmol) in DCM (20 mL) was refluxed
overnight. The resulting mixture was cooled to room temperature,
followed by an aqueous/EtOAc workup. The crude was purified by
prep-HPLC (0.1% TFA as additive) to give Compound IV-24 (18 mg,
yield 11%). .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 8.64-8.48
(m, 1H), 8.38-7.96 (m, 6H), 7.66-7.24 (m, 2H). MS (ESI): m/z 305.7
[M+H].sup.+.
Example 25
Compound IV-25: 3-(dimethylamino)-4-(6-hydroxyquinolin-2-yl)benzoic
acid
##STR00067##
[0426] Step 1: Synthesis of methyl
3-amino-4-(6-methoxyquinolin-2-yl)benzoate: Followed Scheme 2, step
1, B conditions starting from
2-amino-4-(methoxycarbonyl)phenylboronic acid and
2-chloro-6-methoxyquinoline, with a purification by column
chromatography on silica gel (PE/EtOAc=8/1) to give the
product.
[0427] Step 2: Synthesis of methyl
3-(dimethylamino)-4-(6-methoxyquinolin-2-yl)benzoate: To a solution
of above compound (400 mg, 1.30 mmol) in MeOH/CH.sub.2Cl.sub.2 (10
mL/20 mL) was added aqueous HCHO (37% in water, 0.4 mL), followed
by NaBH.sub.3CN (327 mg, 5.19 mmol) and ZnCl.sub.2 (348 mg, 2.60
mmol) at 0.degree. C. The mixture was stirred at 30.degree. C. for
6 hours. The mixture was quenched with ice water, the aqueous layer
was extracted with CH.sub.2Cl.sub.2 (30 mL.times.3), the combined
organic layer was washed with brine (30 mL), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated in vacuo to give the product (400
mg, yield 92%).
[0428] Step 3: Synthesis of methyl
3-(dimethylamino)-4-(6-hydroxyquinolin-2-yl)benzoate: Followed
Scheme 2, step 2, B conditions where crude was purified by column
chromatography on silica gel (PE/EtOAc=5/1) to give the desired
product.
[0429] Step 4: Synthesis of
3-(dimethylamino)-4-(6-hydroxyquinolin-2-yl)benzoic acid: To a
solution of above compound (290 mg, 0.901 mmol) in THF/MeOH (8 mL/4
mL) was added aqueous LiOH (1 M, 4 mL). The mixture was stirred at
30.degree. C. for 3 hours. The mixture was diluted with H.sub.2O
(10 mL), the aqueous layer was neutralized by 2M HCl to pH 7. An
aqueous/CH.sub.2Cl.sub.2 workup was followed by column
chromatography on silica gel (CH.sub.2Cl.sub.2/MeOH=10/1) to give
Compound IV-25 (80 mg, yield 29%). .sup.1H NMR (MeOD-d.sub.4, 400
MHz): .delta. 8.15 (d, J=8.8 Hz, 1H), 7.95 (d, J=9.2 Hz, 1H),
7.87-7.81 (m, 2H), 7.76 (d, J=8.0 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H),
7.38 (dd, J=8.8, 2.4 Hz, 1H), 7.20 (d, J=2.4 Hz, 1H), 2.65 (s, 6H).
MS (ESI): m/z 308.9 [M+H].sup.+.
Example 26
Compound IV-26: 4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid
##STR00068##
[0431] Step 1: Synthesis of
4-(4-fluoro-6-methoxyquinolin-2-yl)benzonitrile: A mixture of
4-(4-chloro-6-methoxyquinolin-2-yl)benzonitrile (See Example 11,
step 1) (1 g, 3.4 mmol), CsF (5.2 g, 34 mmol), and n-Bu.sub.4NBr
(109 mg, 0.34 mmol) in DMSO (10 mL) was heated to 150.degree. C.
for 2 h. An aqueous/EtOAC workup was followed by purification by
column chromatography (PE/EA=10/1) to afford desired product (300
mg, 31.7%).
[0432] Step 2: Synthesis of
4-(4-fluoro-6-hydroxyquinolin-2-yl)benzonitrile: Followed Step 2 of
Scheme 1, where an aqueous/EtOAc workup was followed by column
chromatography (PE:EA=4:1) to give the desired product.
[0433] Step 3: Synthesis of
4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid: A mixture of above
(100 mg, 0.38 mmol) and NaOH (152 mg, 3.8 mmol) in
1,4-dioxane/H.sub.2O (1 mL/1 mL) was heated to reflux overnight.
The volatiles were removed under reduced pressure. The residue was
purified by prep-HPLC and then prep-TLC (EtOAc) to afford Compound
IV-26 (10 mg, 9.3%). .sup.1H NMR (MeOD-d.sub.4, 500 MHz): 8.22-8.17
(m, 4H), 8.04 (d, J=9.5 Hz, 1H), 7.79 (d, J=12.0 Hz, 1H), 7.43 (dd,
J=2.5 Hz, J=9.0 Hz, 1H), 7.31 (d, J=2.0 Hz, 1H). MS (ESI): m/z
284.0 [M+1].sup.+.
Example 27
Compound IV-27: 4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid
##STR00069##
[0435] Followed Scheme 3: Starting Materials: 2-chloroquinolin-6-ol
and methyl
3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate..-
sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 10.45 (brs, 1H),
8.61-8.46 (m, 1H), 8.03 (d, J=8.8 Hz, 1H), 7.96 (s, 1H), 7.92 (d,
J=8.0 Hz, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.66 (d, J=8.0 Hz, 1H), 7.50
(d, J=8.0 Hz, 1H), 7.35 (s, 1H), 2.42 (s, 3H). MS (ESI): m/z 279.9
[M+H].sup.+.
Example 28
Compound IV-28: 4-(3-chloro-6-hydroxyquinolin-2-yl)-3-fluorobenzoic
acid
##STR00070##
[0437] Step 1: Synthesis of
4-(3-chloro-6-methoxyquinolin-2-yl)-3-fluorobenzoic acid: Scheme 3:
starting from 2,3-dichloro-6-methoxyquinoline (Intermediate 4) and
4-borono-3-fluorobenzoic acid. An aqueous/EtOAc workup was
performed followed by purification by silica gel column
(PE/EtOAc=1/1) to give the desired product.
[0438] Step 2: Synthesis of
4-(3-chloro-6-hydroxyquinolin-2-yl)-3-fluorobenzoic acid: Scheme 1,
step 2: where reaction was refluxed for 18 hours, followed by an
aqueous/EtOAc with 10% MeOH workup. Purification by prep-HPLC gave
Compound IV-28. .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 13.45
(brs, 1H), 10.39 (brs, 1H), 8.52 (s, 1H), 7.94-7.88 (m, 2H), 7.80
(d, J=10.4 Hz, 1H), 7.67 (t, J=7.6 Hz, 1H), 7.38 (dd, J=6.8, 2.4
Hz, 1H), 7.21 (d, J=2.8 Hz, 1H). MS (ESI): m/z 317.8
[M+H].sup.+.
Example 29
Compound IV-29:
3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-5(2H)-one
##STR00071##
[0440] Step 1: Synthesis of
N-hydroxy-4-(6-methoxyquinolin-2-yl)benzimidamide: Scheme 4, route
B, step 1: 4-(6-methoxyquinolin-2-yl)benzonitrile (prepared via
scheme 3) (780 mg, 3.00 mmol) was suspended in methanol (10 mL) and
hydroxylamine hydrochloride (639 mg, 10.7 mmol), K.sub.2CO.sub.3
(414 mg, 3.00 mmol) were added. The reaction mixture was refluxed
for 12 hours. Water (15 mL) was added and the precipitated solid
was collected by filtration, washed with ethanol (5 mL) and dried
over high vacuum to give the product (600 mg).
[0441] Step 2: Synthesis of
3-(4-(6-methoxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-5(2H)-one:
Scheme 4, route B, step 2: To a solution of above product (450 mg)
in THF (10 mL) was added TCDI (410 mg, 2.30 mmol) and the mixture
was stirred at 30.degree. C. for 3 hours. After completion of the
reaction, the solvent was removed to give the product (300 mg).
[0442] Step 3: Synthesis of
3-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-5(2H)-one:
Scheme 1, step 2: Reaction was refluxed overnight, followed by an
aqueous/EtOAc workup and purification by prep-HPLC (0.1% TFA as
additive) to give Compound IV-29. .sup.1H NMR (DMSO-d.sub.6, 300
MHz): .delta. 13.50 (brs, 1H), 8.40-8.26 (m, 3H), 8.18-8.04 (m,
3H), 7.95 (d, J=9.0 Hz, 1H), 7.36 (dd, J=9.0, 2.4 Hz, 1H), 7.20 (d,
J=2.7 Hz, 1H). MS (ESI): m/z 322.0 [M+H].sup.+.
Example 30
Compound IV-30:
4-(6-hydroxyquinolin-2-yl)-3-(trifluoromethyl)benzoic acid
##STR00072##
[0444] Followed Scheme 3: starting with 2-chloroquinolin-6-ol and
methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzoa-
te (Intermediate 5). .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.
10.21 (brs, 1H), 8.35-8.25 (m, 3H), 7.89 (d, J=9.2 Hz, 1H), 7.79
(d, J=8.0 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.38 (dd, J=9.2, 2.8 Hz,
1H), 7.23 (d, J=2.4 Hz, 1H). MS (ESI): m/z 333.7 [M+H].sup.+.
Example 31
Compound IV-31:
4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)benzoic acid
##STR00073##
[0446] Followed Scheme 3: starting with 4-carboxyphenylboronic acid
and 2-chloro-3-(trifluoromethyl)quinolin-6-ol (Intermediate 6).
.sup.1H NMR (DMSO, 400 MHz): .delta. 13.10 (brs, 1H), 10.45 (brs,
1H), 8.84 (s, 1H), 8.02 (d, J=8.4 Hz, 2H), 7.97 (d, J=8.8 Hz, 1H),
7.60 (d, J=8.0 Hz, 2H), 7.50 (dd, J=9.2, 2.8 Hz, 1H), 7.40 (d,
J=2.8 Hz, 1H). MS (ESI): m/z 333.9 [M+H].sup.+.
Example 32
Compound IV-32: 2-(4-carboxyphenyl)-6-hydroxyquinoline 1-oxide
##STR00074##
[0448] Step 1: Synthesis of methyl
4-(6-hydroxyquinolin-2-yl)benzoate: Scheme 1, step 1, starting from
4-(methoxycarbonyl)phenylboronic acid and 2-chloroquinolin-6-ol,
using Na.sub.2CO.sub.3 instead of TEA.
[0449] Step 2: Synthesis of
6-hydroxy-2-(4-(methoxycarbonyl)phenyl)quinoline 1-oxide: To a
solution of above compound (200 mg, 0.72 mmol) in 1,4-dioxane (5
mL) was added mCPBA (372 mg, 2.16 mmol). The mixture was stirred at
room temperature for three days. The volatiles were removed under
reduced pressure. The residue was partitioned with sat.
Na.sub.2CO.sub.3 solution (10 mL) and EtOAc (20 mL). The organic
phase was washed with brine (10 mL), dried over Na.sub.2SO.sub.4,
concentrated and purified by column chromatography to afford
product (40 mg, 18.9%).
[0450] Step 3: Synthesis of 2-(4-carboxyphenyl)-6-hydroxyquinoline
1-oxide: A solution of the above compound (40 mg, 0.14 mmol) and
NaOH (16 mg, 0.41 mmol) in 1,4-dioxane/water (1.5 mL/0.5 mL) was
heated at 80.degree. C. for 2 h. The volatiles were removed in
vacuo. The residue was partitioned with water (8 mL) and EtOAc (10
mL). The aqueous phase was separated, acidified with 1 N HCl to
pH=5. The resulting precipitate was filtered, washed with water and
EtOH, and dried in vacuo to afford Compound IV-32 (10 mg, 25.6%).
.sup.1H NMR (MeOD-d.sub.4, 500 MHz): 8.61 (d, J=9.5 Hz, 1H), 8.20
(d, J=8.0 Hz, 2H), 8.04-7.99 (m, 3H), 7.65 (d, J=8.5 Hz, 1H), 7.48
(dd, J=2.0 Hz, J=9.0 Hz, 1H), 7.30 (d, J=2.0 Hz, 1H); MS (ESI): m/z
282.0 [M+1].sup.+.
Example 33
Compound IV-33:
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-thiadiazol-2(3H)-one
##STR00075##
[0452] Example procedure for Scheme 5, Compound A:
[0453] Step 1: Synthesis of tert-butyl
2-(4-(6-methoxyquinolin-2-yl)benzoyl)hydrazinecarboxylate: Scheme
5, step 1 of route A (see Example 24, step 1) starting from
4-(6-methoxyquinolin-2-yl)benzoic acid (prepared following Scheme
3).
[0454] Step 2: Synthesis of tert-butyl
2-(4-(6-methoxyquinolin-2-yl)phenylcarbonothioyl)hydrazinecarboxylate:
A mixture of above compound (2.30 g, 5.85 mmol) and lawesson's
reagent (2.30 g, 5.69 mmol) in anhydrous toluene (150 mL) was
refluxed overnight. The resulting mixture was concentrated in
vacuo. The residue was washed with MeOH and the solid was isolated.
The filtrate was concentrated in vacuo and the residue was purified
by silica gel column (PE/EtOAc=3/1) to give crude tert-butyl
2-(4-(6-methoxyquinolin-2-yl)phenylcarbonothioyl)
hydrazinecarboxylate (2.00 g).
[0455] Step 3: Synthesis of
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,3,4-thiadiazol-2(3H)-one: A
mixture of tert-butyl
2-(4-(6-methoxyquinolin-2-yl)phenylcarbonothioyl)hydrazinecarboxylate
(500 mg, 1.49 mmol) and AlCl.sub.3 (600 mg, 4.50 mmol) in anhydrous
DCM (50 mL) was refluxed overnight. Reaction was cooled, followed
by an aqueous/EtOAc workup. The residue was purified by prep-HPLC
(0.1% TFA as additive) to give Compound IV-33 (35 mg, yield 7%) as
a solid. .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 13.22 (brs,
1H), 10.22 (brs, 1H), 8.40-8.28 (m, 3H), 8.11 (d, J=8.8 Hz, 1H),
7.98 (d, J=8.8 Hz, 1H), 7.86 (d, J=8.4 Hz, 2H), 7.38 (dd, J=9.2,
2.8 Hz, 1H), 7.22 (d, J=2.8 Hz, 1H). MS (ESI): m/z 321.7
[M+H].sup.+.
Example 34
Compound IV-34:
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-3(2H)-one
##STR00076##
[0457] Step 1: Synthesis of 4-(6-methoxyquinolin-2-yl)benzamide: To
a suspension of 4-(6-methoxyquinolin-2-yl)benzonitrile (5.00 g,
15.4 mmol, prepared following Scheme 2, Step 1 starting from
Intermediate 1 and 4-cyanophenylboronic acid) in DMSO (40 mL) was
added aqueous NaOH (1M, 10 mL). The mixture was cooled to 0.degree.
C. The aqueous H.sub.2O.sub.2(30%, 30 mL) was added dropwise. After
addition, the mixture was stirred at 0.degree. C. for 30 minutes.
The mixture was quenched with saturated Na.sub.2SO.sub.3 (100 mL)
and filtered. The precipitate was washed with H.sub.2O (50 mL) and
MeOH (50 mL). The filter cake was dried via high vacuum to give the
desired product (5.50 g, yield: 99+%) as a solid.
[0458] Step 2: Synthesis of
5-(4-(6-methoxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-3-ol: To a
suspension of 4-(6-methoxyquinolin-2-yl)benzamide (2.00 g, 7.19
mmol) in DCE (20 mL) was added oxalyl chloride (1.10 g, 8.99 mmol)
rapidly at 30.degree. C. The mixture was heated to 70.degree. C.
for 16 hours. The solvent was removed in vacuo to give a yellow
solid (2.00 g), which was used directly without further
purification. A suspension of this material (2.00 g) in TMSN.sub.3
(30 mL) was heated to 90.degree. C. for two days. The excess
TMSN.sub.3 was removed in vacuo and the residue was diluted with
EtOH (200 mL). The mixture was filtered off and the filtrate was
concentrated to give
5-(4-(6-methoxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-3-ol (700 mg,
two step yield: 30%) as a solid.
[0459] Step 3: Synthesis of
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-oxadiazol-3-ol: Followed
Scheme 2, Step 2, B conditions to give Compound IV-34 (60 mg,
yield: 18%) as a solid. .sup.1H NMR (DMSO 400 MHz): .delta. 12.90
(brs, 1H), 10.15 (brs, 1H), 8.45 (d, J=8.4 Hz, 2H), 8.30 (d, J=8.4
Hz, 1H), 8.15-8.10 (m, 3H), 7.92 (d, J=9.2 Hz, 1H), 7.5 (dd, J=8.8,
2.4 Hz, 1H), 7.20 (d, J=2.8 Hz, 1H). MS (ESI): m/z 305.9
[M+H].sup.+.
Example 35
Compound IV-35:
(1r,4r)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid
##STR00077##
[0461] Step 1: Synthesis of ethyl
4-(3-chloro-6-methoxyquinolin-2-yl)cyclohex-3-enecarboxylate:
Followed Scheme 2, Step 1 (see Example 8, Step 1) starting from
ethyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate
and 2,3-dichloro-6-methoxyquinoline (Intermediate 4).
[0462] Step 2: Synthesis of ethyl
4-(3-chloro-6-methoxyquinolin-2-yl)cyclohexanecarboxylate: To ethyl
4-(3-chloro-6-methoxyquinolin-2-yl)cyclohex-3-enecarboxylate (900
mg, 2.60 mmol) in EtOH (40 mL) was added Rh(PPh.sub.3).sub.3Cl
(90.0 mg 0.0900 mmol). The mixture was stirred at 30.degree. C. for
4 days under H.sub.2 (15 psi). The mixture was filtered off and the
filtrate was concentrated to give the crude product, which was
purified by silica gel column (PE/EtOAc=10/1) to give the desired
product (234 mg, yield 26%).
[0463] Step 3: Synthesis of
(1r,4r)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid: To a mixture of ethyl
4-(3-chloro-6-methoxyquinolin-2-yl)cyclohexanecarboxylate (200 mg,
0.580 mmol) in anhydrous CH.sub.2Cl.sub.2 (10 mL) was added
BBr.sub.3 (0.3 mL, 2.9 mmol) dropwise at 0.degree. C. The mixture
was stirred at 0.degree. C. for 2 hours. Water (10 mL) was added
and the mixture was extracted with EtOAc (30 mL.times.3). The
combined organic layers were washed with brine (20 mL.times.2),
dried over Na.sub.2SO.sub.4, filtered and concentrated to give the
crude product, which was purified by prep-HPLC (0.1% TFA as
additive) to give
(1r,4r)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid (Compound IV-35, 65 mg, yield 37%) as a solid, and
(1s,4s)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid (Compound IV-36, 26 mg, yield 15%) as a solid. The structure
was confirmed by NOE. Data for Compound IV-35: .sup.1H NMR (DMSO
400 MHz): .delta. 10.08 (brs, 1H), 8.27 (s, 1H), 7.79 (d, J=8.8 Hz,
1H), 7.26 (dd, J=9.2, 2.8 Hz, 1H), 7.08 (d, J=2.8 Hz, 1H), 3.18
(tt, Jaa=12.0 Hz, Jea=3.2 Hz, 1H), 2.28 (tt, Jaa=12.0 Hz, Jea=3.2
Hz, 1H), 2.03 (d, J=10.4 Hz, 2H), 1.91 (d, J=10.8 Hz, 2H),1.72-1.60
(m, 2H), 1.55-1.40 (m, 2H). MS (ESI): m/z 306.0 [M+H].sup.+.
Example 36
Compound IV-36:
(1s,4s)-4-(3-chloro-6-hydroxyquinolin-2-yl)cyclohexanecarboxylic
acid
##STR00078##
[0465] See Example 35 for synthesis. .sup.1H NMR (DMSO 400 MHz):
.delta. 10.11 (brs, 1H), 8.28 (s, 1H), 7.82 (d, J=9.2 Hz, 1H), 7.27
(dd, J=9.2, 2.8 Hz, 1H), 7.09 (d, J=2.8 Hz, 1H), 3.32-3.19 (m, 1H),
2.70-2.60 (m, 1H), 2.25-2.14 (m, 2H), 1.85-1.70 (m, 4H), 1.70-1.58
(m, 2H). MS (ESI): m/z 306.0 [M+H].sup.+.
Example 37
Compound IV-37: 3-chloro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid
##STR00079##
[0467] Followed Scheme 2, B conditions starting with
2-chloro-4-fluoro-6-methoxyquinoline (Intermediate 7) and
4-carboxy-2-chlorophenylboronic acid. .sup.1H NMR (MeOD 400 MHz):
.delta. 8.20 (d, J=1.2 Hz, 1H), 8.10 (dd, J=8.0, 1.6 Hz, 1H), 8.02
(d, J=9.2, 1.2 Hz, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.52-7.45 (m, 2H),
7.47 (d, J=2.4 Hz, 1H). MS (ESI): m/z 317.9 [M+H].sup.+.
Example 38
Compound IV-38:
2-(5-(2H-tetrazol-5-yl)thiophen-2-yl)quinolin-6-ol
##STR00080##
[0469] Step 1 and 2: Synthesis of
5-(6-hydroxyquinolin-2-yl)thiophene-2-carbonitrile: Followed the
two step synthesis shown in Scheme 1 starting with
2-chloro-6-methoxyquinoline and 5-cyanothiophen-2-ylboronic acid,
with minor variations: the base used in step 1 was sodium carbonate
and the solvent was DME (dimethoxyethane)/water. In step 2, after
quenching w/ ice water, a standard ethyl acetate extraction was
preformed followed by purification by prep-TLC (PE:EA=1:1).
[0470] Step 3: Synthesis of
2-(5-(2H-tetrazol-5-yl)thiophen-2-yl)quinolin-6-ol: Followed Scheme
4, route A. .sup.1H-NMR (DMSO-d.sub.6 500 MHz): 10.15 (s, 1H), 8.23
(d, J=9.0 Hz, 1H), 8.05 (d, J=8.5 Hz, 1H), 7.99 (d, J=4.0 Hz, 1H),
7.86 (d, J=9.0 Hz, 1H), 7.78 (d, J=3.5 Hz, 1H), 7.34 (dd, J=2.5,
9.0 Hz, 1H), 7.17 (d, J=2.0 Hz, 1H). MS (ESI): m/z 296.0
[M+1].sup.+.
Example 39
Compound IV-39:
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-3(2H)-one
##STR00081##
[0472] Step 1: Synthesis of
4-(6-methoxyquinolin-2-yl)benzothioamide: To a suspension of
4-(6-methoxyquinolin-2-yl)benzamide (see Example 34 step 1 for
synthesis, 3.00 g, 10.8 mmol) in anhydrous toluene (50 mL) was
added Lawessen Reagent (2.60 g, 6.44 mmol). The mixture was
refluxed for 3 hours. The mixture was diluted with MeOH (50 mL) and
filtered off. The filtrate was concentrated under reduce pressure
to give the crude product, which was purified by silica gel column
(PE/EtOAc=1/1) to give the product (1.30 g, yield 41%) as a
solid.
[0473] Step 2 and 3: Synthesis of
5-(4-(6-methoxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-3(2H)-one: To
a solution of 4-(6-methoxyquinolin-2-yl)benzothioamide (500 mg,
1.07 mmol) in DCE (10 mL) was added oxalylchloride (0.3 mL, 3.9
mmol) dropwise at 0.degree. C. The mixture was heated to 90.degree.
C. for 2 hours. TMSN.sub.3 (0.8 mL, 5.7 mmol) was added dropwise.
The mixture was stirred at 100.degree. C. for 2 hours. Water (10
mL) was added to the mixture. The mixture was filtered and the
filter cake was washed with IPA (20 mL) to product (280 mg, yield
49%).
[0474] Step 4: Synthesis of
5-(4-(6-hydroxyquinolin-2-yl)phenyl)-1,2,4-thiadiazol-3(2H)-one:
Followed Scheme 2, Step 2, B conditions for demethylation. .sup.1H
NMR (DMSO 400 MHz): .delta. 12.76 (brs, 1H), 10.16 (brs, 1H), 8.41
(d, J=8.4 Hz, 2H), 8.29 (d, J=8.8 Hz, 1H), 8.15-8.02 (m, 3H), 7.95
(d, J=9.2 Hz, 1H), 7.36 (dd, J=9.2, 2.8 Hz, 1H), 7.19 (d, J=2.4 Hz,
1H), MS (ESI): m/z 321.9 [M+H].sup.+.
Example 40
Compound IV-40: 3-fluoro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid
##STR00082##
[0476] The compound was prepared following Scheme 2, B conditions
starting from 2-chloro-4-fluoro-6-methoxyquinoline (Intermediate 7)
and 4-carboxy-2-fluorophenylboronic acid. Note: In step 2, after
purification by prep HPLC, the collected fractions were immediately
neutralized with sat. NaHCO.sub.3 to pH 6, followed by extraction
with EtOAc/MeOH (v/v=10/1, 50 mL.times.3). Combined organics were
washed with brine (50 mL), dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to give the desired product. .sup.1H NMR
(MeOD 400 MHz): .delta. 8.10-8.00 (m, 2H), 7.98 (dd, J=8.0, 1.2 Hz,
1H), 7.85 (dd, J=11.6, 1.2 Hz, 1H), 7.62 (dd, J=11.6, 2.0 Hz, 1H),
7.45 (dd, J=9.2, 2.8 Hz, 1H), 7.31 (d, J=2.8 Hz, 1H). MS (ESI): m/z
301.8 [M+H].sup.+.
Example 41
Compound IV-41:
1-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)piperidine-4-carboxylic
acid
##STR00083##
[0478] Step 1: Synthesis of methyl
1-(6-methoxy-3-(trifluoromethyl)quinolin-2-yl)piperidine-4-carboxylate:
To a solution of 2-chloro-6-methoxy-3-(trifluoromethyl)quinoline
(1.00 g, 3.85 mmol) (see Intermediate 6, Step 8 for synthesis) in
IPA (5 mL) was added methyl-4-piperidinecarboxylate (5.50 g, 38.5
mmol) and Et.sub.3N (1.17 g, 11.6 mmol). The mixture was heated to
reflux for 48 hours. The mixture was diluted with water (100 mL)
and extracted with DCM (100 mL.times.3), the combined organic
layers were washed with brine (200 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give the crude product, which was purified by column
chromatography on silica gel (PE/EtOAc=15/1) to give the product
(600 mg, yield 43%) as a solid.
[0479] Step 2: Synthesis of
1-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)piperidine-4-carboxylic
acid: To a solution of methyl
1-(6-methoxy-3-(trifluoromethyl)quinolin-2-yl)piperidine-4-carboxylate
(300 mg, 0.815 mmol) in DCM (5 mL) was added BBr.sub.3 (0.4 mL,
4.08 mmol) dropwise at 0.degree. C. The mixture was stirred at
0.degree. C. for 20 hours. Water (10 mL) was added to the mixture
dropwise at 0.degree. C. The mixture was concentrated in vacuo,
then diluted with EtOAc (150 mL), filtered and concentrated in
vacuo. Purification by prep-HPLC (0.1% TFA as additive) to give
Compound IV-41 (26 mg, yield 9.4%) as a solid. .sup.1H NMR (MeOD
400 MHz): .delta. 8.51 (s, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.41 (dd,
J=8.8, 2.8 Hz, 1H), 7.21 (d, J=2.8 Hz, 1H), 3.55-3.49 (m, 2H),
3.13-3.02 (m, 2H), 2.58-2.49 (m, 1H), 2.09-2.00 (m, 2H), 1.93-1.82
(m, 2H). MS (ESI): m/z 340.7 [M+H].sup.+.
Example 42
Compound IV-42: 4-(5-chloro-6-hydroxyquinolin-2-yl)benzoic acid
##STR00084##
[0481] Step 1: Synthesis of methyl
4-(6-methoxyquinolin-2-yl)benzoate: A mixture of
2-chloro-6-methoxyquinoline (Intermediate 1, 200 mg, 1.0 mmol),
4-(methoxycarbonyl)phenylboronic acid (205 mg,1.1 mmol),
Pd(dppf)Cl.sub.2 (366 mg, 0.5 mmol) and sodium carbonate (212 mg,
2.0 mmol) in 1,4-dioxane/water (3mL/0.6 mL) was heated to
120.degree. C. by microwave for 1 h. The precipitates were
filtered; washed with EA (10 mL), acetone (10 mL) and water (10 mL)
separately; dried to afford product (120 mg, 40.9%).
[0482] Step 2: Synthesis of methyl
4-(5-chloro-6-methoxyquinolin-2-yl)benzoate: To a solution of above
(100 mg, 0.34 mmol) in AcOH (2 mL) was added SO.sub.2Cl.sub.2 (55
mg, 0.41 mmol). The reaction mixture was heated to 60.degree. C.
for 3 h. Then the mixture was stirred at room temperature
overnight. The precipitates were filtrated, washed with AcOH (10
mL.times.3) and dried to give the product as a powder (100 mg,
90.1%).
[0483] Step 3: Synthesis of
4-(5-chloro-6-hydroxyquinolin-2-yl)benzoic acid: Followed Scheme 1,
step 2, with a purification by prep HPLC to give the product.
.sup.1H-NMR (DMSO-d.sub.6 500 MHz): 8.50 (d, J=9.0 Hz, 1H), 8.32
(d, J=8.0 Hz, 2H), 8.25 (d, J=8.5 Hz, 1H), 8.10 (d, J=8.0 Hz, 2H),
7.96 (d, J=9.5 Hz, 1H), 7.62 (d, J=9.0 Hz, 1H); MS (ESI): m/z 300.0
[M+1].sup.+.
Example 43
Compound IV-43:
(1r,4r)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid
##STR00085##
[0485] Step 1: Synthesis of ethyl
4-(6-methoxy-3-(trifluoromethyl)quinolin-2-yl)cyclohex-3-enecarboxylate:
Followed Scheme 2, Step 1 (see Example 8, Step 1) starting from
ethyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate
and 2-chloro-6-methoxy-3-(trifluoromethyl)quinoline (see
Intermediate 6, Step 8 for synthesis), with a purification by
column chromatography (PE/EtOAc=10/1).
[0486] Step 2: Synthesis of ethyl
4-(6-methoxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxylate:
Followed step 2 of Compound IV-35 with 0.15 equiv of catalyst at
20.degree. C. for 4 days under H.sub.2 (15 psi).
[0487] Step 3: Synthesis of
(1r,4r)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid: Followed step 3 of Compound IV-35, where the reaction was
stirred at 10.degree. C. for 20 hours before quenching with water.
Purified crude by prep-HPLC to give ethyl
4-(6-methoxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxylate
(Compound IV-43, 109 mg, yield 29%) as a solid, and
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid (Compound IV-44, 25 mg, yield 7%) as a solid. Compound
IV-43 Data: .sup.1H NMR (DMSO 400 MHz): .delta. 10.27 (brs, 1H),
8.61 (s, 1H), 7.89 (d, J=9.2 Hz, 1H), 7.44 (dd, J=9.2, 2.8 Hz, 1H),
7.32 (d, J=2.8 Hz, 1H), 3.01-2.91 (m, 1H), 2.40-2.30 (m, 1H),
2.00-1.90 (m, 2H), 1.95-1.78 (m, 4H), 1.53-1.38 (m, 2H). MS (ESI):
m/z 339.9 [M+H].sup.+.
Example 44
Compound IV-44:
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)cyclohexanecarboxyl-
ic acid
##STR00086##
[0489] See Example 43 for synthesis. .sup.1H NMR (DMSO 400 MHz):
.delta. 10.26 (br s, 1H), 8.59 (s, 1H), 7.89 (d, J=9.2 Hz, 1H),
7.43 (dd, J=9.2, 2.8 Hz, 1H), 7.31 (d, J=2.0 Hz, 1H), 3.09-2.95 (m,
1H), 2.75-2.62 (m, 1H), 2.28-2.16 (m, 2H), 1.98-1.80 (m, 2H),
1.60-1.55 (m, 4H). MS (ESI): m/z 339.9 [M+H].sup.+.
Example 45
Compound V-1: 4-(6-hydroxyquinazolin-2-yl)benzoic acid
##STR00087##
[0491] Followed Scheme 6, A conditions.
[0492] Step 1: Synthesis of 4-(6-methoxyquinazolin-2-yl)benzoic
acid: A mixture of 2-chloro-6-methoxyquinazoline (Intermediate 8,
200 mg, 1.03 mmol), 4-carboxyphenylboronic acid (205 mg, 1.23 mmol)
and K.sub.2CO.sub.3 (370 mg, 2.68 mmol) in DEGME/H.sub.2O (7.0
mL/2.0 mL) was degassed three times under N.sub.2 atmosphere. Then
PdCl.sub.2(dppf) (75 mg, 0.103 mmol) was added and the mixture was
heated to 100.degree. C. for 3 hours under N.sub.2 atmosphere. The
reaction mixture was diluted with H.sub.2O (10 mL). The aqueous
layer extracted with EtOAc/MeOH (v/v=10:1, 30 mL.times.2). Then the
aqueous layer was acidified with 2M HCl to pH 6. The precipitate
was collected by filtration and washed with MeOH (10 mL), dried
under high vacuum to give the desired product (220 mg, yield 76%).
.sup.1H NMR (DMSO 400 MHz): .delta. 13.10 (brs, 1H), 9.63 (s, 1H),
8.62 (d, J=8.0 Hz, 2H), 8.10 (d, J=8.0 Hz, 2H), 8.05 (d, J=9.2 Hz,
1H), 7.70 (dd, J=9.2, 2.8 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H), 3.98 (s,
3H).
[0493] Step 2: Synthesis of 4-(6-hydroxyquinazolin-2-yl)benzoic
acid: To a suspension of 4-(6-methoxyquinazolin-2-yl)benzoic acid
(220 mg, 0.785 mmol) in anhydrous CH.sub.2Cl.sub.2 (5 mL) was added
AlCl.sub.3 (600 mg, 4.55 mmol), the reaction mixture was refluxed
overnight. The mixture was quenched with sat. NH.sub.4Cl (10 mL),
the aqueous layer was extracted with CH.sub.2Cl.sub.2/MeOH
(v/v=10/1, 30 mL.times.3), the combined organic layer was washed
with brine (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product, which purified by prep-HPLC
(0.1% TFA as additive) to give Compound V-1 (27 mg, yield 13%).
.sup.1H NMR (MeOD 400 MHz): .delta. 9.42 (s, 1H), 8.60 (d, J=8.4
Hz, 2H), 8.17 (d, J=8.4 Hz, 2H), 8.00 (d, J=9.2 Hz, 1H), 7.60 (dd,
J=9.2, 2.8 Hz, 1H), 7.30 (d, J=2.8 Hz, 1H). MS (ESI): m/z 266.9
[M+H].sup.+.
Example 46
Compound V-2: 4-(6-hydroxy-4-methylquinazolin-2-yl)benzoic acid
##STR00088##
[0495] Followed Scheme 6, B conditions.
[0496] Step 1: Synthesis of
4-(6-methoxy-4-methylquinazolin-2-yl)benzoic acid: To a mixture of
2-chloro-6-methoxy-4-methylquinazoline (Intermediate 9, 350 mg,
1.68 mmol), 4-carboxyphenylboronic acid (418 mg, 2.52 mmol), and
K.sub.2CO.sub.3 (464 mg, 3.36 mmol) in DEGME/H.sub.2O (7 mL/1 mL)
was added Pd(dppf)Cl.sub.2 (30.2 mg, 0.0369 mmol) under N.sub.2
atmosphere. Then the mixture was heated to 120.degree. C. for 2
hours. To the reaction mixture was added H.sub.2O (30 mL),
extracted with EtOAc (15 mL.times.2), the aqueous layer was
acidified with 1M HCl to pH=1.about.2, filtered and the filter cake
was washed with MeOH and dried under high vacuum to give the
product (380 mg, yield 78%). .sup.1H NMR (DMSO-d400 MHz): .delta.
8.61 (d, J=8.0 Hz, 2H), 8.10 (d, J=8.4 Hz, 2H), 7.99 (d, J=9.2 Hz,
1H), 7.65 (dd, J=9.2, 2.8 Hz, 1H), 7.54 (d, J=2.8 Hz, 1H), 3.98 (s,
3H), 2.99 (s, 3H).
[0497] Step 2: Synthesis of
4-(6-hydroxy-4-methylquinazolin-2-yl)benzoic acid: To a solution of
4-(6-methoxy-4-methylquinazolin-2-yl)benzoic acid (180 mg, 0.612
mmol) in anhydrous DCM (10 mL) was added BBr.sub.3 (0.29 mL, 3.05
mmol, d=2.64 g/mL) dropwise at 0.degree. C. The resulting mixture
was stirred at 25.degree. C. for 16 hours. The reaction mixture was
quenched with H.sub.2O (30 mL), then extracted with DCM (20
mL.times.3). The combined organic layers were washed with brine (20
mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product. The crude product was
washed with MeOH (10 mL) to give Compound V-2 (130 mg, yield 76%).
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 13.06 (brs, 1H), 10.46
(brs, 1H), 8.60 (d, J=8.4 Hz, 2H), 8.09 (d, J=8.4 Hz, 2H), 7.95 (d,
J=9.2 Hz, 1H), 7.56 (dd, J=8.8, 2.4 Hz, 1H), 7.41 (d, J=2.4 Hz,
1H), 2.90 (s, 3H). MS (ESI): m/z 280.9 [M+H].sup.+.
Example 47
Compound V-3: 3-chloro-4-(6-hydroxyquinazolin-2-yl)benzoic acid
##STR00089##
[0499] Prepared according to Scheme 6, B conditions, starting from
Intermediate 8 and 4-carboxy-2-chlorophenylboronic acid. .sup.1H
NMR (DMSO-d.sub.6 400 MHz): .delta. 10.60 (brs, 1H), 9.56 (s, 1H),
8.10-7.89 (m, 4H), 7.62 (dd, J=9.2, 2.8 Hz, 1H), 7.38 (d, J=2.8 Hz,
1H). MS (ESI): m/z 300.8 [M+H].sup.+.
Example 48
Compound V-4: 4-(6-hydroxyquinazolin-2-yl)-3-methylbenzoic acid
##STR00090##
[0501] Prepared according to Scheme 6, B conditions, starting from
Intermediate 8 and methyl
3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate.
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 9.54 (s, 1H), 8.00-7.86
(m, 4H), 7.60 (dd, J=8.8, 2.4 Hz, 1H), 7.36 (d, J=2.4 Hz, 1H), 2.59
(s, 3H). MS (ESI): m/z 280.9[M+H].sup.+.
Example 49
Compound V-5: 4-(6-hydroxyquinazolin-2-yl)-3-methoxybenzoic
acid
##STR00091##
[0503] Prepared according to the first step of Compound V-2
starting from Intermediate 10 and 4-borono-3-methoxybenzoic acid.
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 9.53 (s, 1H), 7.94 (d,
J=9.2 Hz, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.70-7.58 (m, 3H), 7.37 (d,
J=2.8 Hz, 1H), 3.84 (s, 3H). MS (ESI): m/z 296.9 [M+H].sup.+.
Example 50
Compound V-6: 3-fluoro-4-(6-hydroxyquinazolin-2-yl)benzoic acid
##STR00092##
[0505] Prepared according to Scheme 6, B conditions starting from
Intermediate 8 and 4-carboxy-2-fluorophenylboronic acid, where the
crude product of step 2 was purified by prep-HPLC (0.1% TFA as
additive) after which most of the CH.sub.3CN was removed under
reduced pressure and the remaining solvent was removed by
lyophilization to give the product (40 mg, yield 38%). .sup.1H NMR
(MeOD 400 MHz): .delta. 9.42 (s, 1H), 8.13 (t, J=7.6 Hz, 1H),
8.02-7.95 (m, 2H), 7.86 (d, J=11.2 Hz, 1H), 7.62 (dd, J=9.2, 2.4
Hz, 1H), 7.32 (d, J=2.4 Hz, 1H). MS (ESI): m/z 284.9
[M+H].sup.+.
Example 51
Compound V-7: 1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylic
acid
##STR00093##
[0507] Step 1: Synthesis of methyl
1-(6-methoxyquinazolin-2-yl)piperidine-4-carboxylate: A mixture of
2-chloro-6-methoxyquinazoline (Intermediate 8, 700 mg, 3.60 mmol),
methyl 4-piperidinecarboxylate (2.58 g, 18.0 mmol) and Et.sub.3N
(729 mg, 7.20 mmol) in .sup.iPrOH (15 mL) was heated to 50.degree.
C. for 16 hours. The reaction mixture was diluted with EtOAc (100
mL) and washed with H.sub.2O (30 mL.times.2) and brine (30 mL),
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give the crude product. The crude product
was purified by prep-HPLC (0.1% TFA as additive). Most of
CH.sub.3CN was removed under reduced pressure and the remaining
solvent was removed by lyophilization to give the product (1.10 g,
yield: 73%).
[0508] Step 2: Synthesis of methyl
1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylate: Followed
Scheme 6, Step 2, B conditions for BBr.sub.3 deprotection.
[0509] Step 3: Synthesis of
1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylic acid: To a
solution of methyl
1-(6-hydroxyquinazolin-2-yl)piperidine-4-carboxylate (330 mg, crude
from above) in MeOH (10 mL) was added aqueous NaOH (10 mL, 2M). The
mixture was stirred at 25.degree. C. for 16 hours. The reaction
mixture was acidified with 1N HCl to pH=1.about.2, then
concentrated to give a residue, which was diluted with EtOAc (100
mL), filtered and concentrated to give the crude product which was
purified by prep-HPLC (0.1% TFA as additive). Most of the solvent
was removed in vacuo followed by lyophilization to give the product
(70 mg, 2-step yield: 19%) as a solid. .sup.1H NMR (DMSO-d.sub.6
400 MHz): .delta. 9.15 (s, 1H), 7.51 (d, J=9.2 Hz, 1H), 7.37 (dd,
J=9.2, 2.8 Hz, 1H), 7.13 (d, J=2.8 Hz, 1H), 4.59 (d, J=13.2 Hz,
2H), 3.16 (t, J=11.4 Hz, 2H), 2.68-2.52 (m, 1H), 1.93 (dd, J=13.2,
3.2 Hz, 2H), 1.62-1.48 (m, 2H). MS (ESI): m/z 274.1
[M+H].sup.+.
Example 52
Compound VI-1:
3-chloro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid
##STR00094##
[0511] Step 1: Synthesis of
3-chloro-4-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid: A mixture of
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline (Intermediate 11,
150 mg, 0.571 mmol), 4-carboxy-2-chlorophenylboronic acid (115 mg,
0.571 mmol), K.sub.2CO.sub.3 (160 mg, 1.14 mmol) and
Pd(dppf)Cl.sub.2 (50 mg, 0.0612 mmol) in diethylene glycol
monomethyl ether (2 mL) and water (0.6 mL) was stirred at
120.degree. C. under N.sub.2 atmosphere for 2 hours. The resulting
mixture was cooled to room temperature and diluted with water (50
mL), acidified with aqueous HCl (2M) until pH=5, extracted with
EtOAc (50 mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The residue was purified by column chromatography on
silica gel (PE/EtOAc=1/1) to give the product (150 mg, yield 68%)
as a solid.
[0512] Step 2: Synthesis of
3-chloro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid: A mixture of
3-chloro-4-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid (150 mg, 0.392 mmol) and BBr.sub.3 (3 mL) in anhydrous DCM (30
mL) was stirred at 25.degree. C. overnight. The resulting mixture
was quenched with water (30 mL), extracted with EtOAc (50
mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The residue was purified by prep-HPLC (0.1% TFA as additive) to
give Compound VI-1 (26 mg, yield 18%) as a solid. .sup.1H NMR
(DMSO-d.sub.6 400 MHz): .delta. 11.22 (brs, 1H), 8.14 (d, J=9.2 Hz,
1H), 8.10 (d, J=1.6 Hz, 1H), 8.04 (dd, J=8.0, 1.6 Hz, 1H), 7.77 (d,
J=8.0 Hz, 1H), 7.70 (dd, J=9.2, 1.8 Hz, 1H), 7.47 (d, J=1.8 Hz,
1H). MS (ESI): m/z 369.0 [M+H].sup.+.
Example 53
Compound VI-2:
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic acid
##STR00095##
[0514] Followed the procedure described for Compound VI-1, starting
from Intermediate 11 and 4-boronobenzoic acid. .sup.1H NMR
(MeOH-d.sub.4 500 MHz): .delta. 8.07 (d, J=8.5 Hz, 2H), 7.96 (d,
J=9.0 Hz, 1H), 7.61 (d, J=8.5 Hz, 2H), 7.51 (dd, J=2.5, 9.5 Hz;
1H), 7.35 (d, J=2.5 Hz,1H); MS (ESI): m/z 335 [M+1].sup.+.
Example 54
Compound VI-3:
2-(4-(2H-tetrazol-5-yl)phenyl)-3-(trifluoromethyl)quinoxalin-6-ol
##STR00096##
[0516] Step 1: Synthesis of
2-(4-(2H-tetrazol-5-yl)phenyl)-6-methoxy-3-(trifluoromethyl)quinoxaline:
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline (Intermediate 11,
321 mg) was treated with (4-(2H-tetrazol-5-yl)phenyl)boronic acid
(256 mg), K.sub.2CO.sub.3 (338 mg) and PdCl.sub.2(dppf) (27 mg) in
diethylene glycol methyl ether (3 mL) and water (0.8 mL) in a
sealed microwave tube and heated at 120.degree. C. with microwave
for 1.5 h. The resultant mixture was diluted with water (20 mL) and
acidifed to pH 4 to precipatate the desired product. The solids
were collected by filtration, dried under vacuum and trituated with
DCM to give 360 mg of gray solid.
[0517] Step 2: Synthesis of Compound VI-3: Above product was
treated with excess BBr.sub.3 in DCM over night. After removal of
all solvents, the resultant mixture was suspended in NaHCO.sub.3
solution and stirred for a couple of hours. The solids were
collected, dried and triturated with DCM to afford the desired
product. .sup.1H NMR (DMSO-d.sub.6 300 MHz): .delta. 8.16-8.21 (m,
3H), 7.80 (1H, d, J=9 Hz), 7.61 (1H, dd, J=3 and 9 hz), 7.13 (1H,
d, J=9 Hz), 7.40 (1H, d, J=3Hz). MS (ESI): m/z 359.0
[M+1].sup.+.
Example 55
Compound VI-4:
1-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)piperidine-4-carboxylic
acid
##STR00097##
[0519] Step 1: Synthesis of ethyl
1-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)piperidine-4-carboxylate:
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline (Intermediate 11,
240 mg) was suspended in MeCN (1.5 mL) with ethyl
piperidine-4-carboxylate (173 mg) and TEA (205 mg) in a sealed
microwave tube and heated at 150.degree. C. with microwave for
three hours. The resultant mixture was purified by silica gel
column chromatography to afford 310 mg of ethyl
1-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)
piperidine-4-carboxylate.
[0520] Step 2: Synthesis of Compound VI-4: Followed BBr.sub.3
deprotection described in Step 2 of Compound VI-3, with further
purification by column chromatography. .sup.1H NMR (DMSO-d.sub.6
300 MHz): .delta. 10.52 (1H, s), 7.80 (1H, d, J=12 Hz), 7.47 (1H,
dd, J=3, 12 Hz), 7.26 (1H, d, J=12 Hz), 3.50 (2H, d, J=12 hz), 2.95
(2H, dd, J=12 Hz), 2.44 (1H, m), 1.95 (2H, m), 1.75 (2H, m) ppm. MS
(ESI): m/z 342.0.0 [M+1].sup.+.
Example 56
Compound VI-5,
4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohex-3-enecarboxylic
acid
##STR00098##
[0522] 2-Chloro-3-(trifluoromethyl)quinoxalin-6-ol (Intermediate
14, 109 mg) was suspended with K.sub.2CO.sub.3 (97 mg), ethyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate
(117 mg), PdCl.sub.2(dppf) (13 mg) in dioxane (1 mL) and water (0.2
mL) in a sealed microwave tube and heated at 100.degree. C. over 40
min with microwave. The resultant mixture was diluted with water (5
mL) and MeOH (2 mL) and treated with LiOH (65 mg) overnight. After
filtration through a pad of Celite, the clear aqueous layer was
acidified with 1N HCl to pH 3. After the suspended solution was
stirred over 1 h, filtration and rinsing with water afforded the
desired product (125 mg). .sup.1H NMR (DMSO-d.sub.6 300 MHz):
.delta. 12.30 (1H, s), 10.93 (1H, s), 8.04 (1H, d, J=9 Hz), 7.59
(1H, dd, J=3, 9 hz), 7.35 (1H, d, J=3Hz), 5.84 (1H, s), 2.58 (1H,
m), 2.34 (4H, m), 2.07 (1H, m), 1.75 (1H, m) ppm. MS (ESI): m/z
339.0 [M+1].sup.+.
Example 57
Compound VI-6: 4-(6-hydroxyquinoxalin-2-yl)benzoic acid
##STR00099##
[0524] Step 1: Synthesis of methyl
4-(6-methoxyquinoxalin-2-yl)benzoate: To a solution of methyl
4-acetylbenzoate (1.00 g, 5.61 mmol) in DMSO (5 mL) was slowly
added 40% HBr (1.5 mL) at 20.degree. C. under stirring. The mixture
was stirred at 60.degree. C. for 12 hours. The mixture was diluted
with water (10 mL) and the resulting mixture was extracted with DCM
(10 mL.times.3), washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to give methyl
4-(2-oxoacetyl)benzoate (150 mg), which was taken forward without
further purification. To a solution of 4-methoxybenzene-1,2-diamine
(107 mg, 0.78 mmol) in 5 mL of acetic acid was added the crude
methyl 4-(2-oxoacetyl)benzoate (150 mg). The mixture was refluxed
for 2.5 hours. The solvent was removed in vacuo. The crude product
was purified by prep-TLC (PE/EA: 1/1) to separate the desired
methyl 4-(6-methoxyquinoxalin-2-yl)benzoate (more polar) from the
undesired methyl 4-(7-methoxyquinoxalin-2-yl)benzoate. The two
structures were confirmed by HMBC spectra.
[0525] Step 2: Synthesis of 4-(6-methoxyquinoxalin-2-yl)benzoic
acid: A mixture of methyl 4-(6-methoxyquinoxalin-2-yl)benzoate (80
mg, 0.272 mmol) and aqueous NaOH (5 mL, 2M) in MeOH (5 mL) was
stirred at 30.degree. C. overnight. The resulting mixture was
concentrated in vacuo. The residue was acidified with aqueous HCl
(2M) until pH=3 and concentrated. The solid was dissolved in MeOH
(30 mL) and filtered. The filtrate was concentrated in vacuo to
give crude product (80 mg), which was used for next step directly
without further purification.
[0526] Step 3: Synthesis of 4-(6-hydroxyquinoxalin-2-yl)benzoic
acid: Followed the procedure described in step 2 of Compound VI-1.
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 13.16 (brs, 1H), 10.68
(brs, 1H), 9.50 (s, 1H), 8.41 (d, J=8.4 Hz, 2H), 8.12 (d, J=8.4 Hz,
2H), 8.03 (d, J=8.8 Hz, 1H), 7.47 (dd, J=8.8, 2.8 Hz, 1H), 7.32 (d,
J=2.8 Hz, 1H). MS (ESI): m/z 266.7 [M+H].sup.+.
Example 58
Compound VII-1:
3-(4-carboxyphenyl)-7-hydroxybenzo[e][1,2,4]triazine 1-oxide
##STR00100##
[0528] Step 1: Synthesis of
3-amino-7-hydroxybenzo[e][1,2,4]triazine 1-oxide: this intermediate
was prepared according to the published method in WO 2006024034
starting from 4-amino-3-nitrophenol.
[0529] Step 2: Synthesis of 3,7-dihydroxybenzo[e][1,2,4]triazine
1-oxide: Sodium nitrite (22 mmol) was added in small portions to a
stirred solution of 3-amino-7-hydroxybenzo[e][1,2,4]triazine
1-oxide (20 mmol) in TFA (40 mL) at 5.degree. C., and the solution
stirred at 20.degree. C. for 3 h. The solution was poured into
ice/water (400 mL), stirred 30 min, filtered, washed with water
(3.times.10 mL) and dried.
[0530] Step 3: Synthesis of
3-chloro-7-hydroxybenzo[e][1,2,4]triazine 1-oxide: 1 g of
3,7-dihydroxybenzo[e][1,2,4]triazine 1-oxide was suspended in
POCl.sub.3 (20 mL) and DMF (0.1 mL) and stirred at 100.degree. C.
for 2 h. The solution was cooled, poured into ice/water (200 mL),
stirred for 30 min, filtered, washed with water (3.times.10 mL) and
dried.
[0531] Step 4: Synthesis of
3-(4-carboxyphenyl)-7-hydroxybenzo[e][1,2,4]triazine 1-oxide:
3-chloro-7-hydroxybenzo[e][1,2,4]triazine 1-oxide (2 mmol) was
mixed with 1.0 equivalent of 4-(methoxycarbonyl)phenylboronic acid
and 2 equivalents of K.sub.2CO.sub.3 in 20 ml of 50% dioxane/water.
A catalytic amount of Pd(PPh.sub.3).sub.4 was added and the mixture
was heated to reflux for 2 hours. The reaction was concentrated and
re-dissolved in 20 ml water and 5 ml 1N NaOH was added to hydrolyze
the ester. The mixture was extracted with DCM (3.times.10 ml). The
aqueous layer was filtered and the filtrate was neutralized with 1N
HCl to pH=5. The precipitate was filtered and washed with water and
dried. 500 mg of product was obtained. .sup.1H NMR (DMSO-d.sub.6
400 MHz): .delta. 11.38 (s, 1H), 8.44 (d, 2H), 8.15 (m, 3H), 7.67
(d, 1H), 7.60 (s, 1H). MS (ESI): m/z 284.5 [M+1].sup.+.
Example 59
Compound VII-2: 4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic
acid
##STR00101##
[0533] 3-(4-Carboxyphenyl)-7-hydroxybenzo [e][1,2,4]triazine
1-oxide (Compound VII-1, 350 mg, 1.23 mmol) was dissolved in 70%
ethanol in water (20 ml) at reflux. 5.0 equivalents of
Na.sub.2S.sub.2O.sub.4 were added. The reaction turned dark brown.
After 30 minutes, the solution was concentrated to remove ethanol
and the solid was filtered and washed with water and dried (12 mg).
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 8.67 (d, 2H), 8.16 (d,
2H), 8.09 (d, 1H), 7.77 (d, 1H), 7.67 (s, 1H). MS (ESI): m/z 268.43
[M+1].sup.+.
Example 60
Compound VII-3:
3-(4-carboxy-2-fluorophenyl)-7-hydroxybenzo[e][1,2,4]triazine
1-oxide
##STR00102##
[0535] Prepared following the procedure described for Compound
VII-1 where the boronic acid used in Step 4 was
2-fluoro-4-(methoxycarbonyl)phenylboronic acid and using
PdCl.sub.2(dppf) as the catalyst. .sup.1H NMR (DMSO-d.sub.6 500 MHz
TMS): .delta. 8.12 (m, 2H), 7.92 (dd, 1H), 7.77 (d, 1H) 7.67 (dd,
1H), 7.61 (d, 1H); MS (ESI): m/z 302.52 [M+1].sup.+.
Example 61
Compound VII-4:
3-fluoro-4-(7-hydroxybenzo[e][1,2,4]triazin-3-yl)benzoic acid
##STR00103##
[0537] Prepared following the procedure described for Compound
VII-2, starting from
3-(4-carboxy-2-fluorophenyl)-7-hydroxybenzo[e][1,2,4]triazine
1-oxide (Compound VII-3). .sup.1H NMR (DMSO-d.sub.6 500 MHz):
.delta. 8.22 (t, 1H), 8.10 (d, 1H), 7.94 (dd, 1H), 7.82 (dd, 2H),
7.70 (d, 1H). MS (ESI): m/z 286.52 [M+1].sup.+.
Example 62
Compound VIII-1: 4-(7-hydroxyisoquinolin-3-yl)benzoic acid
##STR00104##
[0539] Step 1: Synthesis of 4-(7-methoxyisoquinolin-3-yl)benzoic
acid: Followed the procedure described in Compound IV-8 step 1,
starting with 3-chloro-7-methoxyisoquinoline (Intermediate 12) and
4-boronobenzoic acid with an alternative isolation procedure: After
reaction was complete, the reaction mixture was diluted with
H.sub.2O (10 mL). The aqueous layer was extracted with EtOAc/MeOH
(v/v=10:1, 30 mL.times.2). Then the aqueous layer was acidified
with 2M HCl to pH=6. The precipitate was collected by filtration
and washed with MeOH (10 mL), dried under high vacuum to give the
product.
[0540] Step 2: Synthesis of Compound VIII-1: Followed the procedure
described in Compound IV-8, step 2. .sup.1H NMR (DMSO-d.sub.6 400
MHz): .delta. 9.27 (s, 1H), 8.45 (s, 1H), 8.25 (d, J=8.4 Hz, 2H),
8.05 (d, J=8.4 Hz, 2H), 7.95 (d, J=8.8 Hz, 1H), 7.42 (dd, J=8.8,
2.4 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H). MS (ESI): m/z 265.9
[M+H].sup.+.
Example 63
Compound IX-1: 4-(7-hydroxyquinolin-3-yl)benzoic acid
##STR00105##
[0542] Step 1: Synthesis of 4-(7-methoxyquinolin-3-yl)benzoic acid:
To a mixture of 3-bromo-7-methoxyquinoline (Intermediate 13, 380
mg, 1.6 mmol), 4-boronobenzoic acid (266 mg, 1.6 mmol) and
Na.sub.2CO.sub.3 (848 mg, 8.0 mmol) in DME/H.sub.2O/EtOH (5 mL,
V/V/V=1/1/0.5) was added Pd(dppf)Cl.sub.2 (585 mg, 0.8 mmol). The
mixture was heated to 120.degree. C. by microwave for 1 h. The
mixture was partitioned between water (20 mL) and ethyl acetate (20
mL). The aqueous phase was separated and acidified to pH=3 with 1 N
HCl. The precipitate was filtered and dried in vacuo to afford
product as a powder (130 mg, 29.1%).
[0543] Step 2: Synthesis of Compound IX-1: To a solution of above
product (130 mg, 0.46 mmol) in DCM (3 mL) was added carefully
BBr.sub.3 (0.4 mL) at room temperature. The mixture was stirred
overnight. Water (5 mL) was added carefully. The volatiles were
evaporated and the residue was purified by prep-HPLC to afford
Compound IX-1 as a powder (80 mg, 65.6%). .sup.1HNMR (MeOH-d.sub.4
500 MHz): .delta. 9.35 (s, 1H), 9.25 (s, 1H), 8.24 (d, J=8.5 Hz,
3H), 8.00 (d, J=8.0 Hz, 2H), 7.53 (d, J=1.5 Hz, 1H), 7.45 (s, 1H);
MS (ESI): m/z 266.0 [M+1].sup.+.
Example 64
Compound IX-2: 3-(4-carboxyphenyl)-7-hydroxyquinoline 1-oxide
##STR00106##
[0545] Step 1: Synthesis of methyl
4-(7-methoxyquinolin-3-yl)benzoate: Followed Step 1 of Compound
IV-1, starting from 4-(methoxycarbonyl)phenylboronic acid and
Intermediate 13, and where the base used was Na.sub.2CO.sub.3, the
solvent DME/H.sub.2O (8:2), and the reaction was run at 100.degree.
C. for 2 h.
[0546] Step 2: Synthesis of
7-methoxy-3-(4-(methoxycarbonyl)phenyl)quinoline 1-oxide: A mixture
of methyl 4-(7-methoxyquinolin-3-yl)benzoate (632 mg, 2.16 mmol),
m-CPBA (742 mg, 4.31 mmol) and DCM (10 mL) was stirred overnight.
Saturated Na.sub.2CO.sub.3 solution was added and adjusted the
pH>7, the organic layer was washed with water (50 mL.times.2),
dried over NaSO.sub.4 and evaporated in vacuo to give the crude
product as a yellow solid (540 mg, 81.0%).
[0547] Step 3: Synthesis of Compound IX-2: To a solution of the
above product (310 mg, 1.0 mmol) in DCM (15 mL) was added BBr.sub.3
(1.0 mL, 10.6 mmol) at 0.degree. C. The reaction mixture was warmed
to room temp. and stirred for 48 h. The mixture was poured into
ice-water, filtered and washed with water, dried and purified by
prep HPLC to give Compound IX-2 (25.0 mg, 8.87%). H-NMR
(DMSO-d.sub.6 500 MHz): 8.94 (s, 1H), 8.26 (s, 1H), 8.01-8.06 (m,
3H), 7.92-7.94 (d, J=8.0 Hz, 2H), 7.81 (s, 1H). MS (ESI): m/z
=282.0 [M+1].sup.+.
Example 65
Compound VIII-2: 3-fluoro-4-(7-hydroxyisoquinolin-3-yl)benzoic
acid
##STR00107##
[0549] Step 1: A mixture of 3-chloro-7-methoxyisoquinoline
(Intermediate 12) (300 mg, 1.55 mmol),
4-carboxy-2-fluorophenylboronic acid (285 mg, 1.55 mmol),
K.sub.2CO.sub.3 (642 mg, 4.65 mmol) and Pd(dppf)Cl.sub.2 (30 mg,
0.037 mmol) in DEGME (7 mL) and water (2 mL) was stirred under
N.sub.2 atmosphere at 120.degree. C. for 3 hours. The resulting
mixture was cooled to room temperature and filtered. The filtrate
was acidified with aqueous HCl (2M) until pH=6 and filtered. The
solid was dried under reduced pressure to give
3-fluoro-4-(7-methoxyisoquinolin-3-yl)benzoic acid (140 mg, yield:
30%) as off-white solid.
[0550] Step 2: A mixture of the above product (70 mg, 0.24 mmol)
and BBr.sub.3 (0.2 mL, 2.1 mmol) in anhydrous DCM (2 mL) was
stirred at 15.degree. C. overnight. The resulting mixture was
quenched with water (10 mL) and basified with aqueous sat.
NaHCO.sub.3 until pH=8. The mixture was concentrated in vacuo and
purified by prep-HPLC (0.1% TFA as additive) to give Compound
VIII-2 (12 mg, yield 18%) as yellow solid. .sup.1H NMR (CD.sub.3OD
400 MHz TMS): .delta. 9.41 (s, 1H), 8.43 (s, 1H), 8.10 (d, J=8.8
Hz, 1H), 8.08-7.96 (m, 2H), 7.93 (dd, J=11.6, 0.8 Hz, 1H), 7.65
(dd, J=8.8, 2.4 Hz, 1H), 7.56 (d, J=2.4 Hz, 1H). MS (ESI): m/z
283.7 [M+H].sup.+.
Example 66
Compound VIII-3: 4-(7-hydroxy-4-methylisoquinolin-3-yl)benzoic
acid
##STR00108##
[0552] Step 1: To a mixture of
3-chloro-7-methoxy-4-methylisoquinoline (Intermediate 15) (470 mg,
2.27 mmol), 4-carboxyphenylboronic acid (451 mg, 2.72 mmol) and
K.sub.2CO.sub.3 (627 mg, 4.54 mmol) in DEGME/H.sub.2O (7 mL/1 mL)
was added Pd(dppf)Cl.sub.2 (40.8 mg, 0.050 mmol) under N.sub.2
atmosphere. Then the mixture was heated to 120.degree. C. for 16
hours. H.sub.2O (30 mL) was added, and the resulting mixture was
extracted with EtOAc (15 mL.times.2). The aqueous layer was
neutralized with 1N aqueous HCl to pH=7, extracted with EtOAc (20
mL.times.3). The combined organic layers were washed with H.sub.2O
(20 mL) and brine (20 mL), dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated. Purification by silica gel column
(PE/EtOAc=20/1 to 1/1, then EtOAc) gave
4-(7-methoxy-4-methylisoquinolin-3-yl)benzoic acid (85.0 mg, yield
13%).
[0553] Step 2: To a solution of the above product (85.0 mg, 0.290
mmol) in anhydrous DCM (2 mL) was added BBr.sub.3 (0.20 mL, 2.1
mmol, d=2.64 g/mL) dropwise at 0.degree. C., then stirred at
25.degree. C. for 16 hours. The reaction mixture was quenched with
H.sub.2O (20 mL) and neutralized with aqueous NaOH (2M) to
pH=6.about.7, followed by DCM extraction/workup. The crude product
was tritutrated with EtOAc (15 mL) to give Compound II-25 (20 mg,
yield 25%) as an off-white solid. .sup.1H NMR (MeOD.sub.4 400 MHz):
.delta. 8.94 (s, 1H), 8.15 (d, J=8.0 Hz, 2H), 8.08 (d, J=8.8 Hz,
1H), 7.63 (d, J=8.0 Hz, 2H), 7.46 (dd, J=9.2, 2.4 Hz, 1H), 7.32 (d,
J=2.4 Hz, 1H), 2.59 (s, 3H). MS (ESI): m/z 279.6 [M+H].sup.+.
Example 67
Compound VI-7:
3-fluoro-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid
##STR00109##
[0555] Step 1: Followed the coupling procedure described in Step 1
of Compound VIII-2 (Example 65), where the starting materials were
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline (Intermediate 11)
and 4-carboxy-2-fluorobezeneboronic acid. After H.sub.2O quench,
the aqueous layer was acidified with 0.1M HCl to pH=1, followed by
EtOAc/aqueous workup and column purification to give
3-fluoro-4-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)benzoic
acid (50 mg, yield 19%).
[0556] Step 2: Followed the BBr.sub.3 deprotection method described
in Compound VIII-2 (Example 65, step 2). Compound VI-7 (16 mg,
yield 33%) was isolated as an off-white solid. .sup.1H NMR (MeOD
400MHz): .delta. 8.09 (d, J=9.2 Hz, 1H), 8.07-7.99 (m, 1H), 7.88
(d, J=8.4 Hz, 1H), 7.70-7.62 (m, 2H), 7.49 (d, J=2.8 Hz, 1H). LC-MS
purity: 100%. MS (ESI): m/z 352.9 [M+H].sup.+.
Example 68
Compound VI-8:
(1r,4)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarboxy-
lic acid
##STR00110##
[0558] Step 1: Followed the coupling procedure similar to that
described in Compound VIII-2 (Example 65), where the starting
materials were ethyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate
and 2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline (Intermediate
11) and where the reaction here was stirred under N.sub.2
atmosphere at 100.degree. C. for 3 hours. Ethyl
4-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohex-3-enecarboxylate
was isolated (800 mg, yield 55%) as yellow solid.
[0559] Step 2: A mixture of the above product (200 mg, 0.526 mmol)
and 10% Pd/C (100 mg, 50% wet) in EtOH (10 mL) was stirred under
H.sub.2 (50 psi) at 30.degree. C. for 2 days. The mixture was
filtered and the filtrate was concentrated to give crude ethyl
4-(6-methoxy-3-(trifluoromethyl)-1,2,3,4-tetrahydroquinoxalin-2-yl)cycloh-
exanecarboxylate (190 mg).
[0560] Step 3: A mixture of the above product (crude 190 mg) and
MnO.sub.2 (200 mg, 2.30 mmol) in DCM (20 mL) was stirred at
10.degree. C. overnight. The mixture was filtered and the filtrate
was concentrated followed by purification by silica gel column
(PE/EtOAc=40/1) to give ethyl
4-(6-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarboxyl-
ate (180 mg, 2-step yield: 90%) as colorless oil.
[0561] Step 4: Followed the BBr.sub.3 deprotection method described
in Compound VIII-3 (Example 66, step 2) to give Compound VI-8
(trans) (23 mg, yield 12%) as an off-white solid and Compound VI-9
(cis) (22 mg, yield 12%) as an off-white solid after prep-HPLC.
.sup.1H NMR of Compound VI-8 (DMSO-d.sub.6 400 MHz): .delta. 7.97
(d, J=9.2 Hz, 1H), 7.88-7.78 (m, 1H), 7.12 (s, 1H), 3.10-2.98 (m,
1H), 2.48-2.38 (m, 2H), 2.40-2.20 (m, 1H), 2.10-1.90 (m, 2H),
1.53-1.51 (m, 2H), 1.51-1.46 (m, 2H). MS (ESI): m/z 340.8
[M+H].sup.+.
Example 69
Compound VI-9:
(1s,4s)-4-(6-hydroxy-3-(trifluoromethyl)quinoxalin-2-yl)cyclohexanecarbox-
ylic acid
##STR00111##
[0563] See Example 68 for synthesis. .sup.1H NMR (DMSO-d.sub.6 400
MHz): .delta. 12.12 (brs, 1H), 10.84 (brs, 1H), 7.99 (d, J=9.2 Hz,
1H), 7.55 (dd, J=9.2, 2.4 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H),
3.08-2.94 (m, 1H), 2.36-2.28 (m, 1H), 2.10-2.00 (m, 2H), 1.92-1.70
(m, 4H), 1.54-1.38 (m, 2H). MS (ESI): m/z 340.7 [M+H].sup.+.
Example 70
Compound IV-45: 3-chloro-4-(5-fluoro-6-hydroxyquinolin-2-yl)benzoic
acid
##STR00112##
[0565] 2-Chloro-5-fluoroquinolin-6-ol (Intermediate 16, 1.0 mmol)
and 4-borono-3-chlorobenzoic acid (1.1 mmol) were mixed with 5%
(Ph.sub.3P).sub.4Pd and 4.0 mmol of NaHCO.sub.3 in 20 ml 50%
dioxane/water. The mixture was degassed three times by evacuation
and argon filling and heated at 95.degree. C. overnight. The
reaction was diluted with 20 ml of water and filtered. The filtrate
was acidified with 1N HCl to pH=4. The precipitate was filtered and
washed with water, dried. The crude was purified by column using
AcOH/MeOH/EtOAC (1/5/94) as solvent B and hexanes as solvent A with
gradient 2 to100%. The fractions with compound were pooled and
evaporated to obtain white solid. The solid was triturated with
diisopropyl ether. 50 mg of final product was obtained. .sup.1H-NMR
(DMSO-d.sub.6, 300 MHz, TMS): .delta. 10.55 (b, 1H), 8.47 (d, 1H),
8.01-8.03 (m, 2H), 7.79 (m, 3H), 7.56 (t, 1H). MS (ESI): m/z=316.3
[M-1].sup.-.
Example 71
Compound IV-46: 4-(5-fluoro-6-hydroxyquinolin-2-yl)-3-methylbenzoic
acid
##STR00113##
[0567] Followed the procedure described for Example 70, starting
from 2-chloro-5-fluoroquinolin-6-ol (Intermediate 16) and
4-borono-3-methylbenzoic acid. .sup.1H-NMR (DMSO-d.sub.6, 300 MHz,
TMS): .delta. 13.03 (b, 1H), 10.47 (b, 1H), 8.43 (d, 1H), 7.93 (s,
1H), 7.90 (d, 1H), 7.78 (d, 1H), 7.72 (d, 1H), 7.62 (d, 1H), 7.52
(t, 1H), 2.43 (s, 3H). MS (ESI): m/z=296.38 [M-1].sup.-.
Example 72
Synthesis of Intermediates
[0568] Intermediate 1: Synthesis of 2-chloro-6-methoxyquinoline
[0569] Step 1: Synthesis of 6-methoxyquinoline 1-oxide: To a
solution of 6-methoxyquinoline (2.00 g, 12.6 mmol) in AcOH (10 mL)
was added H.sub.2O.sub.2 (30% in water, 1.9 mL, 18.9 mmol), the
mixture was heated to 70.degree. C. for 21 hours. The mixture was
basified with 2M NaOH to pH 8-9 and extracted with CH.sub.2Cl.sub.2
(200 mL), the combined organic layer was washed with brine (50 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated to give the
crude product, which was purified by silica gel column
(EtOAc/MeOH=10/1) to give 6-methoxyquinoline 1-oxide (1.20 g, 55%)
as a solid.
[0570] Step 2: Synthesis of 6-methoxyquinolin-2-ol: A solution of
6-methoxyquinoline 1-oxide (300 mg, 1.71 mmol) in Ac.sub.2O (5.0
mL) was refluxed for 2 hours. The solvent was removed under reduced
pressure. The residue was dissolved in EtOAc (50 mL), the organic
layer was washed with brine (10 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated to give the crude product which was
purified by silica gel column (PE/EtOAc=1/2) to give
6-methoxyquinolin-2-ol (200 mg, yield 67%).
[0571] Step 3: Synthesis of 2-chloro-6-methoxyquinoline: A solution
of 6-methoxyquinolin-2-ol (400 mg, 2.29 mmol) in POCl.sub.3 (5.0
mL) was refluxed for 2 hours. The solvent was removed under reduced
pressure and the residue was dissolved in EtOAc (50 mL), the
organic layer was washed with saturated NaHCO.sub.3 (30
mL.times.2), dried over Na.sub.2SO.sub.4, filtered and concentrated
to give the crude product, which was purified by silica gel column
(PE/EtOAc=10/1) to give 2-chloro-6-methoxyquinoline (380 mg, yield
86%) as a solid. .sup.1H NMR (CDCl3 400 MHz): .delta. 7.92 (d,
J=8.4 Hz, 1H), 7.85 (d, J=9.2 Hz, 1H), 7.32-7.25 (m, 2H), 7.00 (d,
J=2.4 Hz, 1H), 3.86 (s, 3H).
[0572] Intermediate 2: Synthesis of 2-chloroquinolin-6-ol
[0573] To a solution of 2-chloro-6-methoxyquinoline (Intermediate
1) (2.00 g, 10.4 mmol) in anhydrous DCM (100 mL) was added
BBr.sub.3 (6 mL, 62.2 mmol) dropwise at 0.degree. C. The reaction
mixture was stirred at 25.degree. C. for 2 hours, then quenched
with aqueous saturated NH.sub.4Cl (50 mL) and filtered. The
filtrate was extracted with CH.sub.2Cl.sub.2/MeOH (v/v =10/1, 30
mL.times.2) and the combined organic layers were washed with brine
(30 mL), dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give 2-chloroquinolin-6-ol (1.30 g, yield
70%) as yellow solid. .sup.1H NMR (CDCl3 300 MHz): .delta. 7.95 (t,
J=8.1 Hz, 2H), 7.35 (dd, J=6.0, 3.3 Hz, 2H), 7.13 (d, J=2.7 Hz,
1H).
[0574] Intermediate 3: Synthesis of
2,4-dichloro-3-fluoro-6-methoxyquinoline
[0575] Step 1: Synthesis of 2-fluoromalonic acid: To a solution of
diethyl 2-fluoromalonate (5.00 g, 28.1 mmol) in EtOH (100 mL) was
added LiOH.H.sub.2O (2.70 g, 64.3 mmol) at 25.degree. C. The
mixture was heated to 50.degree. C. for 16 hours. The mixture was
filtered to collect solid. The filtrate was concentrated to dryness
to get oil. The oil and the solid were dissolved in H.sub.2O (30
mL) and MTBE (100 mL), the mixture was acidified by adding conc.
HCl to pH 1, the aqueous layer was extracted with MTBE (30
mL.times.2), the combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated to give 2-fluoromalonic
acid (3.00 g, yield 88%) as a solid.
[0576] Step 2: Synthesis of
2,4-dichloro-3-fluoro-6-methoxyquinoline: A suspension of
fluoromalonic acid (1.00 g, 8.13 mmol) in POCl.sub.3 (10 mL) was
heated to 85.degree. C. to dissolve the solid. The mixture was
cooled to 60.degree. C. and p-anisidine (900 mg, 7.32 mmol) was
added portion wise over 1 hour. After addition, the reaction
mixture was refluxed for 2 hours. The solvent was removed in vacuo.
The mixture was diluted with ice water and basified by adding
NH.sub.3.H.sub.2O to pH 9. The aqueous layer was extracted with
EtOAc (30 mL.times.3), the combined organic layers were washed with
brine (20 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product, which was purified by
silica gel column (PE/EtOAc=10/1) to give
2,4-dichloro-3-fluoro-6-methoxyquinoline (650 mg, yield 36%).
.sup.1H NMR (CDCl3 300 MHz): .delta. 7.92 (d, J=9.0 Hz, 1H),
7.41-7.31 (m, 2H), 4.00 (s, 3H).
[0577] Intermediate 4: Synthesis of
2,3-dichloro-6-methoxyquinoline
[0578] Step 1: Synthesis of 2-chloro-N-(4-methoxyphenyl)acetamide:
A mixture of 4-methoxyaniline (5.00 g, 40.6 mmol), chloroacetic
acid (8.6 g, 91.5 mmol), EDCI (12.0 g, 61.2 mmol), HOBT (8.4 g,
61.3 mmol) and NMM (13 mL, 122 mmol) in anhydrous
CH.sub.2Cl.sub.2(50 mL) was stirred at 30.degree. C. for 3 hours.
The mixture was quenched with ice water, and then extracted with
CH.sub.2Cl.sub.2 (30 mL.times.2). The combined organic layers were
washed with brine (30 mL), dried over Na.sub.2SO.sub.4, filtered
and concentrated to give the crude product, which was purified by
silica gel column (PE/EtOAc =5/1) to give the product (1.60 g,
yield 20%).
[0579] Step 2: Synthesis of 2,3-dichloro-6-methoxyquinoline:
POCl.sub.3 (1.6 mL, 17.5 mmol) was added dropwise to DMF (0.29 mL,
3.80 mmol) at 0.degree. C. After addition,
2-chloro-N-(4-methoxyphenyl)acetamide (500 mg, 2.50 mmol) was added
portionwise. The mixture was stirred at 25.degree. C. for 15
minutes and heated to 75.degree. C. for 3 hours. The reaction
mixture was quenched with ice water and neutralized by 2M NaOH to
pH 7. An aqueous workup with EtOAc was followed by purification by
silica gel column (PE/EtOAc=20/1) to give Intermediate 4 (50 mg,
yield 9%). .sup.1H NMR (CDCl3 400 MHz): .delta. 8.06 (s, 1H), 7.81
(d, J=9.6 Hz, 1H), 7.30 (dd, J=9.2, 2.8 Hz, 1H), 6.92 (d, J=2.8 Hz,
1H), 3.87 (s, 3H).
[0580] Intermediate 5: Synthesis of methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzoa-
te
[0581] To a mixture of methyl 4-bromo-3-(trifluoromethyl)benzoate
(1.00 g, 3.53 mmol), bis(pinacolato)diboron (1.79 g, 7.06 mmol),
and KOAc (1.04 g, 10.6 mmol) in DMSO (15 mL) was added
Pd(PPh.sub.3).sub.4 (816 mg, 0.706 mmol) under N.sub.2 atmosphere.
Then the mixture was heated to 120.degree. C. for 3 hours. The
reaction mixture was cooled followed by an aqueous/EtOAc workup to
give the crude product (2.3 g) as a yellow oil.
[0582] Intermediate 6: Synthesis of
2-chloro-3-(trifluoromethyl)quinolin-6-ol
[0583] Step 1: Synthesis of (5-methoxy-2-nitrophenyl)methanol: To a
solution of 5-methoxy-2-nitrobenzoic acid (20.0 g, 0.102 mol) in
anhydrous THF (200 mL) was added SOCl.sub.2 (20 mL), the mixture
was refluxed for 4 hours. The solvent was removed under reduced
pressure and the residue was dissolved in anhydrous THF (100 mL).
The solution was added dropwise to a suspension of NaBH.sub.4 (7.70
g, 0.202 mol) in anhydrous THF (100 mL) and DMF (140 mL) at
0.degree. C. over a period of 30 minutes. The mixture was stirred
at 30.degree. C. for 3 hours, then quenched with ice-water (100 mL)
and basified by 2M NaOH to pH 8. An EtOAc workup was followed by
removal of solvent in vacuo and purification by column
chromatography (PE/EtOAc=1/1) to give the product (12.0 g, yield
66%).
[0584] Step 2: Synthesis of
tert-butyl(5-methoxy-2-nitrobenzyloxy)dimethylsilane: To a solution
of (5-methoxy-2-nitrophenyl)methanol (12.0 g, 65.6 mmol) in
anhydrous THF (200 mL) and DMF (20 mL) was added imidazole (9.80 g,
144 mmol). Then TBSC1 (11.8 g, 78.6 mmol) was added portionwise at
0.degree. C. and the mixture was stirred at 30.degree. C. for 2
hours. The mixture was quenched with ice-water (100 mL). An EtOAc
workup was followed by removal of solvent in vacuo and purification
by column chromatography (PE/EtOAc=10/1) to give the product (16.0
g, yield 84%) as a yellow oil.
[0585] Step 3: Synthesis of
2-((tert-butyldimethylsilyloxy)methyl)-4-methoxyaniline: To a
solution of tert-butyl(5-methoxy-2-nitrobenzyloxy)dimethylsilane
(14.0 g, 47.1 mmol) in EtOH (200 mL) was added 10% Pd/C (1.40 g),
the mixture was stirred at 30.degree. C. for 2 hours under H.sub.2
(40 psi). The solids were filtered off and the filtrate was
concentrated under reduced pressure to give the product (14.0 g) as
a yellow oil. .sup.1H NMR (DMSO 400 MHz): .delta. 6.75 (d, J=2.4
Hz, 1H), 6.60-6.55 (m, 2H), 4.55 (s, 2H), 4.40 (brs, 2H), 3.61 (s,
3H), 0.90 (s, 9H), 0.09 (s, 6H).
[0586] Step 4: Synthesis of
N-(2-((tert-butyldimethylsilyloxy)methyl)-4-methoxyphenyl)-3,3,3-trifluor-
opropanamide: A mixture of
2-((tert-butyldimethylsilyloxy)methyl)-4-methoxyaniline (14.0 g),
3,3,3-trifluoro-propionic acid (7.30 g, 57.0 mmol), EDCI (15.0 g,
76.5 mmol), HOBT (11.0 g, 80.2 mmol) and NMM (22 mL, 157 mmol) in
anhydrous CH.sub.2Cl.sub.2 (200 mL) was stirred at 20.degree. C.
for 2 hours. The mixture was diluted with CH.sub.2Cl.sub.2 (100
mL), the organic layer was washed with 1M HCl (100 mL), H.sub.2O
(100 mL) and brine (100 mL), dried over Na.sub.2SO.sub.4 and
concentrated to give the product.
[0587] Step 5: Synthesis of
3,3,3-trifluoro-N-(2-(hydroxymethyl)-4-methoxyphenyl)propanamide:
To a solution of
N-(2-((tert-butyldimethylsilyloxy)methyl)-4-methoxyphenyl)-3,3,3-trifluor-
opropanamide (20.0 g) in anhydrous THF (200 mL) was added a
solution of TBAF (16.6 g, 63.6 mmol) in anhydrous THF (60 mL). The
mixture was stirred at 35.degree. C. for 30 minutes. The mixture
was quenched with ice-water. An aqueous/EtOAc workup was followed
by removal of volatiles in vacuo. The crude product was purified by
column chromatography on silica gel (PE/EtOAc=1/2) to give the
product. .sup.1H NMR (CDCl3 400 MHz): .delta. 8.60 (brs, 1H), 7.82
(d, J=8.8 Hz, 1H), 6.85 (dd, J=9.2, 3.2 Hz, 1H), 6.75 (d, J=2.8 Hz,
1H), 4.65 (s, 2H), 3.80 (s, 3H), 3.23 (q, J=10.4 Hz, 2H).
[0588] Step 6: Synthesis of
3,3,3-trifluoro-N-(2-formyl-4-methoxyphenyl)propanamide: To a
solution of
3,3,3-trifluoro-N-(2-(hydroxymethyl)-4-methoxyphenyl)propanamide
(6.30 g, 23.9 mmol) in anhydrous CH.sub.2Cl.sub.2 (200 mL) was
added MnO.sub.2 (20.0 g, 229 mmol). The mixture was refluxed for 16
hours. The mixture was filtered off and the filtrate was
concentrated to give the product (5.30 g, yield 84%).
[0589] Step 7: Synthesis of
6-methoxy-3-(trifluoromethyl)quinolin-2(1H)-one: To a solution of
3,3,3-trifluoro-N-(2-formyl-4-methoxyphenyl)propanamide (5.30 g,
20.3 mmol) in DMF (100 mL) was added K.sub.2CO.sub.3 (14.0 g, 101
mmol). The mixture was heated to 60.degree. C. for 1.5 hours. The
mixture was diluted with EtOAc (200 mL) and filtered off. The
filtrate was washed with H.sub.2O (100 mL) and brine (100 mL),
dried over Na.sub.2SO.sub.4, and concentrated in vacuo to give the
product (4.60 g, yield 94%). .sup.1H NMR (CDCl3 300 MHz): .delta.
12.25 (brs, 1H), 8.18 (s, 1H), 7.40 (d, J=9.0 Hz, 1H), 7.25 (dd,
J=9.0, 2.7 Hz, 1H), 7.02 (d, J=2.7 Hz, 1H), 3.87 (s, 3H).
[0590] Step 8: Synthesis of
2-chloro-6-methoxy-3-(trifluoromethyl)quinoline: A solution of
6-methoxy-3-(trifluoromethyl)quinolin-2(1H)-one (4.60 g, 18.9 mmol)
in POCl.sub.3 (30 mL) was refluxed for 2.5 hours. The solvent was
removed under reduced pressure and the residue was neutralized by
2M NaOH to pH 7. An EtOAc workup was followed by removal of
volatiles under reduced pressure. The residue was purified by
column chromatography on silica gel (PE/EtOAc=15/1) to give the
product (4.60 g, yield 94%).
[0591] Step 9: Synthesis of
2-chloro-3-(trifluoromethyl)quinolin-6-ol: To a solution of above
product (1.00 g, 3.83 mmol) in anhydrous CH.sub.2Cl.sub.2 (20 mL)
was added BBr.sub.3 (3.0 mL, 31.8 mmol) at 0.degree. C. The mixture
was stirred at 0.degree. C. for 2 hours. The mixture was quenched
with ice-water (10 mL) and extracted with CH.sub.2Cl.sub.2 (30
mL.times.3). The combined organic layer was washed with brine (50
mL), dried over Na.sub.2SO.sub.4 and concentrated under reduced
pressure to give Intermediate 6 (600 mg, yield 63%) as a solid.
.sup.1H NMR (CDCl.sub.3 400 MHz): .delta. 8.37 (s, 1H), 8.00 (d,
J=9.2 Hz, 1H), 7.48 (dd, J=8.8, 2.4 Hz, 1H), 7.22 (d, J=2.8 Hz,
1H).
[0592] Intermediate 7: Synthesis of
2-chloro-4-fluoro-6-methoxyquinoline
[0593] Step 1: Synthesis of 2,4-dichloro-6-methoxyquinoline: A
mixture of p-anisidine (100 g, 0.813 mol), and malonic acid (85.0
g, 0.817 mol) in POCl.sub.3 (500 mL) was refluxed for 6 hours. The
excess POCl.sub.3 was removed in vacuo and the residue was
neutralized with 8 M NaOH to pH 7. The aqueous layer was extracted
with CH.sub.2Cl.sub.2 (300 mL.times.3), washed with brine (500 mL),
dried over Na.sub.2SO.sub.4 and concentrated under reduced
pressure. Purification by column chromatography on silica gel
(PE/EtOAc=15/1) gave desired (35.0 g, yield: 19%).
[0594] Step 2: Synthesis of 2-chloro-6-methoxyquinolin-4-amine: A
suspension of 2,4-dichloro-6-methoxyquinoline (5.00 g, 22.0 mmol)
in NH.sub.3 (g)/MeOH (saturated, 40 mL) was heated to 150.degree.
C. for 16 hours in a sealed tube. The solvent was removed and the
residue was diluted with MeOH (20 mL). The mixture was filtered off
and the filtrate was concentrated to give the crude product.
Purification by column chromatography on silica gel (PE/EtOAc=2/1)
gave product (7.50 g, yield: 55%) as a solid.
[0595] Step 3: Synthesis of 2-chloro-4-fluoro-6-methoxyquinoline: A
solution of 2-chloro-6-methoxyquinolin-4-amine (4.50 g, 21.6 mmol)
in HF-pyridine (45 mL) was cooled to -10-0.degree. C. Then
NaNO.sub.2(1.80 g, 26.1 mmol) was added portionwise and the mixture
was stirred at 0.degree. C. for 1 hour and at 30.degree. C. for 1
hour. Then the mixture was heated to 65.degree. C. for 1.5 hours.
The mixture was quenched with ice-water (100 mL); the aqueous layer
was neutralized with 2 M NaOH to pH 7. The mixture was filtered off
and the filtrate was extracted with EtOAc (50 mL.times.3), the
organic layer was washed with brine (100 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. Purification by column
chromatography on silica gel (PE/EtOAc=15/1) gave Intermediate 7
(3.60 g, yield: 40%). .sup.1H NMR (CDCl3 400 MHz): .delta. 7.92
(dd, J=9.2, 1.6 Hz, 1H), 7.40 (dd, J=9.2, 2.8 Hz, 1H), 7.25 (s,
1H), 7.10 (d, J=9.2 Hz, 1H), 3.97 (s, 3H).
[0596] Intermediate 8: 2-chloro-6-methoxyquinazoline
[0597] Step 1: Synthesis of 6-methoxyquinazoline-2,4(1H,3H)-dione:
A mixture of 2-amino-5-methoxybenzoic acid (5.00 g, 29.9 mmol) and
urea (5.40 g, 90.0 mmol) was heated to 200.degree. C. for 1 hour.
The mixture was cooled to room temperature and diluted with
H.sub.2O (50 mL), the mixture was filtered off and the precipitate
was washed with H.sub.2O (10 mL), dried in vacuo to give the
product (5.10 g, yield 88%).
[0598] Step 2: Synthesis of 2,4-dichloro-6-methoxyquinazoline: To a
solution of 6-methoxyquinazoline-2,4(1H,3H)-dione (5.10 g, 26.6
mmol) in POCl.sub.3 (30 mL) was added N,N-diethylaniline (2.4 mL,
15.0 mmol). The mixture was refluxed for 6 hours. The excess
POCl.sub.3 was removed under reduced pressure and the residue was
dissolved in EtOAc (100 mL), the organic layer was washed with sat.
NaHCO.sub.3 (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product which was purified by silica
gel column (PE/EtOAc=20/1) to give the product (1.70 g, yield
28%).
[0599] Step 3: Synthesis of 2-chloro-6-methoxyquinazoline: To a
solution of 2,4-dichloro-6-methoxyquinazoline (400 mg, 1.75 mmol)
in CH.sub.2Cl.sub.2 (10 mL) was added brine (10 mL) containing 9%
NH.sub.3.H.sub.2O. Then zinc powder (336 mg, 5.25 mmol) was added
and the mixture was refluxed for 2 hours. The mixture was diluted
with CH.sub.2Cl.sub.2 (50 mL) and filtered off, the filtrate was
neutralized by 2M HCl to pH 7. The aqueous layer extracted with
CH.sub.2Cl.sub.2 (20 mL.times.2), the combined organic layer washed
with brine (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product, which was purified by
silica gel column (PE/EtOAc=5/1) to give Intermediate 8 (232 mg,
yield 68%). .sup.1H NMR (CDCl3 300 MHz): .delta. 9.20 (s, 1H), 7.90
(d, J=9.3 Hz, 1H), 7.40 (dd, J=9.3, 2.7 Hz, 1H), 7.15 (d, J=3.0 Hz,
1H), 3.95 (s, 3H).
[0600] Intermediate 9: 2-chloro-6-methoxy-4-methylquinazoline
[0601] A mixture of 2,4-dichloro-6-methoxyquinazoline (synthesis
described in steps 1 and 2 of Intermediate 8) (900 mg, 3.93 mmol),
MeZnCl (2.95 mL, 5.90 mmol, 2M in THF) and Pd(PPh.sub.3).sub.4
(45.0 mg, 0.0393 mmol) in anhydrous THF (15 mL) was stirred at
60.degree. C. under N.sub.2 atmosphere for 16 hours. After cooling
to 25.degree. C., the mixture was quenched with saturated aqueous
NH.sub.4Cl (30 mL), extracted with EtOAc (30 mL.times.3). The
combined organic layers were washed with H.sub.2O (30 mL) and brine
(30 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give the crude product. The
crude product was purified by silica gel column (PE/EtOAc=30/1 to
20/1) to give Intermediate 9 (370 mg, yield 45%). Structure was
confirmed by NOE. .sup.1H NMR (CDCl.sub.3 400 MHz): .delta. 7.88
(d, J=9.2 Hz, 1H), 7.55 (dd, J=9.2, 2.8 Hz, 1H), 7.23 (d, J=2.8 Hz,
1H), 3.97 (s, 3H), 2.92 (s, 3H).
[0602] Intermediate 10: 2-chloroquinazolin-6-ol
[0603] To a solution of 2-chloro-6-methoxyquinazoline (Intermediate
8, 260 mg, 1.34 mmol) in anhydrous DCM (10 mL) was added AlCl.sub.3
(536 mg, 4.02 mmol). The resulting mixture was stirred at
60.degree. C. for 16 hours. The reaction mixture was cooled to room
temperature (26-32.degree. C.) and quenched with ice water (30 mL).
The aqueous layer was extracted with DCM (20 mL.times.3). The
combined organic layers were washed with brine (20 mL), dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
Intermediate 10 (200 mg, yield 83%). .sup.1H NMR (DMSO-d.sub.6 400
MHz): .delta. 10.63 (brs, 1H), 9.41 (s, 1H), 7.85 (d, J=9.2 Hz,
1H), 7.62 (dd, J=8.8, 2.4 Hz, 1H), 7.36 (d, J=2.4 Hz, 1H).
[0604] Intermediate 11:
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline
[0605] Step 1: Synthesis of
6-methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one: A mixture of
4-methoxybenzene-1,2-diamine (2.00 g, 14.5 mmol) and ethyl
trifluoropyruvate (2.47 g, 14.5 mmol) in absolute EtOH (30 mL) was
refluxed overnight. The mixture was cooled to room temperature and
diluted with EtOAc (300 mL), washed with water (100 mL.times.2),
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The residue
was purified by column chromatography on silica gel to give
6-methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one (1.50 g, yield
42%) as solid (also obtained
7-methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one (600 mg, yield
17%)).
[0606] Step 2: Synthesis of
2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline: A mixture of
6-methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one (500 mg, 2.05
mmol) and POCl.sub.3 (4 mL) was stirred under microwave at
140.degree. C. for 2 hours. The reaction was quenched with aqueous
saturated NaHCO.sub.3 (50 mL) and extracted with EtOAc (50
mL.times.3), dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The residue was purified by column chromatography on silica gel
(PE/EtOAc=10/1) to give Intermediate 11 (460 mg, yield 86%).
.sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 8.10 (d, J=9.6 Hz, 1H),
7.76 (dd, J=9.2, 2.8 Hz, 1H), 7.68 (d, J=2.8 Hz, 1H), 4.01 (s,
3H).
[0607] Intermediate 12: 3-chloro-7-methoxyisoquinoline
[0608] Step 1: Synthesis of
(E)-2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one:
6-methoxy-2,3-dihydro-1H-inden-1-one (17.2 g, 106 mmol) was
dissolved in methanol (700 mL). The mixture was heated to
40.degree. C., then isoamyl nitrite (30 mL, 220 mmol) and
concentrated hydrochloric acid (17 mL) were added. The reaction
mixture was stirred at 40.degree. C. for 2 hours. After cooled to
room temperature, the precipitate was collected by filtration and
dried under high vacuum to obtain product (10.0 g, yield 50%).
[0609] Step 2: Synthesis of 1,3-dichloro-7-methoxyisoquinoline: To
a suspension of
(E)-2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one (3.60 g,
20.0 mmol) in POCl.sub.3 (120 mL), PCl.sub.5 (6.50 g, 31.3 mmol)
was added at 0.degree. C., then HCl gas was induced until the
solution was saturated. The reaction mixture was stirred at
30.degree. C. for 2 hours. The solvent was removed in vacuo and ice
water was added to the residue. The precipitate was collected by
filtration, washed with water (30 mL), and dried under high vacuum
to give the product (4.50 g, yield 85%) as a solid.
[0610] Step 3: Synthesis of 3-chloro-7-methoxyisoquinoline:
1,3-dichloro-7-methoxyisoquinoline (1.14 g, 5.00 mmol) was
suspended in glacial acetic acid (6 mL) and concentrated HCl (2
mL), then treated with tin powder (1.77 g, 15.0 mmol) and stirred
at 60.degree. C. for 3 hours. The resulting mixture was basified to
pH=9 with concentrated NH.sub.4OH and then extracted with ethyl
acetate (10 mL.times.3). The combined organic layer was washed with
saturated NaHCO.sub.3 solution (20 mL), dried over Na.sub.2SO.sub.4
and concentrated in vacuo, followed by silica gel column
(EtOAc/PE=20:1) to give Intermediate 12 (200 mg, yield 21%) as a
solid. .sup.1H NMR (DMSO 300 MHz): .delta. 9.00 (s, 1H), 7.94 (s,
1H), 8.87 (d, J=9.0 Hz, 1H), 7.53 (d, J=2.7 Hz, 1H), 7.46 (dd,
J=9.0, 2.7 Hz, 1H), 3.89 (s, 3H).
[0611] Intermediate 13: 3-bromo-7-methoxyquinoline
[0612] To a solution of bromo-malonaldehyde (10 g, 66.2 mmol) in
absolute ethanol (100 mL) was added 3-methoxyaniline (7.3 g, 59.6
mmol). The mixture was heated to 30.degree. C. and stirred at that
temperature for 24 h. Conc. HCl (100 mL) was added, and the
reaction mixture was heated at 100.degree. C. for two days. After
the mixture was concentrated and the residue was partitioned
between ethyl acetate (150 mL) and saturated sodium carbonate (50
mL). The organic phase was washed with brine, dried with anhydrous
Na.sub.2SO.sub.4 and concentrated to give a black oil, which was
purified by column chromatography (PE/EA=3/1) to give Intermediate
13 as a brown oil (500 mg, 3.8%). MS (ESI): m/z 237.9
[M+1].sup.+.
[0613] Intermediate 14:
2-chloro-3-(trifluoromethyl)quinoxalin-6-ol
[0614] Followed the procedure described for preparing Intermediate
10 starting with 2-chloro-6-methoxy-3-(trifluoromethyl)quinoxaline
(Intermediate 11), with a purification by silica gel column
chromatography.
[0615] Intermediate 15, 3-chloro-7-methoxy-4-methylisoquinoline
[0616] Step 1: To a solution of i-Pr.sub.2NH (1.95 g, 19.3 mmol) in
anhydrous THF (40 mL) was added dropwise n-BuLi (7.72 mL, 19.3
mmol, 2.50 M in hexane) at -78.degree. C. under N.sub.2 atmosphere.
After 30 minutes, 1,3-dichloro-7-methoxyisoquinoline (described in
step 2 of Intermediate 12) (4.00 g, 17.5 mmol) in anhydrous THF (20
mL) was added to the reaction. After 15 minutes, MeI (4.97 g, 35.0
mmol) was added dropwise. The resulting mixture was warmed to
25.degree. C. and allowed to stir for 16 hours. The reaction was
quenched with H.sub.2O (150 mL) followed by an ethyl acetate
extraction/workup to give the crude product, which was purified by
prep-HPLC (0.1% TFA as additive). Most of CH.sub.3CN was removed
under reduced pressure and extracted with EtOAc (50 mL.times.3).
The combined organic layers were washed with H.sub.2O (50 mL) and
brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to give
1,3-dichloro-7-methoxy-4-methylisoquinoline (2.0 g, yield 47%) as
an off-white solid.
[0617] Step 2: To a solution of the above product (1.00 g, 4.13
mmol) in CH.sub.3COOH (18 mL) and HCl (6 mL, 36%) was added Sn
(1.46 g, 12.4 mmol) at 25-30.degree. C. The resulting mixture was
stirred at 60.degree. C. for 2.5 hours. The reaction mixture was
basified with aqueous NaOH (2M) to pH=7.about.8, and the resulting
mixture was extracted with EtOAc, followed by purification via
silica gel column (PE/EtOAc=50/1 to 10/1) to give Intermediate 15
(470 mg, yield 55%) as a solid. .sup.1H NMR (CDCl.sub.3 400 MHz):
.delta. 8.82 (s, 1H), 7.89 (d, J=9.6 Hz, 1H), 7.39 (dd, J=9.6, 2.8
Hz, 1H), 7.19 (d, J=2.8 Hz, 1H), 3.95 (s, 3H), 2.69 (s, 3H).
[0618] Intermediate 16: 2-chloro-5-fluoroquinolin-6-ol
[0619] To a solution of 2-chloroquinolin-6-ol (Intermediate 2, 1.8
g, 85% pure, 8.5 mmol) in CH.sub.3CN (50 mL) was added Selectfluor
(4.20 g, 12.0 mmol). The reaction mixture was heated at 60.degree.
C. overnight and concentrated. The residue was partitioned between
water (50 mL) and EtOAc (100 mL). The aqueous phase was separated
and extracted with ethyl acetate. The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by silica gel chromatography
to give 2-chloro-5-fluoroquinolin-6-ol using ethyl acetate and
hexanes as solvents (0.4 g, 21% yield).
Example 73
GSNOR Assays
[0620] Various compounds were tested in vitro for their ability to
inhibit GSNOR activity. GSNOR inhibitor compounds in Examples 1-71
had an IC.sub.50 of about <10 .mu.M. GSNOR inhibitor compounds
in Examples 1-4, 6, 8, 10-14, 16-35, 37-43, 45, 47-50, 52-62,
65-68, 70-71 had an IC.sub.50 of about <0.5 .mu.M. GSNOR
inhibitor compounds in Examples 1-4, 8, 10-14, 17-28, 30, 31, 37,
40-41, 43, 45, 47-50, 52-58, 60-61, 65, 67-68, and 70-71 had an
IC.sub.50 of about <0.1 .mu.M.
[0621] GSNOR expression and purification is described in
Biochemistry 2000, 39, 10720-10729.
[0622] GSNOR fermentation: Pre-cultures were grown from stabs of a
GSNOR glycerol stock in 2XYT media containing 10 ug/ml ampicillin
after an overnight incubation at 37.degree. C. Cells were then
added to fresh 2XYT (4 L) containing ampicillin and grown to an OD
(A.sub.600) of 0.6-0.9 at 37.degree. C. before induction. GSNOR
expression was induced with 0.1% arabinose in an overnight
incubation at 20.degree. C.
[0623] GSNOR Purification: E. coli cell paste was lysed by nitrogen
cavitation and the clarified lysate purified by Ni affinity
chromatography on an AKTA FPLC (Amersham Pharmacia). The column was
eluted in 20 mM Tris pH 8.0/250 mM NaCl with a 0-500 mM imidazole
gradient. Eluted GSNOR fractions containing the Smt-GSNOR fusion
were digested overnight with Ulp-1 at 4.degree. C. to remove the
affinity tag then re-run on the Ni column under the same
conditions. GSNOR was recovered in the flowthrough fraction and for
crystallography is further purified by Q-Sepharose and Heparin
flowthrough chromatography in 20 mM Tris pH 8.0, 1 mM DTT, 10 uM
ZnSO.sub.4.
[0624] GSNOR assay: GSNO and enzyme/NADH Solutions are made up
fresh each day. The solutions are filtered and allowed to warm to
room temperature. GSNO solution: 100 mM NaPO.sub.4 (pH 7.4), 0.480
mM GSNO. 396 .mu.L of GSNO Solution is added to a cuvette followed
by 8 .mu.L of test compound in DMSO (or DMSO only for full reaction
control) and mixed with the pipette tip. Compounds to be tested are
made up at a stock concentration of 10 mM in 100% DMSO. 2 fold
serial dilutions are done in 100% DMSO. 8 .mu.L of each dilution
are added to an assay so that the final concentration of DMSO in
the assay is 1%. The concentrations of compounds tested range from
100 to 0.003 .mu.M. Enzyme/NADH solution: 100 mM NaPO.sub.4 (pH
7.4), 0.600 mM NADH, 1.0 .mu.g/mL GSNO Reductase. 396 .mu.L of the
Enzyme/NADH solution is added to the cuvette to start the reaction.
The cuvette is placed in the Cary 3E UV/Visible Spectrophotometer
and the change in 340 nm absorbance/min at 25.degree. C. is
recorded for 3 minutes. The assays are done in triplicate for each
compound concentration. IC.sub.50's for each compound are
calculated using the standard curve analysis in the Enzyme Kinetics
Module of SigmaPlot.
[0625] Final assay conditions: 100 mM NaPO.sub.4, pH 7.4, 0.240 mM
GSNO, 0.300 mM NADH, 0.5 .mu.g/mL GSNO Reductase, and 1% DMSO.
Final volume: 800 .mu.L/cuvette.
Example 74
Efficacy of GSNORi in Experimental Asthma
[0626] Experimental Asthma Model:
[0627] A mouse model of ovalbumin (OVA)-induced asthma was used to
screen GSNOR inhibitors for efficacy against methacholine
(MCh)-induced bronchoconstriction/airway hyper-responsiveness. This
is a widely used and well characterized model that presents with an
acute, allergic asthma phenotype with similarities to human asthma.
Efficacy of GSNOR inhibitors was assessed using a protocol in which
GSNOR inhibitors were administered after OVA sensitization and
airway challenge, and prior to challenge with MCh.
Bronchoconstriction in response to challenge with increasing doses
of MCh was assessed using whole body plethysmography (P.sub.enh;
Buxco). The amount of eosinophil infiltrate into the bronchoaveolar
lavage fluid (BALF) was also determined as a measure of lung
inflammation. The effects of GSNOR inhibitors were compared to
vehicles and to Combivent (inhaled; IH) as the positive
control.
[0628] Materials and Method
[0629] Allergen Sensitization and Challenge Protocol
[0630] OVA (500 .mu.g/ml) in PBS was mixed with equal volumes of
10% (w/v) aluminum potassium sulfate in distilled water and
incubated for 60 min. at room temperature after adjustment to pH
6.5 using 10 N NaOH. After centrifugation at 750.times.g for 5 min,
the OVA/alum pellet was resuspended to the original volume in
distilled water. Mice received an intraperitoneal (IP) injection of
100 .mu.g OVA (0.2 mL of 500 .mu.g/mL in normal saline) complexed
with alum on day 0. Mice were anesthetized by IP injection of a
0.2-mL mixture of ketamine and xylazine (0.44 and 6.3 mg/mL,
respectively) in normal saline and were placed on a board in the
supine position. Two hundred fifty micrograms (100 .mu.l of a 2.5
mg/ml) of OVA (on day 8) and 125 .mu.g (50 .mu.l of 2.5 mg/ml) OVA
(on days 15, 18, and 21) were placed on the back of the tongue of
each animal.
[0631] Pulmonary Function Testing (Penh)
[0632] In vivo airway responsiveness to methacholine was measured
24 h after the last OVA challenge in conscious, freely moving,
spontaneously breathing mice with whole body plethysmography using
a Buxco chamber (Wilmington, N.C.). Mice were challenged with
aerosolized saline or increasing doses of methacholine (5, 20, and
50 mg/mL) generated by an ultrasonic nebulizer for 2 min. The
degree of bronchoconstriction was expressed as enhanced pause
(P.sub.enh), a calculated dimensionless value, which correlates
with the measurement of airway resistance, impedance, and
intrapleural pressure in the same mouse. P.sub.enh readings were
taken and averaged for 4 min. after each nebulization challenge. P
.sub.enh is calculated as follows:
P.sub.enh=[(T.sub.e/T.sub.r-1).times.(PEF/PIF)], where T.sub.e is
expiration time, T.sub.r is relaxation time, PEF is peak expiratory
flow, and PIF is peak inspiratory flow.times.0.67 coefficient. The
time for the box pressure to change from a maximum to a
user-defined percentage of the maximum represents the relaxation
time. The T.sub.r measurement begins at the maximum box pressure
and ends at 40%.
[0633] Eosinophil Infiltrate in BALF
[0634] After measurement of airway hyper-reactivity, the mice were
exsanguinated by cardiac puncture, and then BALF was collected from
either both lungs or from the right lung after tying off the left
lung at the mainstem bronchus. Total BALF cells were counted from a
0.05 mL aliquot, and the remaining fluid was centrifuged at
200.times.g for 10 min at 4.degree. C. Cell pellets were
resuspended in saline containing 10% BSA with smears made on glass
slides. Eosinophils were stained for 5 min. with 0.05% aqueous
eosin and 5% acetone in distilled water, rinsed with distilled
water, and counterstained with 0.07% methylene blue. Alternatively,
eosinophils and other leukocytes were stained with DiffQuik.
[0635] GSNOR Inhibitors and Controls
[0636] GSNOR inhibitors were reconstituted in phosphate buffered
saline (PBS), pH 7.4, or 0.5% w/v carboxy methylcellulose at
concentrations ranging from 0.00005 to 3 mg/mL. GSNOR inhibitors
were administered to mice (10 mL/kg) as a single dose or multiple
dose either intravenously (IV) or orally via gavage. Dosing was
performed from 30 min. to 72 h prior to MCh challenge. Effects of
GSNOR inhibitors were compared to vehicle dosed in the same
manner.
[0637] Combivent was used as the positive control in all studies.
Combivent (Boehringer Ingelheim) was administered to the lung using
the inhaler device supplied with the product, but adapted for
administration to mice, using a pipet tip. Combivent was
administered 48 h, 24 h, and 1 h prior to MCh challenge. Each puff
(or dose) of Combivent provides a dose of 18 .mu.g ipatropium
bromide (IpBr) and 103 .mu.g albuterol sulfate or approximately 0.9
mg/kg IpBr and 5 mg/kg albuterol.
[0638] Statistical Analyses
[0639] Area under the curve values for P.sub.enh across baseline,
saline, and increasing doses of MCh challenge were calculated using
GraphPad Prism 5.0 (San Diego, Calif.) and expressed as a percent
of the respective (IV or orally administered) vehicle control.
Statistical differences among treatment groups and the respective
vehicle control group within each study were calculated using
one-way ANOVA, Dunnetts or Bonferroni post-hoc tests or t-test (JMP
8.0, SAS Institute, Cary, N.C. or Microsoft Excel). A p value of
<0.05 among the treatment groups and the respective vehicle
control group was considered significantly different.
[0640] Results
[0641] In the OVA model of asthma, the compound of Example 8
significantly (p<0.05) decreased eosinophil infiltration in BAL
by 37% of vehicle control when given via three oral doses of 10
mg/kg at 48 h, 24 h, and 1 h prior to assessment.
[0642] In the OVA model of asthma, the compound of Example 3
significantly (p<0.05) decreased eosinophil infiltration in BAL
by 42% of vehicle control when given via three oral doses of 10
mg/kg at 48 h, 24 h, and 1 h prior to assessment.
[0643] In the OVA model of asthma, the compound of Example 27
significantly (p<0.05) decreased eosinophil infiltration in BAL
by 23% of vehicle control when given via three oral doses of 10
mg/kg at 48 h, 24 h, and 1 h prior to assessment.
[0644] In the OVA model of asthma, the compound of Example 4
significantly (p<0.05) decreased MCh-induced AHR by 19% of
vehicle control and decreased eosiinophil infiltration into BALF by
20% of vehicle control when given as a single IV dose of 10 mg/kg
at 24 h prior to assessment.
Example 75
Mouse Pharmacokinetic (PK) Study
[0645] Experimental Model
[0646] The mouse was used to determine the pharmacokinetics of
compounds of the invention. This species is widely used to assess
the bioavailability of compounds by administering both oral (PO)
and intravenous (IV) test articles. Efficacy of the compounds of
the invention was compared by assessing plasma exposure in male
BALB/c mice either via IV or PO administration at the times of peak
activity.
[0647] Materials and Methods
[0648] IV Administration of Compounds of the Invention
[0649] Compounds of the invention were reconstituted in a phosphate
buffered saline (PBS)/10% Solutol (HS 15) clear solution resulting
in a concentration of 0.2 mg/mL and administered to mice (2 mg/kg)
as a single IV dose. Animals were dosed via the lateral tail vein.
Blood samples were collected at designated time points (0.083,
0.25, 0.5, 1, 2, 4, 8, 16, 24 hours) by cardiac puncture under
isoflurane anesthesia (up to 1 mL blood per animal). The blood was
collected into tubes containing Li-Heparin. The blood samples were
kept on ice until centrifugation within approximately 30 minutes of
collection. The plasma was transferred into labeled polypropylene
tubes and frozen at -70.degree. C. until analyzed by LC/MS/MS.
[0650] PO Administration of Compounds of the Invention
[0651] The compounds of the invention were reconstituted in 40%
Propylene Glycol/40% Propylene Carbonate/20% of a 5% Sucrose clear
solution resulting in a concentration of 2 mg/mL and administered
to mice (10 mg/kg) as a single oral dose via gavage. Blood samples
were collected at 0.25, 0.5, 1, 2, 4, 8, 12, 16, 20 and 24 hours
post dose by cardiac puncture under isoflurane anesthesia. The
blood was collected in tubes containing Li-Heparin. The blood
samples were kept on ice until centrifugation within approximately
30 minutes of collection. The plasma was transferred into labeled
polypropylene tubes and frozen at -70.degree. C. until analyzed by
LC/MS/MS.
[0652] LC/MS/MS Analysis
[0653] Plasma samples at each timepoint were analyzed using a
LC-MS/MS with a lower limit of quantification (LLOQ) of 1 ng/mL.
Plasma was analyzed to determine the amount of the compound of the
invention in each sample and regression curves generated for each
compounds of the invention in the relevant matrixes.
[0654] WinNonlin analysis was used for calculating PK parameters
for both the IV and PO administrations:
[0655] PK parameters for IV portion--AUC.sub.last; AUC.sub.INF;
T1/2; Cl; Vss; C.sub.max; MRT
[0656] PK parameters for PO portion--AUC.sub.last; AUC.sub.INF;
T1/2; C.sub.max; Cl, MRT.
[0657] In addition to the above PK parameters, bioavailability (%
F) was calculated.
[0658] Compounds in Examples 3, 4, 8, 13, 19, 27, and 28 were
tested and all had an oral bioavailability of greater than 9%.
Compounds in Examples 3, 8, 13, and 27 had an oral bioavailability
of greater than 45%.
Example 76
Efficacy of GSNOR Inhibitors in Experimental Inflammatory Bowel
Disease (IBD)
[0659] Overview of the Models:
[0660] Acute and chronic models of dextran sodium sulfate
(DSS)-induced IBD in mice were used to explore efficacy of GSNORi
against this disease. Acute and chronic DSS-induced IBD are widely
used and well characterized models that induce pathological changes
in the colon similar to those observed in the human disease. In
these models and in human disease, epithelial cells within the
crypts of the colon are disrupted, leading to dysfunction of the
epithelial barrier and the ensuing tissue inflammation, edema, and
ulceration. GSNORi therapy may benefit IBD by restoring
s-nitrosoglutathione (GSNO) levels, and thus prevent or reverse the
epithelial barrier dysfunction.
[0661] Acute Prophylactic Model:
[0662] Experimental IBD was induced by administration of DSS in the
drinking water of male C57B1/6 mice (N=8 to 10 mice per group) for
6 consecutive days. GSNORi was dosed orally at doses of 0.1 to 10
mg/kg/day for 10 days starting two days prior to and continuing two
days post DSS exposure. Two days post DSS exposure, the effect of
GSNORi was assessed in a blinded fashion via endoscopy and
histopathology using a five point scale ranging from a score=0
(normal tissue) through a score=4 (ulcerative tissue damage and
marked pathological changes). Levels of circulating cytokines
involved in inflammatory pathways were also assessed. The effect of
GSNORi was compared to vehicle treated controls. The
corticosteroid, prednisolone, was used as the positive control in
this study and was administered daily at 3 mg/kg/day via oral
dosing. Naive mice (N=5) were also assessed as a normal tissue
control.
[0663] Chronic Treatment Model:
[0664] Experimental IBD was induced by administration of DSS in the
drinking water of male C57B1/6 mice (N=10 to 12 mice per group) for
6 consecutive days. GSNORi was dosed orally at doses of 10
mg/kg/day for 14 days starting one day after cessation of DSS
exposure. Efficacy of GSNORi was assessed in a blinded fashion via
endoscopy after 7 days and 14 days of GSNORi dosing and via
histopathology after 14 days of GSNORi dosing using a five point
scale ranging from a score=0 (normal tissue) through a score=4
(ulcerative tissue damage and marked pathological changes). Levels
of circulating cytokines involved in inflammatory pathways were
also assessed. The effect of GSNORi was compared to vehicle treated
controls. The corticosteroid, prednisolone, was used as the
positive control in this study and was administered daily at 3
mg/kg/day via oral dosing. Naive mice (N=5) were also assessed as a
normal tissue control.
[0665] Results:
[0666] The compound of Example 3 attenuated colon injury and
lowered levels of cytokines involved in inflammatory responses in a
mouse model of acute DSS-induced IBD. The percent of mice
presenting with severe colon injury scores via endoscopy and
histopathology assessments was significantly (p<0.05) decreased
by 38% to 88% of vehicle control after oral treatment with the
compound of Example 3 at 0.1, 1, or 10 mg/kg/day for 10 consecutive
days using a prophylactic dosing regimen. The compound of Example 3
also restored circulating inflammatory cytokines towards levels
observed in untreated naive mice. The effects of the compound of
Example 3 were comparable to or greater than those observed for
prednisolone.
[0667] The compound of Example 8 attenuated colon injury in a mouse
model of acute DSS-induced IBD. The percent of mice presenting with
severe colon injury scores via endoscopy or histopathology
assessments was decreased by 44% or 26%, respectively, of vehicle
control after oral treatment with the compound of Example 8 at 10
mg/kg/day for 10 consecutive days using a prophylactic dosing
regimen.
[0668] The compound of Example 19 attenuated colon injury in a
mouse model of acute DSS-induced IBD. The percent of mice
presenting with severe colon injury scores via endoscopy assessment
was decreased by 31% of vehicle control after oral treatment with
the compound of Example 19 at 10 mg/kg/day for 10 consecutive days
using a prophylactic dosing regimen.
[0669] The compound of Example 13 attenuated colon injury in a
mouse model of chronic DSS-induced IBD. The percent of mice
presenting with severe colon injury scores via endoscopy or
histopathology assessment was significantly (p<0.05) decreased
by 52% or 53%, respectively, of vehicle control after oral
treatment with the compound of Example 13 at 10 mg/kg/day for up to
14 consecutive days using a treatment dosing regimen.
Example 77
Efficacy of GSNOR Inhibitors in Experimental Chronic Obstructive
Pulmonary Disease (COPD)
[0670] Short Duration Cigarette Smoke COPD Models
[0671] The efficacy of GSNOR inhibitors was assessed in a mouse
model of chronic obstructive pulmonary disease (COPD) induced by
short duration (4 days or 11 days) of exposure to cigarette smoke.
Infiltration of inflammatory cells into the bronchoalveolar lavage
fluid (BALF) and BALF levels of chemokines involved in inflammation
and tissue turnover/repair were measured to assess the influences
of GSNOR inhibitors on some of the early events associated with the
initiation and progression of COPD.
[0672] Overview of the Models:
[0673] Efficacy of GSNOR inhibitors against COPD was explored using
acute (4 day) and subchronic (11 day) models of cigarette
smoke-induced COPD in mice. Exposure of animals to cigarette smoke
provides a model of COPD in which injury is induced by the same
causative agent as in human disease and in which injury exhibits
similarities to the human disease, including airway obstruction,
airspace enlargement, and involvement of inflammatory responses in
these pathologies. In animal models, changes in lung pathology are
only evident after extended (several months) duration of exposure
to cigarette smoke, thus making chronic models prohibitive as
effective screening tools. More recently, models exploring
inflammatory responses after short duration (2 weeks or less) of
smoke exposure in mice have been utilized as tools for screening
efficacy and mechanisms of action of novel therapeutics against
COPD. The key roles of inflammation in the initiation and
progression of COPD, make these short duration models relevant for
initial tests of efficacy of novel therapeutics.
[0674] Acute (4 day) smoke exposure model: Female C57B1/6 mice (N=8
per group) were exposed to cigarette smoke using a whole body
exposure chamber. Mice were exposed daily for 4 consecutive days to
4 cycles of smoke from 6 sequential cigarettes (Kentucky 3R.sub.4F
without filter) with a 30 minute smoke free interval between
cycles. GSNOR inhibitors were administered daily via oral dosing at
10 mg/kg/day for 7 days starting 2 days prior to smoke exposure and
continuing 1 day post-exposure. The effects of GSNOR inhibitors
were assessed by quantitating the numbers of total cells,
leukocytes, and leukocytes differentials in the BALF via light
microscopy and the levels of BALF chemokines via ELISA at
approximately 24 h after the last smoke exposure. The effect of
GSNOR inhibitors were compared to vehicle treated controls. The
PDE4 inhibitor, roflumilast, was used as the positive control for
the study. A group of naive mice (N=8) was exposed to air and used
as a negative control for the study.
[0675] Subchronic (11 day) smoke exposure model: Female C57B1/6
mice (N=10 per group) were exposed to cigarette smoke generated
from Marlboro 100 cigarettes without filters. Exposure times were
25 min. on study day 1, 35 min. on study day 2, and 45 min. on
study days 3 to 11. GSNOR inhibitors were administered one hour
prior to smoke exposure on each day. GSNOR inhibitors were dosed
orally at 1 to 10 mg/kg/day for 11 days. The effects of GSNOR
inhibitors were assessed by quantitating the number of total cells,
and leukocytes differentials in the BALF via light microscopy at 24
h after the last exposure. The effect of GSNOR inhibitors were
compared to vehicle treated controls and expressed as percent
inhibition of the cigarette smoke induced increases in BALF cell
numbers. Roflumilast was used as the positive control for the study
and was dosed at 5 mg/kg/day. A group of naive mice (N=10) was
exposed to air and dosed with vehicle as a negative control for the
study.
[0676] Results:
[0677] The compound of Example 3 attenuated the smoke-induced
changes in BALF cellular infiltrate and BALF inflammatory
chemokines. The compound of Example 3 significantly (p<0.05)
decreased total cells, leukocytes, macrophages, neutrophils, and
eosinophils in BALF by 66%, 80%, 75%, 84%, and 95%, respectively,
compared to vehicle treated controls when dosed orally at 10
mg/kg/day for 7 days in the acute 4 day smoke model. These effects
of the compound of Example 3 were comparable to or greater than
those observed for roflumilast. The compound of Example 3 also
restored BALF chemokines towards levels observed in naive mice. In
the subchronic 11 day model, the compound of Example 3 inhibited
the smoke-induced increase in total cells (p<0.05), macrophages,
neutrophils (p<0.05), eosinophils, and lymphocytes (p<0.05)
in BALF by 25%, 24%, 41%, 70%, and 49%, respectively, when dosed
orally at 10 mg/kg/day for 11 days. When dosed orally at 5
mg/kg/day, the compound of Example 3 inhibited total cells,
macrophages, neutrophils (p<0.05), and lymphocytes (p<0.05)
in BALF by 22%, 23%, 29%, and 46%, respectively.
[0678] The compound of Example 8 significantly (p<0.05)
inhibited the smoke-induced increase in total cells, macrophages,
neutrophils, and lymphocytes in BAL by 35% to 48%, 24% to 43%, 41%
to 70%, and 49 to 65%, respectively, when dosed orally at 1 to 10
mg/kg/day for 11 days in the subchronic 11 day model. There was no
dose response of effect with 1, 5, or 10 mg/kg/day. The effects of
the compound of Example 8 were comparable to those of
roflumilast.
[0679] The compound of Example 13 significantly (p<0.05)
inhibited the smoke-induced increase in total cells, macrophages,
neutrophils, and lymphocytes in BAL by 56%, 53%, 67%, and 60%,
respectively, when dosed orally at 1 mg/kg/day for 11 days in the
subchronic 11 day model. These effects of the compound of Example
13 were comparable to those of roflumilast.
[0680] The compound of Example 27 significantly (p<0.05)
inhibited the smoke-induced increase in total cells, macrophages,
neutrophils, and lymphocytes in BAL by 44%, 41%, 64%, and 46%,
respectively, when dosed orally at 1 mg/kg/day for 11 days in the
subchronic 11 day model. These effects of the compound of Example
27 were comparable to those of roflumilast.
Example 78
An Exploratory Mouse Study of Acetaminophen Toxicity
[0681] S-nitrosoglutathione reductase (GSNOR) inhibition has been
previously shown in our hands to ameliorate the negative
manifestations of gastrointestinal injury in animal models. As an
extension of these observations, the effects of
S-nitrosoglutathione (GSNO) or GSNOR inhibitors (GSNORi) on
acetaminophen (ACAP) induced liver toxicity can be evaluated in a
mouse model of liver injury. Blood samples are collected for liver
function assays and tissue samples are collected at the end of the
study for histopathologic examination.
[0682] Materials and Methods
[0683] GSNORi, GSNO, acetaminophen (ACAP, Sigma) Vehicles (1/2 cc
syringes for dosing), Isoflurane, 18 1 cc syringes w/26 g needles
for blood collection, 90 serum separator tubes for clinical
chemistry.
[0684] General Study Design: Animals (5/group) are acclimated for
at least 3 days prior to dosing. On Study Day 1, acetaminophen
treatment (300 mg/kg PO) was given a single time=0 to fasted
animals. Two hours later, GSNORi (10 mg/kg/dose) or GSNO (5
mg/kg/dose) are intravenously administered to the treatment groups.
GSNORi or GSNO are given at 24 and 48 hours-post their initial
administration to the treatment groups. Mice are observed for signs
of clinical toxicity and blood was collected at 6, 24, and 72 hours
post-ACAP administration for liver function tests: Alkaline
phosphatase (ALK); Alanine aminotransferase (ALT); Aspartate
aminotransferase (AST); Gamma glutamyltransferase (GGT) and Total
bilirubin (TBILI). Livers are collected at 72 hours for
histopathologic examination.
TABLE-US-00001 Study Outline Drug Group Treatment Dose
Concentration N 1 ACAP PO 300 mg/kg 10 ml/kg 5 2 Saline PO 0 mg/kg
10 ml/kg 5 3 GSNORi IV 10 mg/kg 1 mg/mL 5 4 GSNO IV 5 mg/kg 1 mg/mL
5 5 GSNORi IV + ACAP 10 m/k/300 m/k 1 mg/mL 5 6 GSNO IV + ACAP 5
m/k/300 m/k 1 mg/mL 5
[0685] Study Calendar:
TABLE-US-00002 Day -6 Receive mice and place in regular cages Day
-1 Fast animals overnight Day 0 Weigh, PO ACAP time = 0, time = 2
IV GSNO or GSNORi bleed all groups at 6 hr post-ACAP Day 1 Weigh,
bleed all groups for 24 hr LFTs, IV GSNO or GSNORi Day 2 Weigh, IV
GSNO or GSNORi Day 3 Bleed for 72 hr LFTs, collect livers for
weight and histology
[0686] Vehicle, GSNO and GSNORi Preparation
[0687] The vehicle control article is Phosphate Buffered Saline
(PBS) (not containing calcium, potassium, or magnesium) adjusted to
pH 7.4. The vehicle components are weighed into a container on a
tared balance and brought to volume with purified water (w/v). The
10.times. stock solution is mixed using a magnetic stirrer, as
necessary. Thereafter, the 10.times. stock solution is diluted with
deionized water at a ratio of 1:9 (v/v). GSNO is warmed to room
temperature before preparation of solutions. Prior to use, the PBS
solution is nitrogen sparged. 1 mg/mL GSNO solutions are kept cold
(i.e., kept on an ice bath) and protected from light and used
within 4 hours of preparation. GSNORi Preparation, the 1 mg/mL
concentration is reconstituted in phosphate buffered saline (PBS),
pH 7.4. GSNORi is administered to mice (10 mL/kg) as a single (IV)
daily dose. Dosing is performed 2 hours post-ACAP administration
and then 26 and 50 hours later. Effects of GSNO or GSNORi are
compared to ACAP and saline vehicle dosed in the same manner.
[0688] Calculations: Mean body weights, mean liver organ weights
and clinical pathology endpoints (+/-SD) with T-test and ANOVA
(alpha=0.05) comparison to vehicle control group. The clinical
pathology data are prepared as mean values unless the data are not
normally distributed, in which case, median values can be presented
with the minimum and maximum value range.
Example 79
An Exploratory Study to Assess the Anti NASH Fibrotic Activity of
GSNORi in STAM Mice
[0689] S-nitrosoglutathione reductase (GSNOR) inhibition has been
previously shown in our hands to ameliorate the negative
manifestations of gastrointestinal injury and ACAP injury in mouse
models. As an extension of these observations, the effects of GSNOR
inhibitors (GSNORi) ability to reverse fibrotic activity in
nonalcoholic steatohepatitis (NASH)-induced liver disease is
evaluated in STAM (signal transducing adaptor molecule) mice. In
these mice sequential changes are seen from liver steatosis to
fibrosis within two weeks and there are close similarities to human
NASH histopathology.
[0690] Materials and Methods
[0691] GSNORi, Telmisartan, Vehicles (1/2 cc syringes for dosing),
Isoflurane, 18 1 cc syringes w/26 g needles for blood collection,
90 serum separator tubes for clinical chemistry.
[0692] General Study Design: Animals (6/group) are acclimated prior
to beginning the Study. At 4 weeks of age the animals are put on a
diet, group 1 (normal mice) receives a normal diet while groups 2-4
(STAM mice) are put on a high fat diet for the duration of the
Study. At Study Week 7 the mice begin oral daily dosing with GSNORi
and are sacrificed at Study Week 9. Mice are observed for signs of
clinical toxicity and blood/tissue is collected for liver analyses:
Plasma triglycerides (TG); Alanine aminotransferase (ALT);
Aspartate aminotransferase (AST); Gene Expression: Timp-1,
.alpha.-SMA, collagen 3, TNF-.alpha. and MCP-1 as well as
histopathologic examination using HE staining for (NAFLD) activity
score and Sirius-red staining (fibrosis area).
TABLE-US-00003 Study Outline Drug Group Treatment Diet Dose
Concentration N 1 normal ND 0 mg/kg 0 ml/kg 6 2 STAM + vehicle HFD
10 mg/kg 1 mg/mL 6 3 STAM + GSNORi IV HFD 10 mg/kg 1 mg/mL 6 4 STAM
+ Telmisarten HFD 10 mg/kg 1 mg/mL 6 ND: normal diet, HFD: high fat
diet
[0693] Calculations: Mean body weights, mean liver organ weights
and clinical pathology endpoints (+/-SD) with T-test and ANOVA
(alpha=0.05) comparison to vehicle control group. The clinical
pathology data are prepared as mean values unless the data are not
normally distributed, in which case, median values were presented
with the minimum and maximum value range.
[0694] It will be apparent to those skilled in the art that various
modifications and variations can be made in the methods and
compositions of the present invention without departing from the
spirit or scope of the invention.
* * * * *